Document and Entity Information |
12 Months Ended |
|---|---|
|
Dec. 31, 2016
shares
| |
| Document Information [Line Items] | |
| Document Type | 20-F |
| Amendment Flag | false |
| Document Period End Date | Dec. 31, 2016 |
| Document Fiscal Year Focus | 2016 |
| Document Fiscal Period Focus | FY |
| Trading Symbol | ICLR |
| Entity Registrant Name | ICON PLC |
| Entity Central Index Key | 0001060955 |
| Current Fiscal Year End Date | --12-31 |
| Entity Well-known Seasoned Issuer | Yes |
| Entity Current Reporting Status | Yes |
| Entity Filer Category | Large Accelerated Filer |
| Entity Common Stock, Shares Outstanding | 54,530,843 |
| X | ||||||||||
- Definition If the value is true, then the document is an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
- Definition End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
- Definition This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
- Definition This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
- Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". No definition available.
|
| X | ||||||||||
- Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. No definition available.
|
| X | ||||||||||
- Definition Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
- Definition Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
- Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No definition available.
|
| X | ||||||||||
- Definition Trading symbol of an instrument as listed on an exchange. No definition available.
|
| X | ||||||||||
- Definition Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
- Definition Capital Redemption Reserve No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of noncurrent assets classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Consolidated Balance Sheets (Parenthetical) - € / shares |
Dec. 31, 2016 |
Dec. 31, 2015 |
[1] | ||
|---|---|---|---|---|---|
| Ordinary shares, par value | € 0.06 | € 0.06 | |||
| Ordinary shares, shares authorized | 100,000,000 | 100,000,000 | |||
| Ordinary shares, shares issued | 54,530,843 | 54,958,912 | |||
| Ordinary shares, shares outstanding | 54,530,843 | 54,958,912 | |||
| |||||
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Consolidated Statements of Operations - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Revenue: | |||
| Gross revenue | $ 2,364,956 | $ 2,161,618 | $ 2,030,286 |
| Reimbursable expenses | (698,469) | (586,640) | (526,970) |
| Net revenue | 1,666,487 | 1,574,978 | 1,503,316 |
| Costs and expenses: | |||
| Direct costs | 961,333 | 908,979 | 903,167 |
| Selling, general and administrative | 325,726 | 326,786 | 336,461 |
| Depreciation and amortization | 59,575 | 57,677 | 52,542 |
| Restructuring and other items, net (Note 14) | 8,159 | 8,796 | |
| Total costs and expenses | 1,354,793 | 1,293,442 | 1,300,966 |
| Income from operations | 311,694 | 281,536 | 202,350 |
| Interest income | 1,484 | 1,306 | 1,151 |
| Interest expense | (13,006) | (3,992) | (785) |
| Income before provision for income taxes | 300,172 | 278,850 | 202,716 |
| Provision for income taxes (Note 13) | (37,993) | (39,311) | (30,248) |
| Net income | $ 262,179 | $ 239,539 | $ 172,468 |
| Net income per ordinary share: | |||
| Basic | $ 4.75 | $ 4.08 | $ 2.80 |
| Diluted | $ 4.65 | $ 3.97 | $ 2.73 |
| Weighted average number of ordinary shares outstanding: | |||
| Basic (Note 2 (u)) | 55,248,900 | 58,746,935 | 61,496,115 |
| Diluted (Note 2 (u)) | 56,407,136 | 60,290,033 | 63,131,417 |
| X | ||||||||||
- Definition Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense for debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Net income | $ 262,179 | $ 239,539 | $ 172,468 |
| Currency translation adjustment | (12,839) | (35,105) | (45,038) |
| Currency impact of long-term funding | (8,824) | 7,342 | 9,806 |
| Income tax on currency impact of long term funding | 396 | (3,574) | (178) |
| Unrealized capital gain/(loss) - investments | 11 | (54) | 20 |
| Actuarial (loss)/gain on defined benefit pension plan | (2,485) | 2,693 | (4,125) |
| Realized (loss)/gain on interest rate hedge | (923) | 4,617 | |
| Total comprehensive income | $ 237,515 | $ 215,458 | $ 132,953 |
| X | ||||||||||
- Definition Adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
- Definition Tax impact on the adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of reclassification adjustment from accumulated other comprehensive income (loss) for net transition asset (obligation) related to pension and other postretirement benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Consolidated Statements of Shareholders' Equity and Comprehensive Income - USD ($) $ in Thousands |
Total |
Ordinary Shares |
Additional Paid-in Capital |
Capital Redemption Reserve |
Accumulated Other Comprehensive Income |
Retained Earnings |
|||
|---|---|---|---|---|---|---|---|---|---|
| Balance (in shares) at Dec. 31, 2013 | 61,587,257 | ||||||||
| Balance at Dec. 31, 2013 | $ 910,579 | $ 5,168 | $ 279,572 | $ 100 | $ 1,960 | $ 623,779 | |||
| Comprehensive Income: | |||||||||
| Net income | 172,468 | 172,468 | |||||||
| Currency translation adjustment | (45,038) | (45,038) | |||||||
| Currency impact of long-term funding | 9,806 | 9,806 | |||||||
| Income tax on currency impact of long- term funding | (178) | (178) | |||||||
| Unrealized capital gain (loss) - investments | 20 | 20 | |||||||
| Actuarial gain (loss) on defined benefit pension plan | (4,125) | (4,125) | |||||||
| Total comprehensive income | 132,953 | ||||||||
| Exercise of share options (in shares) | 926,407 | ||||||||
| Exercise of share options | 22,256 | $ 74 | 22,182 | ||||||
| Issue of restricted share units / performance share units (in shares) | 233,726 | ||||||||
| Issue of restricted share units / performance share units | 18 | 18 | |||||||
| Share based compensation expense | 23,078 | 23,078 | |||||||
| Share issue costs | (20) | (20) | |||||||
| Repurchase of ordinary shares (in shares) | (2,640,610) | ||||||||
| Repurchase of ordinary shares | (140,030) | $ (205) | 205 | (140,030) | |||||
| Share repurchase costs | (1,032) | (1,032) | |||||||
| Excess income tax benefit on exercise of equity compensation (net of deferred tax) | 2,404 | 2,404 | |||||||
| Balance (in shares) at Dec. 31, 2014 | 60,106,780 | ||||||||
| Balance at Dec. 31, 2014 | 950,206 | $ 5,037 | 327,234 | 305 | (37,555) | 655,185 | |||
| Comprehensive Income: | |||||||||
| Net income | 239,539 | 239,539 | |||||||
| Currency translation adjustment | (35,105) | (35,105) | |||||||
| Currency impact of long-term funding | 7,342 | 7,342 | |||||||
| Income tax on currency impact of long- term funding | (3,574) | (3,574) | |||||||
| Unrealized capital gain (loss) - investments | (54) | (54) | |||||||
| Actuarial gain (loss) on defined benefit pension plan | 2,693 | 2,693 | |||||||
| Gain on interest rate hedge | 4,617 | 4,617 | |||||||
| Total comprehensive income | 215,458 | ||||||||
| Exercise of share options (in shares) | 773,753 | ||||||||
| Exercise of share options | 20,981 | $ 52 | 20,929 | ||||||
| Issue of restricted share units / performance share units (in shares) | 276,860 | ||||||||
| Issue of restricted share units / performance share units | 18 | 18 | |||||||
| Share based compensation expense | 33,317 | 33,317 | |||||||
| Share issue costs | (8) | (8) | |||||||
| Repurchase of ordinary shares (in shares) | (6,198,481) | ||||||||
| Repurchase of ordinary shares | (457,892) | $ (410) | 410 | (457,892) | |||||
| Share repurchase costs | (889) | (889) | |||||||
| Excess income tax benefit on exercise of equity compensation (net of deferred tax) | $ 1,905 | 1,905 | |||||||
| Balance (in shares) at Dec. 31, 2015 | 54,958,912 | [1] | 54,958,912 | ||||||
| Balance at Dec. 31, 2015 | $ 763,096 | [1] | $ 4,679 | 383,395 | 715 | (61,636) | 435,943 | ||
| Comprehensive Income: | |||||||||
| Net income | 262,179 | 262,179 | |||||||
| Currency translation adjustment | (12,839) | (12,839) | |||||||
| Currency impact of long-term funding | (8,824) | (8,824) | |||||||
| Income tax on currency impact of long- term funding | 396 | 396 | |||||||
| Unrealized capital gain (loss) - investments | 11 | 11 | |||||||
| Actuarial gain (loss) on defined benefit pension plan | (2,485) | (2,485) | |||||||
| Amortization of interest rate hedge | (923) | (923) | |||||||
| Total comprehensive income | 237,515 | ||||||||
| Exercise of share options (in shares) | 393,240 | ||||||||
| Exercise of share options | 10,139 | $ 26 | 10,113 | ||||||
| Issue of restricted share units / performance share units (in shares) | 607,878 | ||||||||
| Issue of restricted share units / performance share units | 41 | 41 | |||||||
| Share based compensation expense | 40,343 | 40,343 | |||||||
| Share issue costs | (17) | (17) | |||||||
| Repurchase of ordinary shares (in shares) | (1,429,187) | ||||||||
| Repurchase of ordinary shares | (110,000) | $ (94) | 94 | (110,000) | |||||
| Share repurchase costs | (275) | (275) | |||||||
| Excess income tax benefit on exercise of equity compensation (net of deferred tax) | $ 4,332 | 4,332 | |||||||
| Balance (in shares) at Dec. 31, 2016 | 54,530,843 | 54,530,843 | |||||||
| Balance at Dec. 31, 2016 | $ 945,174 | $ 4,611 | $ 438,207 | $ 809 | $ (86,300) | $ 587,847 | |||
| |||||||||
| X | ||||||||||
- Definition Adjustment to Retained Earning Share Repurchase costs No definition available.
|
| X | ||||||||||
- Definition Adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
- Definition Tax impact on the adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
- Definition This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation". Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of reclassification adjustment from accumulated other comprehensive income (loss) for net transition asset (obligation) related to pension and other postretirement benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares that have been repurchased and retired during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Consolidated Statements of Cash Flows - USD ($) $ in Thousands |
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|||||
| Cash flows from operating activities: | |||||||
| Net income | $ 262,179 | $ 239,539 | $ 172,468 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Loss on disposal of property, plant and equipment | 151 | 55 | 248 | ||||
| Depreciation expense | 42,125 | 40,210 | 42,200 | ||||
| Amortization of intangibles | 17,450 | 17,467 | 10,342 | ||||
| Amortization of government grants | (44) | 53 | (213) | ||||
| Interest on short term investments | (823) | (571) | (910) | ||||
| Realized (gain)/loss on sale of short term investments | (50) | 113 | |||||
| Amortization of gain on interest rate hedge | (923) | (41) | |||||
| Amortization of financing costs | 566 | ||||||
| Stock compensation expense | 40,343 | 33,317 | 22,742 | ||||
| Deferred taxes | 1,545 | 3,157 | (7,900) | ||||
| Changes in assets and liabilities: | |||||||
| Decrease/(increase) in accounts receivable | 2,526 | (18,671) | (7,032) | ||||
| Increase in unbilled revenue | (16,753) | (29,281) | (13,671) | ||||
| Increase in other receivables | (1,829) | (14,519) | (4,259) | ||||
| Decrease/(increase) in prepayments and other current assets | 1,872 | (8,631) | (3,574) | ||||
| Increase in other non-current assets | (2,157) | (55) | (2,264) | ||||
| (Decrease)/increase in payments on account | (45,754) | 34,644 | (47,548) | ||||
| (Decrease)/increase in other current liabilities | (44,713) | (26,266) | 15,111 | ||||
| Increase in other non-current liabilities | 3,008 | 6,378 | 1,283 | ||||
| (Decrease)/increase in income taxes payable | (690) | (949) | 3,021 | ||||
| Increase/(decrease) in accounts payable | 1,175 | 3,124 | (11,006) | ||||
| Net cash provided by operating activities | 259,204 | 279,073 | 169,038 | ||||
| Cash flows from investing activities: | |||||||
| Purchase of property, plant and equipment | (42,601) | (49,730) | (32,779) | ||||
| Purchase of subsidiary undertakings and acquisition costs | (54,209) | (166,292) | (124,301) | ||||
| Cash acquired with subsidiary undertaking | 3,168 | 194 | 3,527 | ||||
| Sale of short term investments | 40,858 | 25,708 | 103,475 | ||||
| Purchase of short term investments | (22,030) | (14,194) | (61,328) | ||||
| Net cash used in investing activities | (74,814) | (204,314) | (111,406) | ||||
| Cash flows from financing activities: | |||||||
| Drawdown of credit lines and facilities | 73,000 | 851,500 | |||||
| Repayment of credit lines and facilities | (73,000) | (501,500) | |||||
| Proceeds from the exercise of equity compensation | 10,180 | 20,999 | 22,274 | ||||
| Share issue costs | (17) | (8) | (20) | ||||
| Excess tax benefit on exercise of equity compensation | 6,402 | 1,905 | 2,404 | ||||
| Repurchase of ordinary shares | (110,000) | (457,892) | (140,030) | ||||
| Share repurchase costs | (275) | (889) | (1,032) | ||||
| Repayment of government grant | (159) | ||||||
| Proceeds from interest rate hedge | 4,658 | ||||||
| Net cash used in financing activities | (93,710) | (81,386) | (116,404) | ||||
| Effect of exchange rate movements on cash | (2,050) | (8,362) | (4,847) | ||||
| Net increase/(decrease) in cash and cash equivalents | 88,630 | (14,989) | (63,619) | ||||
| Cash and cash equivalents at beginning of year | 103,911 | [1] | 118,900 | 182,519 | |||
| Cash and cash equivalents at end of year | $ 192,541 | $ 103,911 | [1] | $ 118,900 | |||
| |||||||
| X | ||||||||||
- Definition Amortization Of Gain On Interest Rate Hedge No definition available.
|
| X | ||||||||||
- Definition Interest On Short Term Investments No definition available.
|
| X | ||||||||||
- Definition Payments for Share Repurchase Costs No definition available.
|
| X | ||||||||||
- Definition Amortization of Government Grants. No definition available.
|
| X | ||||||||||
- Definition Repayments of Government Grant No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of amortization expense attributable to debt issuance costs. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred income tax expense (benefit) and income tax credits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in current liabilities classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in noncurrent assets classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in noncurrent operating liabilities classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in receivables classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in prepaid expenses, and assets classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow to reacquire common stock during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Description of business |
12 Months Ended |
|---|---|
Dec. 31, 2016 | |
| Description of business |
1. Description of business
ICON plc and its subsidiaries ("the Company" or "ICON") is a
contract research organization ("CRO"), providing outsourced
development services on a global basis to the pharmaceutical,
biotechnology and medical device industries. We specialize in the
strategic development, management and analysis of programs that
support all stages of the clinical development process from
compound selection to Phase I-IV clinical studies. Our vision is to
be the Global CRO partner of choice in drug development by
delivering best in class information, solutions and performance in
clinical and outcomes research.
We believe that we are one of a select group of CROs with the
expertise and capability to conduct clinical trials in most major
therapeutic areas on a global basis and have the operational
flexibility to provide development services on a stand-alone basis
or as part of an integrated "full service" solution. At December
31, 2016 we had approximately 12,500 employees, in 87 locations in
38 countries. During the year ended December 31, 2016, we derived
approximately 45.8%, 43.4% and 10.8% of our net revenue in the
United States, Europe and Rest of World, respectively.
We began operations in 1990 and have expanded our business
predominately through internal growth, together with a number of
strategic acquisitions to enhance our capabilities and expertise in
certain areas of the clinical development process. We are
incorporated in Ireland and our principal executive office is
located at: South County Business Park, Leopardstown, Dublin 18,
Republic of Ireland. The contact telephone number of this office is
+353 1 2912000.
|
| X | ||||||||||
- Definition The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Significant Accounting Policies |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Significant Accounting Policies |
2. Significant Accounting Policies
The accounting policies noted below were applied in the preparation
of the accompanying financial statements of the Company and are in
conformity with accounting principles generally accepted in the
United States.
(a)
Basis
of consolidation
The consolidated financial statements include the financial
statements of the Company and all of its subsidiaries. All
significant intercompany profits, transactions and account balances
have been eliminated. The results of subsidiary undertakings
acquired in the period are included in the consolidated statement
of operations from the date of acquisition.
(b)
Use
of estimates
The preparation of financial statements in conformity with
generally accepted accounting principles in the United States
requires management to make estimates and judgments that affect the
reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during
the reported period. Actual results could differ from those
estimates. The principle management estimates and judgments used in
preparing the financial statements relate to revenue recognition,
taxation, goodwill and business combinations.
(c)
Revenue
recognition
The Company primarily earns revenues by providing a number of
different services to its customers. These services, which are
integral elements of the clinical development process, include
clinical trials management, biometric activities, consulting,
imaging, contract staffing, informatics and laboratory services.
Contracts range in duration from a number of months to several
years. Revenue for services, as rendered, is recognized only after
persuasive evidence of an arrangement exists, the sales price is
fixed or determinable and collectability is reasonably
assured.
Clinical trials management revenue
is recognized on a proportional performance method. Depending on
the contractual terms revenue is either recognized on the
percentage of completion method based on the relationship between
hours incurred and the total estimated hours of the trial or on the
unit of delivery method. Contract costs equate to the product of
labor hours incurred and compensation rates. For the percentage of
completion method, the input (effort expended) method has been used
to measure progress towards completion as there is a direct
relationship between input and productivity. Contract revenue is
the product of the aggregated labor hours required to complete the
specified contract tasks at the agreed contract rates. The Company
regularly reviews the estimate of total contract time to ensure
such estimates remain appropriate taking into account actual
contract stage of completion, remaining time to complete and any
identified changes to the contract scope. Remaining time to
complete depends on the specific contract tasks, the complexity of
the contract and can include geographical site selection and
initiation, patient enrollment, patient testing and level of
results analysis required. While the Company may routinely adjust
time estimates, the Company's estimates and assumptions
historically have been accurate in all material respects in the
aggregate. Where revenue is recognized on the unit of delivery
method, the basis applied is the number of units completed as a
percentage of the total number of contractual units.
Biometrics revenue is recognized on a fee-for-service method as
each unit of data is prepared on the basis of the number of units
completed in a period as a percentage of the total number of
contracted units. Imaging revenue is recognized on a
fee-for-service basis recognizing revenue for each image completed.
Consulting revenue is recognized on a fee-for-service basis as each
hour of the related service is performed. Contract
staffing revenue is recognized on a fee-for-service basis, over the
time the related service is performed, or in the case of permanent
placement, once the candidate has been placed with the client.
Informatics revenue is recognized on a fee-for-service
basis. Informatics contracts are treated as multiple element
arrangements, with contractual elements comprising license fee
revenue, support fee revenue and revenue from software services,
each of which can be sold separately. Sales prices for contractual
elements are determined by reference to objective and reliable
evidence of their sales price. License and support fee revenues are
recognized rateably over the period of the related agreement.
Revenue from software services is recognized using the percentage
of completion method based on the relationship between hours
incurred and the total estimated hours required to perform the
service.
Laboratory service revenue is recognized on a fee-for-service
basis. The Company accounts for laboratory service contracts as
multiple element arrangements, with contractual elements comprising
laboratory kits and laboratory testing, each of which can be sold
separately. Sales prices for contractual elements are determined by
reference to objective and reliable evidence of their sales price.
Revenues for contractual elements are recognized on the basis of
the number of deliverable units completed in the period.
Contracts generally contain provisions for renegotiation in the
event of changes in the scope, nature, duration, or volume of
services of the contract. Renegotiated amounts are recognized as
revenue by revision to the total contract value arising as a result
of an authorized customer change order.
The difference between the amount of revenue recognized and the
amount billed on a particular contract is included in the balance
sheet as unbilled revenue or payments on account. Normally, amounts
become billable upon the achievement of certain milestones, for
example, target patient enrolment rates, clinical testing sites
initiated or case report forms completed. Once the milestone target
is reached, amounts become billable in accordance with pre-agreed
payment schedules included in the contract or on submission of
appropriate billing detail. Such cash payments are not
representative of revenue earned on the contract as revenues are
recognized over the period in which the specified contractual
obligations are fulfilled. Amounts included in unbilled revenue are
expected to be collected within one year and are included within
current assets. Advance billings to customers, for which revenue
has not been recognized, are recognized as payments on account
within current liabilities.
In the event of contract termination, if the value of work
performed and recognized as revenue is greater than aggregate
milestone billings at the date of termination, cancellation clauses
usually ensure that the Company is paid for all work performed to
the termination date.
(d)
Reimbursable
expenses
Reimbursable expenses comprise investigator payments and certain
other costs which are reimbursed by clients under terms specific to
each contract and are deducted from gross revenue in arriving at
net revenue. Investigator payments are accrued based on patient
enrollment over the life of the contract. Investigator payments are
made based on predetermined contractual arrangements, which may
differ from the accrual of the expense.
(e)
Direct
costs
Direct costs consist of compensation, associated employee benefits
and share-based payments for project-related employees and other
direct project-related costs.
(f)
Advertising
costs
All costs associated with advertising and promotion are expensed as
incurred. The advertising and promotion costs were $7,167,050,
$4,513,750 and $3,563,900 for the years ended December 31, 2016,
December 31, 2015 and December 31, 2014 respectively.
(g)
Foreign
currencies and translation of subsidiaries
The Company's financial statements are prepared in United States
dollars. Transactions in currencies other than United States
dollars are recorded at the rate ruling at the date of the
transaction. Monetary assets and liabilities denominated in
currencies other than United States dollars are translated into
United States dollars at exchange rates prevailing at the balance
sheet date. Adjustments resulting from these translations are
charged or credited to income. Amounts charged or credited to the
statement of operations for the years ended December 31, 2016,
December 31, 2015 and December 31, 2014 were as follows:
The financial statements of subsidiaries with other functional
currencies are translated at period end rates for the balance sheet
and average rates for the statement of operations. Translation
gains and losses arising are reported as a movement on accumulated
other comprehensive income.
(h)
Disclosure
about fair value of financial instruments
The following methods and assumptions were used to estimate the
fair value of each material class of financial instrument:
Cash, cash equivalents, unbilled revenue, other receivables, short
term investments, prepayments and other current assets, accounts
receivable, accounts payable, investigator payments, payments on
account, accrued liabilities, accrued bonuses and income taxes
payable have carrying amounts that approximate fair value due to
the short term maturities of these instruments. Other liabilities'
carrying amounts approximate fair value based on net present value
of estimated future cash flows.
Financial instruments are measured in the statement of financial
position at fair value using a fair value hierarchy of valuation
inputs. The hierarchy prioritizes the inputs into three levels
based on the extent to which inputs used in measuring fair value
are observable in the market. Each fair value measurement is
reported in one of three levels, which is determined by the lowest
level input that is significant to the fair value measurement in
its entirety. These levels are:
The Company classifies its short term investments as available for
sale, as it does not actively trade such securities nor does it
intend to hold them to maturity. The fair value of short term
investments are represented by level 1 fair value measurements
– quoted prices in active markets for identical assets. The
unrealized movements in fair value are recognized in equity until
disposal or sale, at which time, those unrealized movements from
prior periods are recognized in profit or loss. For losses other
than temporary, which reduce the carrying amount below cost is
recognized in profit or loss.
(i)
Business
combinations
The cost of a business combination is measured as the aggregate of
the fair values at the date of exchange of assets given,
liabilities incurred or assumed and equity instruments issued in
exchange for control. Where a business combination agreement
provides for an adjustment to the cost of the acquisition which is
contingent upon future events, the amount of the estimated
adjustment is recognized at the acquisition date at the fair value
of the contingent consideration. Any changes to this estimate
outside the measurement period will depend on the classification of
the contingent consideration. If the contingent consideration is
classified as equity it shall not be re-measured and the settlement
shall be accounted for within equity. If the contingent
consideration is classified as a liability any adjustments will be
accounted for through the Consolidated Statement of Operations or
Other Comprehensive Income depending on whether the liability is
considered a financial instrument.
The assets, liabilities and contingent liabilities of
businesses acquired are measured at their fair values at the date
of acquisition. In the case of a business combination which is
completed in stages, the fair values of the identifiable assets,
liabilities and contingent liabilities are determined at the date
of each exchange transaction. When the initial accounting for a
business combination is determined provisionally, any subsequent
adjustments to the provisional values allocated to the identifiable
assets, liabilities and contingent liabilities are made within
twelve months of the acquisition date and presented as adjustments
to goodwill in the reporting period in which the adjustments are
determined.
(j)
Goodwill
and Impairment
Goodwill represents the excess of the cost of acquired entities
over the net amounts assigned to assets acquired and liabilities
assumed. Goodwill primarily comprises acquired workforce in place
which does not qualify for recognition as an asset apart from
goodwill. Goodwill is stated net of any provision for impairment.
The Company tests goodwill annually for any impairments or whenever
events occur which may indicate impairment. The first step is to
compare the carrying amount of the reporting unit's assets to the
fair value of the reporting unit. If the carrying amount exceeds
the fair value then a second step is completed which involves the
fair value of the reporting unit being allocated to each asset and
liability with the excess being implied goodwill. The impairment
loss is the amount by which the recorded goodwill exceeds the
implied goodwill. No impairment was recognized as a result of the
impairment testing carried out for the years ended December 31,
2016, December 31, 2015 and December 31, 2014.
(k)
Intangible
assets
Intangible assets are amortized on a straight line basis over their
estimated useful life.
(l)
Cash
and cash equivalents
Cash and cash equivalents include cash and highly liquid
investments with initial maturities of three months or less and are
stated at cost, which approximates market value.
(m)
Short
term investments - available for sale
The Company classifies short-term investments as available for sale
in accordance with the terms of FASB ASC 320,
Investments – Debt and Equity Securities. Realized
gains and losses are determined using specific identification. The
investments are reported at fair value, with unrealized gains or
losses reported in a separate component of shareholders' equity.
Any differences between the cost and fair value of the investments
are represented by accrued interest and unrealized
gains/losses.
(n)
Inventory
Inventory is valued at the lower of cost and market value and after
provisions for obsolescence. The cost of inventories comprises the
purchase price and attributable costs, less trade discounts. At
December 31, 2016 the carrying value of inventory, included within
prepayments and other current assets on the balance sheet, was $2.4
million (2015: $1.8 million).
(o)
Property,
plant and equipment
Property, plant and equipment is stated at cost less accumulated
depreciation. Depreciation of property, plant and equipment is
computed using the straight line method based on the estimated
useful lives of the assets as listed below:
Leasehold improvements are amortized using the straight-line method
over the estimated useful life of the asset or the lease term,
whichever is shorter.
(p)
Leased
assets
Costs in respect of operating leases are charged to the statement
of operations on a straight line basis over the lease term.
Assets acquired under capital finance leases are included in the
balance sheet at the present value of the future minimum lease
payments and are depreciated over the shorter of the lease term and
their remaining useful lives. The corresponding liabilities are
recorded in the balance sheet and the interest element of the
capital lease rental is charged to interest expense.
(q)
Income
taxes
The Company applies the asset and liability method of accounting
for income taxes. Under the asset and liability method, deferred
tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and
their respective tax bases and operating loss and tax credit
carryforwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the
years in which these temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the
period that includes the enactment date. The Company recognizes the
effect of income tax positions only if those positions will more
likely than not be sustained. Recognized income tax positions are
measured at the largest amount of tax benefit that is greater than
50 percent likely of being realized upon settlement. Interest and
penalties related to income taxes are included in income tax
expense and classified with the related liability on the
consolidated balance sheet.
On November 21, 2015 FASB issued ASU 2015-17 on the balance sheet
classification of deferred taxes. The new standard requires that
all deferred taxes are presented as non-current in a classified
Statement of Financial Position. The new guidance is effective for
public business entities for annual periods beginning after
December 15, 2016 and for non-public business entities for annual
periods beginning after December 15, 2017. Early adoption is
available for all entities for any set of financial statements that
had not been released as at November 21, 2015 with an option to
apply on either a prospective or a retrospective basis. The Company
elected for early adoption of ASU 2015 – 17 on a prospective
basis for all financial statements issued after November 21, 2015.
The effect of this is that all deferred tax assets and liabilities
are classified as non-current assets and liabilities in the
December 31, 2016 and December 31, 2015 balance sheets.
(r)
Government
grants
Government grants received relating to capital expenditures are
shown as deferred income and credited to income on a basis
consistent with the depreciation policy of the relevant assets.
Grants relating to categories of operating expenditures are
credited to income in the period in which the expenditure to which
they relate is charged.
Under the grant agreements amounts received may become repayable in
full should certain circumstances specified within the grant
agreements occur, including downsizing by the Company, disposing of
the related assets, ceasing to carry on its business or the
appointment of a receiver over any of its assets. The Company has
not recognized any loss contingency having assessed as remote the
likelihood of these events arising.
(s)
Research
and development credits
Research and development credits are available to the Company under
the tax laws in certain jurisdictions, based on qualifying research
and development spend as defined under those tax laws. Research and
development credits are generally recognized as a reduction of
income tax expense. However, certain tax jurisdictions provide
refundable credits that are not wholly dependent on the Company's
ongoing income tax status or income tax position. In these
circumstances the benefit of these credits is not recorded as a
reduction to income tax expense, but rather as a reduction of
operating expenditure.
(t)
Pension
costs
The Company contributes to defined contribution plans covering all
eligible employees. The Company contributes to these plans based
upon various fixed percentages of employee compensation and such
contributions are expensed as incurred.
The Company operates, through a subsidiary, a defined benefit plan
for certain of its United Kingdom and Swiss employees. The Company
accounts for the costs of these plans using actuarial models
required by FASB ASC 715-30 and these plans are presented in
accordance with the requirements of FASB ASC 715-60
Defined Benefit Plans – Other Post retirement.
(u)
Net
income per ordinary share
Basic net income per ordinary share has been computed by dividing
net income available to ordinary shareholders by the weighted
average number of ordinary shares outstanding during the period.
Diluted net income per ordinary share is computed by adjusting the
weighted average number of ordinary shares outstanding during the
period for all potentially dilutive ordinary shares outstanding
during the period and adjusting net income for any changes in
income or loss that would result from the conversion of such
potential ordinary shares.
There is no difference in net income used for basic and diluted net
income per ordinary share. The reconciliation of the number of
shares used in the computation of basic and diluted net income per
ordinary share is as follows:
(v)
Share-based
compensation
The Company accounts for its share options, restricted share units
("RSUs") and performance share units ("PSUs") in accordance with
the provisions of FASB ASC 718,
Compensation – Stock Compensation. Share-based
compensation expense for equity-settled awards made to employees
and Directors is measured and recognized based on estimated grant
date fair values. These equity-settled awards include employee
share options, RSUs and PSUs.
Share-based compensation expense for share options awarded to
employees and Directors is estimated at the grant date based on
each option's fair value as calculated using the Black-Scholes
option-pricing model. Share-based compensation for RSUs and PSUs
awarded to employees and Directors is calculated based on the
market value of the Company's shares on the date of award of the
RSUs and PSUs. The value of awards expected to vest is recognized
as an expense over the requisite service periods. Forfeitures are
estimated on the date of grant and revised if actual or expected
forfeiture activity differs materially from original
estimates.
Estimating the grant date fair value of share options as of the
grant date using an option-pricing model, such as the Black-Scholes
model, is affected by the Company's share price as well as
assumptions regarding a number of complex variables. These
variables include, but are not limited to, the expected share price
volatility over the term of the awards, risk-free interest rates
and the expected term of the awards.
(w)
Impairment
of long-lived assets
Long-lived assets are reviewed for impairment whenever events or
changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. Recoverability of assets to be held
and used is measured by a comparison of the carrying amount of the
asset to future undiscounted net cash flows expected to be
generated by the asset. If such assets are considered to be
impaired, the impairment to be recognized is measured at the amount
by which the carrying amount of the asset exceeds the fair value of
the asset. Assets to be disposed of are reported at the lower of
the carrying amount of the asset or fair value less selling
costs.
(x)
Derivative
financial instruments
We enter into transactions in the normal course of business using
various financial instruments in order to hedge against exposure to
fluctuating exchange and interest rates. We use derivative
financial instruments to reduce exposure to fluctuations in
interest rates. A derivative is a financial instrument or other
contract whose value changes in response to some underlying
variable, which has an initial net investment smaller than would be
required for other instruments that have a similar response to the
variable and that will be settled at a future date. We do not enter
into derivative financial instruments for trading or speculative
purposes. We did not hold any interest rate swap contracts or
forward currency contracts at December 31, 2016, December 31, 2015
or December 31, 2014.
Our accounting policies for derivative financial instruments are
based on whether they meet the criteria for designation as cash
flow or fair value hedges. A designated hedge of the exposure to
variability in the future cash flows of an asset or a liability, or
of a forecasted transaction, is referred to as a cash flow hedge. A
designated hedge of the exposure to changes in fair value of an
asset or a liability is referred to as a fair value hedge. The
criterion for designating a derivative as a hedge includes the
assessment of the instrument's effectiveness in risk reduction,
matching of the derivative instrument to its underlying transaction
and the probability that the underlying transaction will occur. For
derivatives with cash flow hedge accounting designation, we report
the gain or loss from the effective portion of the hedge as a
component of Other Comprehensive Income and reclassify it into
earnings in the same period or periods in which the hedged
transaction affects earnings and within the same income statement
line item as the impact of the hedged transaction. For derivatives
with fair value hedge accounting designation, we recognize gains or
losses from the change in fair value of these derivatives, as well
as the offsetting change in the fair value of the underlying hedged
item, in earnings. Fair value gains and losses arising on
derivative financial instruments not qualifying for hedge
accounting are reported in our Consolidated Statement of
Operations.
(y)
Financing
costs and gain on interest rate hedge
The interest rate in respect of the Senior Notes is fixed at 3.64%
for the five year term of the agreement. The associated interest
cost is recognized in interest expense in the period since drawdown
in December 2015.
On October 5, 2015, the Company entered into an interest rate hedge
in respect of the planned issuance of the Senior Notes in December
2015. The interest rate hedge matured on November 17, 2015 when the
interest rate on the Senior Notes was fixed. The interest rate
hedge was effective in accordance with Financial Accounting
Standards Board ("FASB") ASC 815, "Derivatives and Hedging". The
cash proceeds ($4.6 million), representing the realized gain on the
interest rate hedge, were received on maturity in November 2015 and
are recorded within Other Comprehensive Income. The realized gain
will be amortized to the income statement, net against interest
payable, over the period of the Senior Notes.
Deferred financing costs (including issue costs relating to the
Senior Notes) are reported at cost less accumulated amortization
and the related amortization expense is included in interest
expense, in our consolidated statement of income.
(z)
Reclassifications
Certain amounts in the consolidated financial statements have been
reclassified where necessary to conform to the current year
presentation.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for all significant accounting policies of the reporting entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Short term investments - available for sale |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Short term investments - available for sale |
3. Short term investments - available for sale
The Company classifies its short term investments as available for
sale. Short term investments comprise highly liquid investments
with maturities of greater than three months and minimum "A-" rated
fixed and floating rate securities. Short term investments at
December 31, 2016 have an average maturity of 1.37 years compared
to 1.35 years at December 31, 2015. The investments are reported at
fair value with unrealized gains or losses reported in a separate
component of shareholders' equity. Any differences between the cost
and fair value of investments are represented by accrued interest
and unrealized gains/losses. The fair value of short term
investments are represented by level 1 fair value measurements
– quoted prices in active markets for identical assets.
The following table represents our available for sale short term
investments by major security type as of December 31, 2016:
The company recognizes the unrealized losses in fair value in
equity as these unrealized losses on short term investments have
been considered as temporary.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Available For Sale Securities Disclosure No definition available.
|
Goodwill |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
4. Goodwill
The Company has made a number of strategic acquisitions since
inception to enhance its capabilities and experience in certain
areas of the clinical development process. Goodwill arising on
acquisition represents the excess of the cost of acquired entities
over the net amounts assigned to assets acquired and liabilities
assumed. Goodwill primarily comprises of the acquired workforce in
place which does not qualify for recognition as an asset apart from
goodwill.
The Company acquired ClinicalRM during the year-ended December 31,
2016 resulting in the recognition of goodwill of $34.6 million
(note 4(a)).
The Company tests goodwill annually for impairment or whenever
events occur which may indicate impairment. The results of the
Company's goodwill impairment testing (assessed at September 30,
2016) during the year ended December 31, 2016 provided no evidence
of impairment and indicated the existence of sufficient headroom
such that a reasonably possible change to the key assumptions used
would be unlikely to result in an impairment of the related
goodwill.
On September 15, 2016, a subsidiary of the Company, ICON US
Holdings Inc. acquired Clinical Research Management, Inc.
("ClinicalRM") which resulted in initial net cash outflows of $52.4
million (including certain payments made on behalf of ClinicalRM
totaling $9.2 million). ClinicalRM is a full-service CRO
specializing in preclinical through Phase IV support of clinical
research and clinical trial services for biologics, drugs and
devices. The organization helps customers progress their products
to market faster with a wide array of research, regulatory and
sponsor services within the U.S. and around the globe. ClinicalRM
provide full service and functional research solutions to a broad
range of US government agencies. Their extensive expertise extends
across basic and applied research, infectious diseases, vaccines
development, testing and the response to bio-threats. They have
worked in collaboration with government and commercial customers to
respond to the threat of global viral epidemics. Further
consideration of up to $12.0 million is payable if certain
performance milestones are achieved in respect of periods up to
December 31, 2017. The fair value of the deferred consideration on
acquisition has been estimated as $6 million.
The acquisition of ClinicalRM has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The Company has made a provisional
assessment of the fair value of assets acquired and liabilities
assumed as at that date. The table following summarizes the
Company's provisional estimates of the fair values of the assets
acquired and liabilities assumed:
*Goodwill represents the acquisition of an established
workforce with experience in preclinical through Phase IV support
of clinical research and clinical trial services for biologics,
drugs and devices. Goodwill related to the US portion of the
business acquired is tax deductible.
**The Company has made an initial estimate of separate intangible
assets (comprised of customer relationships and order book)
acquired of $8.6 million. This assessment is under review and will
be finalized within 12 months of the date of acquisition.
The proforma effect of the ClinicalRM acquisition if completed on
January 1, 2015 would have resulted in net revenue, net income and
earnings per share for the fiscal years ended December 31, 2016 and
December 31, 2015 as follows:
(b) Acquisition of PMG
On December 4, 2015, a subsidiary of the Company, ICON Clinical
Research LLC. acquired PMG for cash consideration of $53.7 million.
The Company also made certain payments on behalf of PMG totaling
$10.1 million. PMG is an integrated network of 48 clinical research
sites in North Carolina, South Carolina, Tennessee and Illinois.
The site network includes wholly owned facilities and dedicated
clinical research sites. PMG conducts clinical trials in all major
therapeutic areas and has particular expertise in vaccine,
gastroenterology, cardiovascular, neurology and endocrinology
studies. It has a proprietary database of clinical trial
participants. It also has access to in excess of 2 million active
patients via electronic medical records through its partnerships
with health care institutions and community physical practices. The
acquisition agreement provides for working capital targets to be
achieved by PMG.
The acquisition of PMG has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The table following summarizes the
fair values of the assets acquired and liabilities assumed;
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. In finalizing the goodwill on
acquisition of PMG in the twelve month period from acquisition,
fair value adjustments were made to deferred tax liabilities ($3.1
million), accounts receivable acquired ($1.4 million), other
liabilities ($1.2 million) and the value of the customer list and
order backlog assets acquired ($0.4 million). Additional
consideration of $1.6 million was provided on completion of the
contractual working capital process.
The proforma effect of the PMG acquisition if completed on January
1, 2014 would have resulted in net revenue, net income and earnings
per share for the fiscal years ended December 31, 2015 and December
31, 2014 as follows:
(c) Acquisition of MediMedia Pharma
Solutions
On February 27, 2015, a subsidary of the Company, ICON Holdings
Unlimited Company (formerly ICON Holdings), acquired MediMedia
Pharma Solutions for cash consideration of $104.8 million (net of
working capital adjustments of $3.9 million). In addition to the
cash consideration, certain payments were made on behalf of
MediMedia Pharma Solutions on completion totaling $11.3 million.
Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions
includes MediMedia Managed Markets and Complete Healthcare
Communications. MediMedia Managed Markets is a leading provider of
strategic payer-validated market access solutions. Complete
Healthcare Communications is one of the leading medical and
scientific communication agencies working with medical affairs,
commercial and brand development teams within life science
companies. The acquisition agreement provides for certain working
capital targets to be achieved by MediMedia Pharma Solutions.
The acquisition of MediMedia Pharma Solutions has been accounted
for as a business combination in accordance with FASB ASC 805
Business Combinations. The following table summarizes the
fair values of the assets acquired and liabilities assumed:
The proforma effect of the MediMedia Pharma Solutions acquisition
if completed on January 1, 2014 would have resulted in net revenue,
net income and earnings per share for the fiscal years ended
December 31, 2015 and December 31, 2014 as follows:
(d) Acquisitions of Aptiv Solutions
On May 7, 2014, a subsidiary of the Company, ICON US Holdings Inc.,
acquired 100% of the common stock of Aptiv Solutions, Inc.
("Aptiv"), a global biopharmaceutical and medical device
development services company and leader in adaptive clinical trials
for cash consideration of $143.5 million, including certain
payments to be made on behalf of the Company on completion totaling
$22.4 million. The acquisition agreement provided for working
capital targets to be achieved. On March 25, 2015, the Company
received $1.9 million in respect of these targets on completion of
the working capital review. Aptiv offers full-service clinical
trial consulting and regulatory support for drugs, medical devices
and diagnostics with a specific focus on strategies to increase
product development efficiency and productivity. It is a market
leader in the integrated design and execution of adaptive clinical
trials for exploratory and late phase development as well as being
an industry leader in medical device and diagnostic development in
key medical technology segments.
The acquisition of Aptiv has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The following table summarizes the
fair values of the assets acquired and the liabilities
assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. Goodwill related to the US
portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time
liabilities (including loan notes) identified at the acquisition
date which have subsequently been paid.
The proforma effect of the Aptiv Solutions acquisition if completed
on January 1, 2013 would have resulted in net revenue, net income
and earnings per share for the fiscal years ended December 31, 2013
and December 31, 2014 as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for goodwill. No definition available.
|
Intangible Assets |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets |
5. Intangible Assets
On September 15, 2016, a subsidiary of the Company, ICON US
Holdings Inc., acquired ClinicalRM, a full-service CRO specializing
in preclinical through Phase IV support of clinical research and
clinical trial services for biologics, drugs and devices. The
organization helps customers progress their products to market
faster with a wide array of research, regulatory and sponsor
services within the U.S. and around the globe. ClinicalRM provide
full service and functional research solutions to a broad range of
US government agencies. The value of intangible assets have been
provisionally identified of $8.6 million is being amortized over
approximately 6 years, the estimated period of benefit. In total,
$0.9 million has been amortized in the period since the date of
acquisition.
On December 4, 2015, a subsidiary of the Company, ICON Clinical
Research LLC, acquired PMG, an integrated network of 48 clinical
research sites in North Carolina, South Carolina, Tennessee and
Illinois. The site network includes wholly owned facilities and
dedicated clinical research sites. PMG conducts clinical trials in
all major therapeutic areas and has particular expertise in
vaccine, gastroenterology, cardiovascular, neurology and
endocrinology studies. The value of certain customer relationship
and order backlog assets identified of $6.9 million and $3.0
million respectively are being amortized over approximately 7 years
and 2 years respectively, the estimated period of benefit. In
total, $2.7 million has been amortized in the period since the date
of acquisition.
On February 27, 2015, a subsidiary
of the Company, ICON Holdings Unlimited Company (formerly ICON
Holdings), acquired MediMedia Pharma Solutions. Headquartered in
Yardley, Pennsylvania, MediMedia Pharma Solutions includes
MediMedia Managed Markets and Complete Healthcare Communications.
MediMedia Managed Markets is a leading provider of strategic
payer-validated market access solutions. Complete Healthcare
Communications is one of the leading medical and scientific
communication agencies working with medical affairs, commercial and
brand development teams within life science companies. The value of
certain customer relationships and order backlog identified of
$22.8 million and $2.5 million respectively are being amortized
over approximately 7 years and 1 year, the estimated period of
benefit. $8.5 million has been amortized in the period since the
date of acquisition. The order backlog is fully amortized at
December 31, 2016.
On May 7, 2014, a subsidiary of the Company, ICON US Holdings Inc.,
acquired Aptiv Solutions, Inc. ("Aptiv"), a global
biopharmaceutical and medical device development services company
and leader in adaptive clinical trials. Aptiv offers full-service
clinical trial consulting and regulatory support for drugs, medical
devices and diagnostics with a specific focus on strategy to
increase product development efficiency and productivity. The value
of certain customer relationships and order backlog identified of
$21.4 million and $7.9 million respectively are being amortized
over approximately 7 years and 3 years, the estimated period of
benefit. In total, $15.2 million has been amortized in the period
since the date of acquisition.
On February 15, 2013, subsidiaries of the Company, ICON Clinical
Research LLC (formerly ICON Clinical Research, Inc.) and ICON
Clinical Research (U.K.) Limited, acquired the Clinical Trial
Services division of Cross Country Healthcare, Inc. Cross Country
Healthcare's Clinical Trial Services division includes US
resourcing providers, ClinForce and Assent Consulting, whose
services include contract staffing, permanent placement and
functional service provision ("FSP"). The value of certain customer
relationships and order backlog identified of $3.3 million and $0.6
million respectively are being amortized over approximately 3 years
and 1 year, the estimated period of benefit. The full $3.9 million
has been amortized in the period since the date of
acquisition.
On February 28, 2012, a subsidiary of the Company, ICON Clinical
Research LLC (formerly ICON Clinical Research, Inc.), acquired
PriceSpective, a strategy consulting company. The value of certain
customer relationships identified of $10.2 million is being
amortized over approximately 10 years, the estimated period of
benefit. The value of order backlog and certain non-compete
arrangements identified of $0.4 million and $0.4 million
respectively are being amortized over approximately 0.8 year and 3
years, the estimated period of benefit. In total, $5.7 million has
been amortized in the period since the date of acquisition.
On February 15, 2012, a subsidiary of the Company, ICON Clinical
Research Limited, acquired BeijingWits Medical, a Chinese CRO. The
value of certain customer relationships and order backlog
identified of $1.8 million and $0.4 million respectively are being
amortized over approximately 10 years and 4 years, the estimated
period of benefit. The value of certain non-compete arrangements
identified of $0.01 million are being amortized over approximately
5 years, the estimated period of benefit. In total, $1.3 million
has been amortized in the period since the date of
acquisition.
On July 14, 2011, a subsidiary of the Company, ICON Clinical
Research Limited, acquired Firecrest Clinical Limited, a provider
of technology solutions that boost investigator site performance
and study management. The value of certain technology assets and
customer relationships identified of $11.2 million and $5.2 million
respectively are being amortized over approximately 7.5 years, the
estimated period of benefit. The value of the Firecrest trade name
and order backlog identified of $1.4 million and $1.2 million
respectively are being amortized over approximately 4.5 years and
1.2 years, the estimated period of benefit. In total, $12.8 million
has been amortized in the period since the date of
acquisition.
On January 14, 2011, a subsidiary of the Company, ICON Clinical
Research (U.K.) Limited, acquired Oxford Outcomes Limited, an
international health outcomes consultancy business. The value of
certain customer relationships and order backlog identified of $6.6
million and $0.6 million respectively are being amortized over
approximately 6.5 years and 2 years, the estimated period of
benefit. In total, $6.7 million has been amortized in the period
since the date of acquisition.
On November 14, 2008, subsidiaries of the Company, ICON Holdings
Clinical Research International Limited and ICON Clinical Research
LLC (formerly ICON Clinical Research, Inc.), acquired Prevalere
Life Sciences, a US provider of
bioanalytical and immunoassay laboratory services. The value
of certain customer relationships identified of $7.4 million is
being amortized over periods ranging from approximately 7 to 11
years, the estimated period of the benefit. In total, $6.4 million
has been amortized in the period since the date of
acquisition.
On February 11, 2008, a subsidiary of the Company, ICON Clinical
Research LLC (formerly ICON Clinical Research, Inc.), acquired
Healthcare Discoveries, a US provider of Phase I clinical trial
services. The value of certain client relationships identified of
$1.6 million is being amortized over periods ranging from
approximately 2 to 9 years, the estimated periods of benefit. The
value of certain volunteer lists identified of $1.3 million is
being amortized over approximately 6 years, the estimated period of
benefit. The full $2.9 million has been amortized in the period
since the date of acquisition.
Future intangible asset amortization expense for the years
ended December 31, 2017 to December 31, 2021 is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for all or part of the information related to intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Property, Plant and Equipment, net |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment, net |
6. Property, Plant and Equipment, net
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Other Liabilities |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities |
7. Other Liabilities
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for other liabilities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Other Non-Current Liabilities |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Non-Current Liabilities |
8. Other Non-Current Liabilities
*An amount of $6.0 million is included within other non-current
liabilities in respect of contingent consideration for the
acquisition of ClinicalRM. See note 4 (a).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period. No definition available.
|
Employee Benefits |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Employee Benefits |
9. Employee Benefits
Certain Company employees are eligible to participate in a defined
contribution plan (the "Plan"). Participants in the Plan may elect
to defer a portion of their pre-tax earnings into a pension plan,
which is run by an independent party. The Company matches
participant's contributions typically at 6% of the participant's
annual compensation. Contributions to the plan are recorded as an
expense in the Consolidated Statement of Operations. Contributions
for the years ended December 31, 2014, December 31, 2015 and
December 31, 2016 were $22,370,000, $20,439,000 and $20,952,000
respectively.
The Company's United States operations maintain a retirement plan
(the "U.S. Plan") that qualifies as a deferred salary arrangement
under Section 401(k) of the Internal Revenue Code. Participants in
the U.S. Plan may elect to defer a portion of their pre-tax
earnings, up to the Internal Revenue Service annual contribution
limit. The Company matches 50% of each participant's contributions;
each participant can contribute up to 6% of their annual
compensation. Contributions to this U.S. Plan are recorded, in the
year contributed, as an expense in the Consolidated Statement of
Operations. Contributions for the years ended December 31, 2014,
December 31, 2015 and December 31, 2016 were $10,514,000,
$12,802,000 and $15,223,000 respectively.
One of the Company's subsidiaries, ICON Development Solutions
Limited, operates a defined benefit pension plan in the United
Kingdom for its employees. The plan is managed externally and the
related pension costs and liabilities are assessed in accordance
with the advice of a professionally qualified actuary. Plan assets
at December 31, 2016, December 31, 2015 and December 31, 2014,
consist of units held in independently administered funds. The
pension costs of this plan are presented in the following tables in
accordance with the requirements of ASC 715-60,
Defined Benefit Plans – Other Postretirement. The plan
has been closed to new entrants with effect from July 1,
2003.
The fair values of the assets above do not
include any of the Company's own financial instruments, property
occupied by, or other assets used by, the Company.
The following assumptions were used at the commencement of the year
in determining the net periodic pension benefit cost for the years
ended December 31, 2014, December 31, 2015 and December 31,
2016:
The estimated net loss and prior service cost for the defined
benefit pension plan that will be amortized from accumulated other
comprehensive income into net periodic benefit cost over the next
year are $0.2 million and $Nil respectively.
Amounts recognized in accumulated other comprehensive income that
have not yet been recognized as components of net periodic benefit
cost are as follows:
Benefit Obligation
The following assumptions were used in determining the benefit
obligation at December 31, 2016 and December 31, 2015:
The discount rate is determined by reference to UK long dated
government and corporate bond yields at the balance sheet date.
This is represented by the iboxx corporate bond over 15 year index
plus 10 basis points.
Plan Assets
The assets of the scheme are invested with Legal and General and
held in a combination of the Active Corporate Bond over 10 Year
fund, Gilt and Index Linked Gilt funds. The overall investment
strategy is that approximately 75% of investments are in government
bonds (both fixed interest and index linked) and approximately 25%
of investments are held in corporate bonds. There is no
self-investment in employer related assets. The expected long-term
rate of return on assets at December 31, 2016 of 2.1% was
calculated as the value of the fund after application of a market
value reduction factor. The expected long term rates of return on
different asset classes are as follows:
The long-term expected return on corporate bonds and gilts (fixed
interest and index linked) is determined by reference to bond
yields and gilt yields at the balance sheet date.
The underlying asset split of the fund is shown below.
Applying the above expected long term
rates of return to the asset distribution at December 31, 2016,
gives rise to an expected overall rate of return of scheme assets
of approximately 2.1% per annum.
Plan Asset Fair Value Measurements
Cash Flows
The Company expects to contribute $0.1 million to the pension fund
in the year ending December 31, 2017.
The following annual benefit payments, which reflect expected
future service as appropriate, are expected to be paid.
The expected cash flows are estimated figures based on the members
expected to retire over the next 10 years assuming no early
retirements plus an additional amount based on recent average
withdrawal experience. At the present time it is not clear whether
annuities will be purchased when members reach retirement or
whether pensions will be paid each month out of scheme assets. The
cash flows above have been estimated on the assumption that
pensions will be paid monthly out of scheme assets. If annuities
are purchased, then the expected benefit payments will be
significantly different from those shown above.
On May 7, 2014 the Company acquired 100% of the common stock of
Aptiv Solutions ("Aptiv"). The acquisition of Aptiv was accounted
for as a business combination in accordance with FASB ASC 805
Business Combinations. The Company has a defined benefit
plan covering its employees in Switzerland as mandated by the Swiss
government. Benefits are based on the employee's years of service
and compensation. Benefits are paid directly by the Company when
they become due, in conformity with the funding requirements of
applicable government regulations. The plan is managed externally
and the related pension costs and liabilities are assessed in
accordance with the advice of a professionally qualified actuary.
Plan assets at December 31, 2016 and December 31, 2015 consist of
units held in independently administered funds. The pension costs
of this plan are presented in the following tables in accordance
with the requirements of ASC 715-60,
Defined Benefit Plans – Other Postretirement.
The fair values of the assets above do not include any of the
Company's own financial instruments, property occupied by, or other
assets used by, the Company.
The following assumptions were used at the commencement of the year
in determining the net periodic pension benefit cost for the years
ended December 31, 2016 and December 31, 2015:
The estimated net loss and prior service cost for the defined
benefit pension plan that will be amortized from accumulated other
comprehensive income into net periodic benefit cost over the next
year are $41,000 and $8,000 respectively.
Amounts recognized in accumulated other comprehensive income that
have not yet been recognized as components of net periodic benefit
cost are as follows:
Benefit Obligation
The following assumptions were used in determining the benefit
obligation at December 31, 2016 and December 31, 2015:
The discount rate is determined by reference to Swiss corporate
bond yields at the balance sheet date.
Plan Assets
The assets of the scheme are invested in an insured plan with Swiss
Life and held in a combination of debt securities, equity
securities and in real estate. There is no self-investment in
employer related assets.
Cash Flows
The Company expects to contribute $0.2 million to its pension fund
in the year ending December 31, 2017.
The following annual benefit payments, which reflect expected
future service as appropriate, are expected to be paid.
The expected cash flows are estimated figures based on the members
expected to retire over the next 10 years assuming no early
retirements plus an additional amount based on recent average
withdrawal experience. At the present time it is not clear whether
annuities will be purchased when members reach retirement or
whether pensions will be paid each month out of scheme assets. The
cash flows above have been estimated on the assumption that
pensions will be paid monthly out of scheme assets. If annuities
are purchased, then the expected benefit payments will be
significantly different from those shown above.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for pension and other postretirement benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Equity Incentive Schemes and Stock Compensation Charges |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Incentive Schemes and Stock Compensation Charges |
10. Equity Incentive Schemes and Stock Compensation Charges
Share Options
On July 21, 2008 the Company adopted the Employee Share Option Plan
2008 (the "2008 Employee Plan") pursuant to which the Compensation
and Organization Committee of the Company's Board of Directors may
grant options to any employee, or any Director holding a salaried
office or employment with the Company or a Subsidiary for the
purchase of ordinary shares. On the same date, the Company also
adopted the Consultants Share Option Plan 2008 (the "2008
Consultants Plan"), pursuant to which the Compensation and
Organization Committee of the Company's Board of Directors may
grant options to any consultant, adviser or non-executive Director
retained by the Company or any Subsidiary for the purchase of
ordinary shares.
On February 14, 2017 both the 2008 Employee Plan and the 2008
Consultants Plan (together the "2008 Option Plans") were amended
and restated in order to increase the number of options that can be
issued under the 2008 Consultants Plan from 400,000 to 1 million
and to extend the date for options to be granted under the 2008
Option Plans.
An aggregate of 6.0 million ordinary shares have been reserved
under the 2008 Employee Plan, as reduced by any shares issued or to
be issued pursuant to options granted under the 2008 Consultants
Plan, under which a limit of 1 million shares applies. Further, the
maximum number of ordinary shares with respect to which options may
be granted under the 2008 Employee Option Plan, during any calendar
year to any employee shall be 400,000 ordinary shares. There is no
individual limit under the 2008 Consultants Plan. No options may be
granted under the 2008 Option Plans after February 14, 2027.
Each option granted under the 2008 Option Plans will be an employee
stock option, or NSO, as described in Section 422 or 423 of the
Internal Revenue Code. Each grant of an option under the 2008
Options Plans will be evidenced by a Stock Option Agreement between
the optionee and the Company. The exercise price will be specified
in each Stock Option Agreement, however option prices will not be
less than 100% of the fair market value of an ordinary share on the
date the option is granted.
On January 17, 2003 the Company adopted the Share Option Plan 2003
(the "2003 Share Option Plan") pursuant to which the Compensation
and Organization Committee of the Board could grant options to
officers and other employees of the Company or its subsidiaries for
the purchase of ordinary shares. An aggregate of 6.0 million
ordinary shares were reserved under the 2003 Share Option Plan; and
in no event could the number of ordinary shares issued pursuant to
options awarded under this plan exceed 10% of the outstanding
shares, as defined in the 2003 Share Option Plan, at the time of
the grant, unless the Board expressly determined otherwise.
Further, the maximum number of ordinary shares with respect to
which options could be granted under the 2003 Share Option Plan
during any calendar year to any employee was 400,000 ordinary
shares. The 2003 Share Option Plan expired on January 17, 2013. No
new options may be granted under this plan.
Share option awards are granted with an exercise price equal to the
market price of the Company's shares at date of grant. Share
options typically vest over a period of five years from date of
grant and expire eight years from date of grant. The maximum
contractual term of options outstanding at December 31, 2016 is
eight years.
The following table summarizes the transactions for the Company's
share option plans for the years ended December 31, 2016, December
31, 2015 and December 31, 2014:
The weighted average remaining contractual life of options
outstanding and options exercisable at December 31, 2016, was 4.67
years and 3.30 years respectively (2015: 4.76 years and 3.39 years
respectively). 333,433 options are expected to vest during the year
ended December 31, 2017 (336,993 options were expected to vest
during the year ended December 31, 2016).
The intrinsic value of options exercised during the year ended
December 31, 2016 amounted to $19.6 million. The intrinsic value of
options outstanding and options exercisable at December 31, 2016
amounted to $46.6 million and $29.6 million respectively. Intrinsic
value is calculated based on the market value versus strike price
of the Company's shares at the date of exercise.
Non-vested shares outstanding as at December 31, 2016 are as
follows:
Outstanding and exercisable share options:
The following table summarizes information concerning outstanding
and exercisable share options as of December 31, 2016:
Options outstanding include both vested and unvested options as at
December 31, 2016. Options exercisable represent options which have
vested at December 31, 2016. From the date of grant, substantially
all options vest over a five year period at 20% per annum.
Fair value of Stock Options
Assumptions
The weighted average fair value of options granted during the years
ended December 31, 2016, December 31, 2015 and December 31, 2014
was calculated using the Black-Scholes option pricing model. The
weighted average fair values and assumptions were as follows:
Expected volatility is based on the historical volatility of our
common stock over a period equal to the expected term of the
options; the expected life represents the weighted average period
of time that options granted are expected to be outstanding given
consideration to vesting schedules and our historical experience of
past vesting and termination patterns. The risk-free rate is based
on the U.S. government zero-coupon bonds yield curve in effect at
time of the grant for periods corresponding with the expected life
of the option.
Restricted Share Units and Performance Share Units
On July 21, 2008 the Company adopted the 2008 Employees Restricted
Share Unit Plan (the "2008 RSU Plan") pursuant to which the
Compensation and Organization Committee of the Company's Board of
Directors may select any employee, or any Director holding a
salaried office or employment with the Company, or a Subsidiary to
receive an award under the plan. An aggregate of 1.0 million
ordinary shares have been reserved for issuance under the 2008 RSU
Plan.
On April 23, 2013 the Company adopted the 2013 Employees Restricted
Share Unit and Performance Share Unit Plan (the "2013 RSU Plan")
pursuant to which the Compensation and Organization Committee of
the Company's Board of Directors may select any employee, or any
Director holding a salaried office or employment with the Company,
or a Subsidiary to receive an award under the plan. On May 11, 2015
the 2013 RSU Plan was amended and restated in order to increase the
number of shares that can be issued under the RSU Plan by 2.5
million shares. Accordingly, an aggregate of 4.1 million ordinary
shares have been reserved for issuance under the 2013 RSU Plan. The
shares are awarded at par value and vest over a service period.
Awards under the 2013 RSU Plan may be settled in cash or shares at
the option of the Company.
The Company has awarded RSUs and PSUs to certain key individuals of
the Group. The following table summarizes RSU and PSU activity for
the year ended December 31, 2016:
The fair value of RSUs vested for the year ended December 31, 2016
totaled $10.8 million (2015: $7.0 million).
The fair value of PSUs vested for the year ended December 31, 2016
totaled $10.3 million (2015: $0.3 million).
The PSUs vest based on service and specified EPS targets over the
period 2013 – 2016, 2014 – 2017, 2015 – 2018 and
2016 - 2019. Since 2013, 421,079 PSUs (net of forfeitures) have
been granted. Depending on the actual amount of EPS from 2013 to
2019, up to an additional 409,444 PSUs may also be granted.
Non-cash stock compensation expense
Income from operations for the year ended December 31, 2016 is
stated after charging $40.3 million in respect of non-cash stock
compensation expense. Non-cash stock compensation expense has been
allocated as follows:
Total non-cash stock compensation expense not yet recognized at
December 31, 2016 amounted to $64.9 million. The weighted average
period over which this is expected to be recognized is 2.07 years.
Total tax benefit recognized in additional paid in capital related
to the non-cash compensation expense amounted to $4.3 million for
the year ended 31 December 2016 (2015: $1.9 million, 2014: $2.4
million).
The income tax expense for the year ended December 31, 2016
reflects a net income tax benefit of $3.5 million in connection
with stock compensation and the cash tax benefit realized in
connection with stock options exercised during 2016 was $3.4
million. The income tax expense for the year ended 31 December 2015
reflects a net income tax benefit of $1.5 million in connection
with stock compensation and the cash tax benefit realized in
connection with stock options exercised during 2015 was $5.6
million.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Government Grants |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government Grants |
11. Government Grants
Capital grants received may be refundable in full if certain events
occur. Such events, as set out in the related grant agreements,
include sale of the related asset, liquidation of the Company or
failure to comply with other conditions of the grant agreements. No
loss contingency has been recognized as the likelihood of such
events arising has been assessed as remote. Government grants
amortized to the profit and loss account amounted to $44,000 for
the year ended December 31, 2016. A net charge of $53,000 was
recorded in respect of government grants during the year ended
December 31, 2015. As at December 31, 2016 the Company had $0.6
million in restricted retained earnings, pursuant to the terms of
grant agreements.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Government Grants Disclosure No definition available.
|
Share Capital |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 | |||
| Share Capital |
12. Share Capital
Holders of ordinary shares will be entitled to receive such
dividends as may be recommended by the Board of Directors of the
Company and approved by the shareholders and/or such interim
dividends as the Board of Directors of the Company may decide. On
liquidation or a winding up of the Company, the par value of the
ordinary shares will be repaid out of the assets available for
distribution among the holders of the ordinary shares of the
Company. Holders of ordinary shares have no conversion or
redemption rights. On a show of hands, every holder of an ordinary
share present in person or proxy at a general meeting of
shareholders shall have one vote, for each ordinary share held with
no individual having more than one vote.
During the year ended December 31, 2016, 393,240 options were
exercised by employees at an average exercise price of $25.79 per
share for total proceeds of $10.1 million. During the year ended
December 31, 2016, 296,386 ordinary shares were issued in respect
of certain RSUs and 311,492 ordinary shares were issued in respect
of PSUs previously awarded by the Company.
During the year ended December 31, 2015, 773,753 options were
exercised by employees at an average exercise price of $27.13 per
share for total proceeds of $21.0 million. During the year ended
December 31, 2015, 268,870 ordinary shares were issued in respect
of certain RSUs and 7,990 ordinary shares were issued in respect of
PSUs previously awarded by the Company.
During the year ended December 31, 2014, 926,407 options were
exercised by employees at an average exercise price of $24.02 per
share for total proceeds of $22.3 million. During the year ended
December 31, 2014, 233,726 ordinary shares were issued in respect
of certain RSUs previously awarded by the Company.
On October 3, 2016 the Company commenced a previously announced
share buyback program of up to $400 million. The Company can
acquire up to 10% of its outstanding ordinary shares (by way of
redemption), in accordance with Irish law, the United States
securities laws and the Company's constitutional documents through
open market share acquisitions. At December 31, 2016 a total of
1,429,187 ordinary shares were redeemed by the Company under this
buyback program for a total consideration of $110.0 million. All
ordinary shares that were redeemed under the buyback program were
canceled in accordance with the Constitution of the Company and the
nominal value of these shares transferred to a capital redemption
reserve fund as required under Irish Company Law.
On May 1, 2015 the Company commenced a buyback program of up to $60
million under which the Company could acquire its outstanding
ordinary shares (by way of redemption), in accordance with Irish
law, the United States securities laws and the Company's
constitutional documents through open market share acquisitions. A
total of 882,419 ordinary shares were redeemed by the Company under
this buyback program for a total consideration of $57.9 million.
All ordinary shares that were redeemed under the buyback program
were canceled in accordance with the Constitution of the Company
and the nominal value of these shares transferred to a capital
redemption reserve fund as required under Irish Company Law.
On July 31, 2015 the Company commenced a further buyback program of
up to $400 million under which the Company could acquire its
outstanding ordinary shares (by way of redemption), in accordance
with Irish law, the United States securities laws and the Company's
constitutional documents through open market share acquisitions. A
total of 5,316,062 ordinary shares were redeemed by the Company
under this buyback program for a total consideration of $400
million. All ordinary shares that were redeemed under the buyback
program were canceled in accordance with the Constitution of the
Company and the nominal value of these shares transferred to a
capital redemption reserve fund as required under Irish Company
Law. The share buyback program was completed in December 2015, with
a total of 6,198,481 ordinary shares redeemed during the year ended
December 31, 2015 for total consideration of $457.9 million.
During the year ended December 31, 2014 2,640,610 ordinary shares
were repurchased by the Company for a total consideration of $140.0
million. All ordinary shares repurchased by the Company were
canceled and the nominal value of these shares transferred to a
capital redemption reserve fund as required under Irish Company
Law.
Under the repurchase program, a broker purchased the Company's
shares from time to time on the open market or in privately
negotiated transactions in accordance with agreed terms and
limitations. The program was designed to allow share repurchases
during periods when the Company would ordinarily not be permitted
to do so because it may be in possession of material non-public or
price-sensitive information or due to applicable insider trading
laws or self-imposed trading blackout periods. The Company's
instructions to the broker were irrevocable and the trading
decisions in respect of the repurchase program were made
independently of and uninfluenced by the Company. The Company
confirms that on entering the share repurchase plans it had no
material non-public, price-sensitive or inside information
regarding the Company or its securities. Furthermore, the Company
will not enter into additional plans whilst in possession of such
information. The timing and actual number of shares acquired by way
of the redemption will be dependent on market conditions, legal and
regulatory requirements and the other terms and limitations
contained in the program. In addition, acquisitions under the
program may be suspended or discontinued in certain circumstances
in accordance with the agreed terms. Therefore, there can be no
assurance as to the timing or number of shares that may be acquired
under the program.
|
| X | ||||||||||
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Income Taxes |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes |
13. Income Taxes
The Company's United States and Irish based subsidiaries file tax
returns in the United States and Ireland respectively. Other
foreign subsidiaries are taxed separately under the laws of their
respective countries.
The components of income before provision for income taxes are as
follows:
The components of provision for income taxes are as
follows:
Ireland's statutory income tax rate is 12.5%. The Company's
consolidated reported provision for income taxes differed from the
amount that would result from applying the Irish statutory rate as
set forth below;
The tax effects of temporary differences that give rise to
significant portions of deferred tax assets and deferred tax
liabilities are presented below:
In 2015, the Company early adopted the provisions of ASU 2015-17
which requires entities with a classified balance sheet to present
all deferred tax assets and liabilities as noncurrent on the basis
that it is a more useful presentation of the Company's position.
The prior period amounts were not retrospectively adjusted.
At December 31, 2016 Ireland subsidiaries had additional tax credit
carryforwards for income tax purposes that may be carried forward
indefinitely, available for offset against future tax liabilities,
if any, of $3.3 million (2015: $2.9 million).
At December 31, 2016 other non U.S. subsidiaries had operating loss
carryforwards for income tax purposes that may be carried forward
indefinitely, available to offset against future taxable income, if
any, of approximately $70.1 million (2015: $68.6 million). In
addition at December 31, 2016 other non U.S. subsidiaries had tax
credit carryforwards for income tax purposes that may be carried
forward indefinitely, available to offset against future tax
liabilities, if any, of $3.9 million (2015: $3.0 million). At
December 31, 2016 Other non U.S. subsidiaries also had additional
operating loss carry forwards of $3.5 million which are due to
expire between 2017 and 2023.
At December 31, 2016 U.S. subsidiaries had U.S. federal and state
net operating loss ("NOL") carry forwards of approximately $50.6
million and $50.2 million, respectively. These NOLs are available
for offset against future taxable income and expire between 2017
and 2036. Of the $50.6 million U.S. federal NOLs, approximately
$22.8 million is currently available for offset against future U.S.
federal taxable income. Of the $50.6 million U.S. federal NOLs,
approximately $16.1 million would be recorded in additional paid in
capital upon utilization. Of the $50.2 million of state NOLs,
approximately $30.9 million would be recorded in additional paid in
capital upon utilization. The subsidiary's ability to use the U.S.
federal and state NOL carry forwards is limited on an annual basis
due to changes of ownership in 2000, 2010 and 2014, as defined by
Section 382 of the Internal Revenue Code of 1986, as amended. Of
the U.S. federal NOLs, $28.6 million are limited by Section 382. Of
the $28.6 million of losses, the amount available during 2016
totaled $2.9 million. The remaining losses are available as
follows: $12.8 million for the years 2017 – 2019, $7.7
million in 2020-2022, $5.2 million for the years 2023 –
2026.
The expected expiry dates of these
losses are as follows:
In addition US subsidiaries have alternative minimum tax credit
carry forwards of approximately $0.4 million that are available to
reduce future U.S. federal regular income taxes, over an indefinite
period. They also have general business credit carry forwards of
approximately $0.3 million that are available to offset future U.S.
federal income taxes.
The valuation allowance at December 31, 2016 was approximately
$20.3 million. The valuation allowance for deferred tax assets as
of December 31, 2015 and December 31, 2014 was $17.2 million and
$23.1 million respectively. The net change in the total valuation
allowance was an increase of $3.1 million during 2016 and a
decrease of $5.9 million during 2015. Of the total increase of $3.1
million in 2016, $1.2 million resulted in a current year income tax
expense, $2.4 million was acquired and impacted goodwill, and these
were offset by a decrease of $0.5 million recognized in Other
Comprehensive Income. Of the total decrease of $5.9 million in
2015, $4.1 million resulted in a current year income tax benefit
with the remaining decrease of $1.8 million recognized in Other
Comprehensive Income.
The valuation allowances at December 31, 2016 and December 31, 2015
were primarily related to operating losses and tax credits carried
forward that, in the judgment of management, are not more likely
than not to be realized. In assessing the realizability of deferred
tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will not be
realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income during the
periods in which those temporary differences become deductible.
Management considers the scheduled reversal of deferred tax
liabilities and projected future taxable income in making this
assessment. In respect of deferred tax assets not subject to a
valuation allowance, management considers that it is more likely
than not that these deferred tax assets will be realized on the
basis that there will be sufficient reversals of deferred tax
liabilities and taxable income in future periods. During 2015, a UK
subsidiary utilized losses for which a full beginning-of-year
valuation allowance had been retained resulting in a tax benefit of
$3.2 million. During 2016, there were no movements to valuation
allowance that had a material impact on the effective tax
rate.
The Company has not recognized a deferred tax liability for the
undistributed earnings of foreign subsidiaries that arose in 2016
and prior years as the Company considers these earnings to be
indefinitely reinvested. It is not practicable to calculate the
exact unrecognized deferred tax liability, however it is not
expected to be material as Ireland allows a tax credit in respect
of distributions from foreign subsidiaries at the statutory tax
rate in the jurisdiction of the subsidiary so that no material tax
liability would be expected to arise in the event these earnings
were ever remitted. In addition, withholding taxes applicable to
remittances from foreign subsidiaries would not be expected to be
material given Ireland's tax treaty network and the EU parent
subsidiary directive.
A reconciliation
of the beginning and ending amount of total unrecognized tax
benefits is as follows:
The relevant statute of limitations for unrecognized tax benefits
totaling $4.9 million could potentially expire during 2017.
There
was no movement during the year ended 31 December 2016
(2015: $0.8 million) in respect of pre-acquisition tax positions
taken by companies acquired.
Included in the balance of total unrecognized tax benefits at
December 31, 2016 were potential benefits of $26.6 million, which
if recognized, would affect the effective rate on income tax from
continuing operations. The balance of total unrecognized tax
benefits at December 31, 2015 and December 31, 2014 included
potential benefits which, if recognized, would affect the effective
rate of income tax from continuing operations of $28.2 million and
$23.2 million respectively.
Interest and penalties recognized as a net expense during the year
ended December 31, 2016 amounted to $0.1 million (2015: net expense
of $0.9 million, 2014: net benefit of $0.2 million) and are
included within the provision for income taxes. Total accrued
interest and penalties as of December 31, 2016 and December 31,
2015 were $3.3 million and $3.3 million respectively and are
included in closing income taxes payable at those dates.
Our major tax jurisdictions are the United States and Ireland. We
may potentially be subjected to tax audits in both our major
jurisdictions. In the United States tax periods open to audit
include the years ended December 31, 2013, December 31, 2014,
December 31, 2015 and December 31, 2016. In Ireland, tax periods
open to audit include the years ended December 31, 2012, December
31, 2013, December 31, 2014, December 31, 2015 and December 31,
2016. During such audits, local tax authorities may challenge the
positions taken by us in tax returns.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Restructuring and other items |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring and other items |
14. Restructuring and other items
Restructuring and other items recognized during the year ended
December 31, 2016 comprise:
Restructuring Charges
A restructuring charge of $8.2 million was recognized during the
year ended December 31, 2016 under a restructuring plan adopted
following a review by the Company of its operations. The
restructuring plan includes resource rationalizations in certain
areas of the business to improve resource utilization, resulting in
a charge of $6.2 million and office consolidation resulting in the
recognition of an onerous lease obligation of $2.0 million.
Prior Period Restructuring Charges
A restructuring charge of $8.8 million was recognized during the
year ended December 31, 2014. Following the closure of the
Company's European Phase 1 services in 2013, the Company recognized
a charge in 2014 in relation to its Manchester, United Kingdom
facility; $5.6 million in relation to asset impairments and $3.2
million in relation to an onerous lease charge associated with this
facility. We expect this to be paid by 2024.
The total onerous lease obligation at December 31, 2016 is $2.0
million and is included within other liabilities.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Provision for Doubtful Debts |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Provision for Doubtful Debts |
15. Provision for Doubtful Debts
The Company does business with most major international pharmaceutical companies. Provision for doubtful debts at December 31, 2016 comprises:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Allowance For Doubtful Accounts [Text Block] No definition available.
|
Commitments and Contingencies |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Commitments and Contingencies |
16. Commitments and Contingencies
Litigation
The Company is not party to any litigation or other legal
proceedings that the Company believes could reasonably be expected
to have a material adverse effect on the Company's business,
results of operations and financial condition.
Operating Leases
The Company has several non-cancelable operating leases, primarily
for facilities, that expire over the next 10 years. These leases
generally contain renewal options and require the Company to pay
all executory costs such as maintenance and insurance. The Company
recognized $44.0 million, $49.9 million and $54.3 million in rental
expense, including rates, for the years ended December 31, 2016,
December 31, 2015 and December 31, 2014 respectively. Future
minimum rental commitments for operating leases with non-cancelable
terms in excess of one year are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Segment and Geographical Information |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Segment and Geographical Information |
17. Business Segment and Geographical Information
The Company is a contract research organization ("CRO"), providing
outsourced development services on a global basis to the
pharmaceutical, biotechnology and medical device industries. It
specializes in the strategic development, management and analysis
of programs that support all stages of the clinical development
process - from compound selection to Phase I-IV clinical studies.
The Company has the expertise and capability to conduct clinical
trials in most major therapeutic areas on a global basis and has
the operational flexibility to provide development services on a
stand-alone basis or as part of an integrated "full service"
solution. The Company has expanded predominately through internal
growth, together with a number of strategic acquisitions to enhance
its expertise and capabilities in certain areas of the clinical
development process.
The Company determines and presents operating segments based on the
information that is internally provided to the Chief Executive
Officer, Chief Financial Officer and Chief Operating Officer, who
together are considered the Company's chief operating decision
maker, in accordance with FASB ASC 280-10
Disclosures about Segments of an Enterprises and Related
Information.
We have determined that we operate in one
single business segment, which is the provision of outsourced
development services on a global basis to the pharmaceutical,
biotechnology and medical devices industries.
Revenues are allocated to individual entities based on where the
work is performed in accordance with the Company's global transfer
pricing model. Revenues and income from operations in Ireland are a
function of this transfer pricing model.
Given ICON Clinical Research Limited's ("ICON Ireland") role in the
development and management of the group, it's ownership of key
intellectual property, customer relationships, its key role in the
mitigation of risks faced by the group, plus the responsibility for
maintaining the group's global network, ICON Ireland acts as the
group entrepreneur and enters into the majority of the Company's
customer contracts. As such, ICON Ireland remunerates most of the
other operating entities ("cost plus service providers") in the
ICON Group on the basis of a guaranteed cost plus mark up for the
services they perform in each of their local territories.
The cost plus mark up for each ICON entity is established to ensure
that each of ICON Ireland and the ICON entities in the various
geographical areas that are involved in the conduct of services for
customers, earn an appropriate arms-length return having regard to
the assets owned, risks borne and functions performed by each
entity from these intercompany transactions. The cost plus mark-up
policy is reviewed annually to ensure that it is market
appropriate.
Under this method, the residual operating profits (or losses) of
the group, once the cost plus service providers have been paid
their respective intercompany service fee are retained by ICON
Ireland. The geographic split of revenue disclosed for each region
outside Ireland is the cost plus revenue attributable to these
entities. The revenues disclosed as relating to Ireland are the net
revenues after deducting the cost plus revenues attributable to the
activities performed outside Ireland.
The Company's areas of operation outside of Ireland include the
United States, United Kingdom, Belgium, France, Germany, Italy,
Spain, The Netherlands, Sweden, Turkey, Poland, Czech Republic,
Latvia, Russia, Ukraine, Hungary, Israel, Romania, Switzerland,
Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India,
China, South Korea, Japan, Thailand, Taiwan, Singapore, The
Philippines, Australia, New Zealand, and South Africa.
There have been no changes to the basis of segmentation or the
measurement basis for the segment results since the prior
year.
Reportable
segment information at December 31, 2016 and December 31, 2015 and
for the years ended December 31, 2016, December 31, 2015 and
December 31, 2014 is as follows:
a) The distribution of net revenue by geographical area was as
follows:
b) The distribution of income from operations, including
restructuring and other items, by geographical area was as
follows:
c) The distribution of income from operations, excluding
restructuring and other items, by geographical area was as
follows:
d) The distribution of property, plant and equipment, net, by
geographical area was as follows:
e) The distribution of depreciation and amortization by
geographical area was as follows:
f) The distribution of total assets by geographical area was as
follows:
* The December 31, 2015 Balance Sheet has been retrospectively
restated as required to reflect the requirements of new guidance in
respect of the presentation of debt issue costs.
g) The distribution of capital expenditures by geographical area
was as follows:
h) The following table sets forth the clients which represented 10%
or more of the Company's net revenue in each of the periods set out
below.
i) The distribution of interest income by geographical area
was as follows:
j) The distribution of the income tax charge by geographical area
was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Supplemental Disclosure of Cash Flow Information |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Supplemental Disclosure of Cash Flow Information |
18. Supplemental Disclosure of Cash Flow Information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Accumulated Other Comprehensive Income |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accumulated Other Comprehensive Income |
19. Accumulated Other Comprehensive Income
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Disclosure of the components of accumulated other comprehensive income (loss). No definition available.
|
Long-Term Debt - Senior Notes |
12 Months Ended |
|---|---|
Dec. 31, 2016 | |
| Long-Term Debt - Senior Notes |
20. Long-Term Debt – Senior Notes
In December 2015 the Company issued $350 million in the private
placement market. The December 31, 2015 Balance Sheet has been
retrospectively restated as required to reflect the requirements of
new guidance in respect of the presentation of debt issue costs
($1,694,000).
The interest rate in respect of the Senior Notes is fixed at 3.64%
for the five year term of the agreement. The associated interest
cost is recognized in interest expense in the period since drawdown
in December 2015.
In October 2015, the Company entered into an interest rate hedge in
respect of the planned issuance of the Senior Notes in December
2015. The interest rate hedge matured in November 2015 when the
interest rate on the Senior Notes was fixed. The interest rate
hedge was effective in accordance with Financial Accounting
Standards Board ("FASB") ASC 815, "Derivatives and Hedging". The
cash proceeds ($4.6 million), representing the realized gain on the
interest rate hedge, were received on maturity in November 2015 and
are recorded within Other Comprehensive Income. The realized gain
is being amortized to the income statement, net against interest
payable, over the period of the Senior Notes.
The Senior Notes agreement also includes certain financial
covenants that require compliance with a consolidated leverage
ratio, a minimum EBIT to consolidated net interest charge ratio and
a maximum amount of priority debt, each of which are defined in the
Note Purchase and Guarantee Agreement.
The Senior Notes have not been, and will not be, registered under
the Securities Act of 1933, as amended, and may not be offered or
sold in the United States absent registration or an applicable
exemption from registration requirements.
|
| X | ||||||||||
- Definition The entire disclosure for long-term debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Impact of New Accounting Pronouncements |
12 Months Ended | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||
| Impact of New Accounting Pronouncements |
21. Impact of New Accounting Pronouncements
ASU 2015-03 'Interest-Imputation of Interest' was issued in April
2015 to simplify the presentation of debt issuance costs. The
guidance requires debt issuance costs related to term loans to be
presented as a direct deduction from the carrying amount of the
associated debt liability. The new guidance is reflected in the
Consolidated Financial Statements including application on a
retrospective basis. The Consolidated Balance Sheet at December 31,
2015 has therefore been restated to reflect the accounting
standards update.
ASU 2015-16 'Business Combinations' was issued in February 2016 to
simplify the accounting and presentation for changes in provisional
amounts accounted for in a business combination during the
measurement period. The amendments require that an acquirer
recognize adjustments to provisional amounts that are identified
during the measurement period in the reporting period in which the
adjustment amounts are determined. The amendments require that the
acquirer record, in the same period's financial statements, the
effect on earnings of changes in depreciation, amortization or
other income effects, if any, as a result of the change to the
provisional accounts, calculated as if the accounting had been
completed at the acquisition date. See Note 4 for details of the
impact of adoption.
In
July 2015, the FASB issued ASU 2015-11, which, for entities that do
not measure inventory using the last-in, first-out (LIFO) or retail
inventory method, changes the measurement principle for inventory
from the lower of cost or market to lower of cost and net
realizable value. The ASU also eliminates the requirement for these
entities to consider replacement cost or net realizable value less
an approximately normal profit margin when measuring
inventory. This ASU is effective for public business
entities in fiscal years beginning after December 15, 2016. The
adoption of ASU 2015-11 is not expected to have a significant
impact on the financial statements.
In May 2014, the FASB issued ASU 2014-09 ("ASU 2014-09"), Revenue
from Contracts with Customers, which provides that an entity should
recognize revenue to depict the transfer of promised goods or
services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those
goods or services. The updated standard will replace most existing
revenue recognition guidance in U.S. GAAP when it becomes effective
and permits the use of either the retrospective or cumulative
effect transition method. To achieve the core principle of the new
standard, an entity should apply the following steps: (1) identify
the contract(s) with a customer; (2) identify the performance
obligations in the contract; (3) determine the transaction price;
(4) allocate the transaction price to the performance obligations
in the contract; and (5) recognize revenue when (or as) the entity
satisfies a performance obligation. As originally issued, ASU
2014-09 will be effective prospectively for fiscal years and
interim periods within those years beginning after December 15,
2016. On July 9, 2015, the FASB approved the proposal to defer the
effective date of this standard by one year. Early adoption is
permitted for annual periods beginning after December 16, 2016.
Subsequent to issuing ASU 2014-09, the FASB issued the following
amendments concerning clarification of ASU 2014-09. In March 2016,
the FASB issued ASU 2016-08 ("ASU 2016-08"), Revenue from Contracts
with Customers (Topic 606), Principal versus Agent Considerations
(Reporting Revenue Gross versus Net), which further clarifies the
implementation guidance on principal versus agent considerations.
The new guidance requires either a retrospective or a modified
retrospective approach to adoption. In April 2016, the FASB issued
ASU 2016-10, ("ASU 2016-10") Revenue from Contracts with Customers
(Topic 606), Identifying Performance Obligations and Licensing,
which clarifies the identification of performance obligations and
the licensing implementation guidance, while retaining the related
principles for those areas. In May 2016, the FASB issued ASU
2016-12 ("ASU 2016-12"), Revenue from Contracts with Customers
(Topic 606): Narrow-Scope Improvements and Practical Expedients,
which provides clarification on assessing the collectability
criterion, presentation of sales taxes, measurement date for
noncash consideration and completed contracts at transition.
The updated standard is effective for us in the first quarter of
the year-ended 31 December 2018. We are continuing to evaluate a
method of transition and are currently evaluating the effect that
the updated standard will have on our consolidated financial
statements and related disclosures. While we are continuing to
assess all potential impacts of the new standard, we currently
believe the most significant impact relates to our assessment of
measurement of performance and percentage of completion. Under
current GAAP, the revenue attributable to performance is determined
based on both input and output methods of measurement. .Due to the
complexity of certain of our contracts, the actual revenue
recognition treatment required under the new standard for these
arrangements may be dependent on contract-specific terms and vary
in some instances. Our preparatory work is also focused on the
increased disclosure obligations (including in respect of
retrospective revenue and backlog).
In January 2016, the FASB issued ASU 2016-01, which will
significantly change the income statement impact of equity
investments and the recognition of changes in fair value of
financial liabilities when the fair value option is elected. The
ASU is effective for public business entities for interim and
annual periods in fiscal years beginning after December 15, 2017.
The adoption of ASU 2016-01 is not expected to have a significant
impact on the financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases, requiring
lessees to recognize a right-of-use asset and a lease liability on
the balance sheet for all leases with the exception of short-term
leases. For lessees, leases will continue to be classified as
either operating or finance leases in the income statement. Lessor
accounting is similar to the current model but updated to align
with certain changes to the lessee model. Lessors will continue to
classify leases as operating, direct financing or sales-type
leases. The effective date of the new standard for public companies
is for fiscal years beginning after December 15, 2018 and interim
periods within those fiscal years. Early adoption is permitted. The
new standard must be adopted using a modified retrospective
transition and requires application of the new guidance at the
beginning of the earliest comparative period presented. The updated
standard is effective for us beginning in the first quarter of the
year-ended December 31, 2019. We are currently evaluating the
effect that the updated standard will have on our consolidated
financial statements and related disclosures.
In March 2016, the FASB issued ASU 2016-04,
Recognition of Breakage for Certain Prepaid Stored-Value
Products, which allows entities to recognize breakage on
prepaid stored-value products consistent with how breakage is
recognized under the new revenue standard. The exception applies to
prepaid stored-value products in physical or digital form, with
stored monetary values that are redeemable for goods and services,
including those that can be redeemed for cash (e.g., prepaid gift
cards issued on a specific payment network and redeemable at
network-accepting merchant locations, prepaid telecommunication
cards, and traveler's checks). The ASU is effective for public
business entities for interim and annual periods in fiscal years
beginning after December 15, 2017. The adoption of ASU 2016-04 is
not expected to have a significant impact on the financial
statements.
In March 2016, the FASB issued ASU 2016-05,
Effect of Derivative Contract Novations on Existing Hedge
Accounting Relationships, which clarifies that a change in
one of the parties to a derivative contract (through novation) that
is part of a hedge accounting relationship does not, by itself,
require de-designation of that relationship, as long as all other
hedge accounting criteria continue to be met. The ASU is effective
for public business entities for interim and annual periods in
fiscal years beginning after December 15, 2016. The adoption of ASU
2016-05 is not expected to have a significant impact on the
financial statements.
In March 2016, the FASB issued ASU 2016-06,
Contingent Put and Call Options in Debt Instruments, which
clarifies that determining whether the economic characteristics of
a put or call are clearly and closely related to its debt host
requires only an assessment of the four-step decision sequence
outlined in FASB ASC paragraph 815-15-25-24. Additionally, entities
are not required to separately assess whether the contingency
itself is clearly and closely related. The ASU is effective for
public business entities for interim and annual periods in fiscal
years beginning after December 15, 2016. The adoption of ASU
2016-06 is not expected to have a significant impact on the
financial statements.
In March 2016, the FASB issued ASU 2016-07,
Simplifying the Transition to the Equity Method of
Accounting, which eliminates the requirement for an investor to
retroactively apply the equity method when its increase in
ownership interest (or degree of influence) in an investee triggers
equity method accounting. The ASU is effective for public business
entities for interim and annual periods in fiscal years beginning
after December 15, 2016. The adoption of ASU 2016-07 is not
expected to have a significant impact on the financial
statements.
In March 2016, the FASB issued ASU 2016-09, Improvements to
Employee Share-Based Payment Accounting, which simplifies various
aspects related to the accounting and presentation of share-based
payments. The amendments require entities to record all tax effects
related to share-based payments at settlement or expiration through
the income statement and the windfall tax benefit to be recorded
when it arises, subject to normal valuation allowance
considerations. All tax-related cash flows resulting from
share-based payments are required to be reported as operating
activities in the statement of cash flows. The updates relating to
the income tax effects of the share-based payments including the
cash flow presentation must be adopted either prospectively or
retrospectively. Further, the amendments allow the entities to make
an accounting policy election to either estimate forfeitures or
recognize forfeitures as they occur. If an election is made, the
change to recognize forfeitures as they occur must be adopted using
a modified retrospective approach with a cumulative effect
adjustment recorded to opening retained earnings. The effective
date of the new standard for public companies is for fiscal years
beginning after December 15, 2016 and interim periods within those
fiscal years. We will apply the updated standard in the first
quarter of the year-ended December 31, 2017. We believe the new
standard will cause limited volatility in our effective tax rates
and a resulting impact on our diluted earnings per share due to the
tax effects related to share-based payments being recorded in the
income statement. The volatility in future periods will depend on
our stock price at the awards' vest dates and the number of awards
that vest in each period. If the share price at the vest date of an
award exceeds the share price at its grant date, an additional tax
benefit will be recognized in the income statement, reducing our
effective tax rate. Conversely, if the share price at the vest date
of an award is lower than the share price at its grant date, an
additional tax expense will be recognized in the income statement,
increasing our effective tax rate for that period.
In June 2016, the FASB issued ASU 2016-13,
Measurement of Credit Losses on Financial Instruments, which
significantly changes the way entities recognize impairment of many
financial assets by requiring immediate recognition of estimated
credit losses expected to occur over their remaining life. The ASU
is effective for public business entities that are SEC filers for
interim and annual periods in fiscal years beginning after December
15, 2019. The adoption of ASU 2016-13 is not expected to have a
significant impact on the financial statements.
In August 2016, the FASB issued ASU 2016-15,
Classification of Certain Cash Receipts and Cash Payments,
which addresses eight classification issues related to the
statement of cash flows:
The ASU is effective for public business entities for interim and
annual periods in fiscal years beginning after December 15, 2017.
The adoption of ASU 2016-15 is not expected to have a significant
impact on the financial statements.
In October 2016, the FASB issued ASU 2016-16,
Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other
Than Inventory, which requires entities to recognize at the
transaction date the income tax consequences of intercompany asset
transfers other than inventory. This ASU is effective for public
business entities for annual and interim periods in fiscal years
beginning after December 15, 2017. For all other entities, the ASU
is effective for annual periods in fiscal years beginning after
December 15, 2018, and interim periods in fiscal years beginning
after December 15, 2019. We are considering the impact, if any, of
the adoption of ASU 2016-16 on the financial statements.
In October 2016, the FASB issued ASU 2016-17,
Consolidation (Topic 810): Interests Held through Related Parties
That Are under Common Control, which requires a single
decision maker or service provider, in evaluating whether it is the
primary beneficiary, to consider on a proportionate basis indirect
interests held through related parties under common control. This
ASU is effective for public business entities for annual and
interim periods in fiscal years beginning after December 15, 2016.
For all other entities, the ASU is effective for annual periods in
fiscal years beginning after December 15, 2016, and interim periods
in fiscal years beginning after December 15, 2017. The
adoption of ASU 2016-17 is not expected to have an impact on the
financial statements.
In November 2016, the FASB issued ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash, which
requires companies to include cash and cash equivalents that have
restrictions on withdrawal or use in total cash and cash
equivalents on the statement of cash flows. This ASU is effective
for public business entities for annual and interim periods in
fiscal years beginning after December 15, 2017. For all other
entities, the ASU is effective for annual periods in fiscal years
beginning after December 15, 2018, and interim periods in fiscal
years beginning after December 15, 2019. The
adoption of ASU 2016-18 is not expected to have a material impact
on the financial statements.
In December 2016, the FASB issued ASU 2016-19,
Technical Corrections and Improvements, which amends a
number of Topics in the FASB ASC. The ASU is part of an ongoing
FASB project to facilitate Codification updates for non-substantive
technical corrections, clarifications, and improvements that are
not expected to have a significant effect on accounting practice or
create a significant administrative cost to most entities. The ASU
will apply to all reporting entities within the scope of the
affected accounting guidance.
|
| X | ||||||||||
- Definition New And Recent Accounting Pronouncements Disclosure No definition available.
|
Related Parties |
12 Months Ended |
|---|---|
Dec. 31, 2016 | |
| Related Parties |
22. Related Parties
Subsidiaries of the Company earned revenue of $100,000 (2015:
$100,000) from Dignity Sciences Limited during the year. Dr. John
Climax is Chief Executive Officer and both Dr. John Climax and Dr.
Ronan Lambe are Directors and shareholders of Dignity Sciences
Limited. $45,700 was recorded as due from Dignity Sciences Limited
at December 31, 2016. The contract terms were agreed on an arm's
length basis.
On July 22, 2016, Mr. Thomas Lynch retired as a Director of the
Company, having previously resigned as Chairman of the Company in
March 2016. The Company entered into an agreement with a company
controlled by Mr. Lynch, for the provision of consultancy services
for a period of three years from August 1, 2016, at an agreed fee
of €231,750 ($256,315) per annum. €96,560 was recorded
as due to Mr. Lynch under the terms of this agreement at December
31, 2016. Mr. Lynch also agreed to certain restrictions that will
apply to him during the period of the consultancy agreement
including non-disclosure, non-competition and
non-solicitation.
|
| X | ||||||||||
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Significant Accounting Policies (Policies) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basis of Consolidation |
(a) Basis
of consolidation
The
consolidated financial statements include the financial statements
of the Company and all of its subsidiaries. All significant
intercompany profits, transactions and account balances have been
eliminated. The results of subsidiary undertakings acquired in the
period are included in the consolidated statement of operations
from the date of acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Use of Estimates |
(b) Use
of estimates
The
preparation of financial statements in conformity with generally
accepted accounting principles in the United States requires
management to make estimates and judgments that affect the reported
amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reported
period. Actual results could differ from those estimates. The
principle management estimates and judgments used in preparing the
financial statements relate to revenue recognition, taxation,
goodwill and business combinations.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue Recognition |
(c) Revenue
recognition
The
Company primarily earns revenues by providing a number of different
services to its customers. These services, which are integral
elements of the clinical development process, include clinical
trials management, biometric activities, consulting, imaging,
contract staffing, informatics and laboratory services. Contracts
range in duration from a number of months to several years. Revenue
for services, as rendered, is recognized only after persuasive
evidence of an arrangement exists, the sales price is fixed or
determinable and collectability is reasonably assured.
Clinical
trials management revenue is recognized on a proportional
performance method. Depending on the contractual terms revenue is
either recognized on the percentage of completion method based on
the relationship between hours incurred and the total estimated
hours of the trial or on the unit of delivery method. Contract
costs equate to the product of labor hours incurred and
compensation rates. For the percentage of completion method, the
input (effort expended) method has been used to measure progress
towards completion as there is a direct relationship between input
and productivity. Contract revenue is the product of the aggregated
labor hours required to complete the specified contract tasks at
the agreed contract rates. The Company regularly reviews the
estimate of total contract time to ensure such estimates remain
appropriate taking into account actual contract stage of
completion, remaining time to complete and any identified changes
to the contract scope. Remaining time to complete depends on the
specific contract tasks, the complexity of the contract and can
include geographical site selection and initiation, patient
enrollment, patient testing and level of results analysis required.
While the Company may routinely adjust time estimates, the
Company's estimates and assumptions historically have been accurate
in all material respects in the aggregate. Where revenue is
recognized on the unit of delivery method, the basis applied is the
number of units completed as a percentage of the total number of
contractual units.
Biometrics
revenue is recognized on a fee-for-service method as each unit of
data is prepared on the basis of the number of units completed in a
period as a percentage of the total number of contracted units.
Imaging revenue is recognized on a fee-for-service basis
recognizing revenue for each image completed. Consulting revenue is
recognized on a fee-for-service basis as each hour of the related
service is performed. Contract
staffing revenue is recognized on a fee-for-service basis, over the
time the related service is performed, or in the case of permanent
placement, once the candidate has been placed with the client.
Informatics revenue is recognized on a fee-for-service
basis. Informatics contracts are treated as multiple element
arrangements, with contractual elements comprising license fee
revenue, support fee revenue and revenue from software services,
each of which can be sold separately. Sales prices for contractual
elements are determined by reference to objective and reliable
evidence of their sales price. License and support fee revenues are
recognized rateably over the period of the related agreement.
Revenue from software services is recognized using the percentage
of completion method based on the relationship between hours
incurred and the total estimated hours required to perform the
service.
Laboratory
service revenue is recognized on a fee-for-service basis. The
Company accounts for laboratory service contracts as multiple
element arrangements, with contractual elements comprising
laboratory kits and laboratory testing, each of which can be sold
separately. Sales prices for contractual elements are determined by
reference to objective and reliable evidence of their sales price.
Revenues for contractual elements are recognized on the basis of
the number of deliverable units completed in the
period.
Contracts
generally contain provisions for renegotiation in the event of
changes in the scope, nature, duration, or volume of services of
the contract. Renegotiated amounts are recognized as revenue by
revision to the total contract value arising as a result of an
authorized customer change order.
The
difference between the amount of revenue recognized and the amount
billed on a particular contract is included in the balance sheet as
unbilled revenue or payments on account. Normally, amounts become
billable upon the achievement of certain milestones, for example,
target patient enrolment rates, clinical testing sites initiated or
case report forms completed. Once the milestone target is reached,
amounts become billable in accordance with pre-agreed payment
schedules included in the contract or on submission of appropriate
billing detail. Such cash payments are not representative of
revenue earned on the contract as revenues are recognized over the
period in which the specified contractual obligations are
fulfilled. Amounts included in unbilled revenue are expected to be
collected within one year and are included within current assets.
Advance billings to customers, for which revenue has not been
recognized, are recognized as payments on account within current
liabilities.
In
the event of contract termination, if the value of work performed
and recognized as revenue is greater than aggregate milestone
billings at the date of termination, cancellation clauses usually
ensure that the Company is paid for all work performed to the
termination date.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reimbursable Expenses |
(d) Reimbursable
expenses
Reimbursable
expenses comprise investigator payments and certain other costs
which are reimbursed by clients under terms specific to each
contract and are deducted from gross revenue in arriving at net
revenue. Investigator payments are accrued based on patient
enrollment over the life of the contract. Investigator payments are
made based on predetermined contractual arrangements, which may
differ from the accrual of the expense.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Direct Costs |
(e) Direct
costs
Direct
costs consist of compensation, associated employee benefits and
share-based payments for project-related employees and other direct
project-related costs.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Advertising Costs |
(f) Advertising
costs
All costs associated with advertising and promotion are expensed as
incurred. The advertising and promotion costs were $7,167,050,
$4,513,750 and $3,563,900 for the years ended December 31, 2016,
December 31, 2015 and December 31, 2014
respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign Currencies and Translation of Subsidiaries |
(g) Foreign
currencies and translation of subsidiaries
The
Company's financial statements are prepared in United States
dollars. Transactions in currencies other than United States
dollars are recorded at the rate ruling at the date of the
transaction. Monetary assets and liabilities denominated in
currencies other than United States dollars are translated into
United States dollars at exchange rates prevailing at the balance
sheet date. Adjustments resulting from these translations are
charged or credited to income. Amounts charged or credited to the
statement of operations for the years ended December 31, 2016,
December 31, 2015 and December 31, 2014 were as
follows:
The
financial statements of subsidiaries with other functional
currencies are translated at period end rates for the balance sheet
and average rates for the statement of operations. Translation
gains and losses arising are reported as a movement on accumulated
other comprehensive income.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disclosure About Fair Value of Financial Instruments |
(h) Disclosure
about fair value of financial instruments
Thefollowing
methods and assumptions were used to estimate the fair value of
each material class of financial instrument:
Cash,
cash equivalents, unbilled revenue, other receivables, short term
investments, prepayments and other current assets, accounts
receivable, accounts payable, investigator payments, payments on
account, accrued liabilities, accrued bonuses and income taxes
payable have carrying amounts that approximate fair value due to
the short term maturities of these instruments. Other liabilities'
carrying amounts approximate fair value based on net present value
of estimated future cash flows.
Financial
instruments are measured in the statement of financial position at
fair value using a fair value hierarchy of valuation inputs. The
hierarchy prioritizes the inputs into three levels based on the
extent to which inputs used in measuring fair value are observable
in the market. Each fair value measurement is reported in one of
three levels, which is determined by the lowest level input that is
significant to the fair value measurement in its entirety. These
levels are:
The
Company classifies its short term investments as available for
sale, as it does not actively trade such securities nor does it
intend to hold them to maturity. The fair value of short term
investments are represented by level 1 fair value measurements
– quoted prices in active markets for identical assets. The
unrealized movements in fair value are recognized in equity until
disposal or sale, at which time, those unrealized movements from
prior periods are recognized in profit or loss. For losses other
than temporary, which reduce the carrying amount below cost is
recognized in profit or loss.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations |
(i) Business
combinations
The
cost of a business combination is measured as the aggregate of the
fair values at the date of exchange of assets given, liabilities
incurred or assumed and equity instruments issued in exchange for
control. Where a business combination agreement provides for an
adjustment to the cost of the acquisition which is contingent upon
future events, the amount of the estimated adjustment is recognized
at the acquisition date at the fair value of the contingent
consideration. Any changes to this estimate outside the measurement
period will depend on the classification of the contingent
consideration. If the contingent consideration is classified as
equity it shall not be re-measured and the settlement shall be
accounted for within equity. If the contingent consideration is
classified as a liability any adjustments will be accounted for
through the Consolidated Statement of Operations or Other
Comprehensive Income depending on whether the liability is
considered a financial instrument.
The
assets, liabilities and contingent liabilities of businesses
acquired are measured at their fair values at the date of
acquisition. In the case of a business combination which is
completed in stages, the fair values of the identifiable assets,
liabilities and contingent liabilities are determined at the date
of each exchange transaction. When the initial accounting for a
business combination is determined provisionally, any subsequent
adjustments to the provisional values allocated to the identifiable
assets, liabilities and contingent liabilities are made within
twelve months of the acquisition date and presented as adjustments
to goodwill in the reporting period in which the adjustments are
determined.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill and Impairment |
(j) Goodwill
and Impairment
Goodwill
represents the excess of the cost of acquired entities over the net
amounts assigned to assets acquired and liabilities assumed.
Goodwill primarily comprises acquired workforce in place which does
not qualify for recognition as an asset apart from goodwill.
Goodwill is stated net of any provision for impairment. The Company
tests goodwill annually for any impairments or whenever events
occur which may indicate impairment. The first step is to compare
the carrying amount of the reporting unit's assets to the fair
value of the reporting unit. If the carrying amount exceeds the
fair value then a second step is completed which involves the fair
value of the reporting unit being allocated to each asset and
liability with the excess being implied goodwill. The impairment
loss is the amount by which the recorded goodwill exceeds the
implied goodwill. No impairment was recognized as a result of the
impairment testing carried out for the years ended December 31,
2016, December 31, 2015 and December 31, 2014.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets |
(k) Intangible
assets
Intangible
assets are amortized on a straight line basis over their estimated
useful life.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash and Cash Equivalents |
(l) Cash
and cash equivalents
Cash
and cash equivalents include cash and highly liquid investments
with initial maturities of three months or less and are stated at
cost, which approximates market value.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Short Term Investments - Available for Sale |
(m) Short
term investments - available for sale
The
Company classifies short-term investments as available for sale in
accordance with the terms of FASB ASC 320, Investments
– Debt and Equity Securities. Realized gains and
losses are determined using specific identification. The
investments are reported at fair value, with unrealized gains or
losses reported in a separate component of shareholders' equity.
Any differences between the cost and fair value of the investments
are represented by accrued interest and unrealized
gains/losses.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory |
(n) Inventory
Inventory
is valued at the lower of cost and market value and after
provisions for obsolescence. The cost of inventories comprises the
purchase price and attributable costs, less trade discounts. At
December 31, 2016 the carrying value of inventory, included within
prepayments and other current assets on the balance sheet, was $2.4
million (2015: $1.8 million).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment |
(o) Property,
plant and equipment
Property,
plant and equipment is stated at cost less accumulated
depreciation. Depreciation of property, plant and equipment is
computed using the straight line method based on the estimated
useful lives of the assets as listed below:
Leasehold
improvements are amortized using the straight-line method over the
estimated useful life of the asset or the lease term, whichever is
shorter.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Leased Assets |
(p) Leased
assets
Costs
in respect of operating leases are charged to the statement of
operations on a straight line basis over the lease
term.
Assets
acquired under capital finance leases are included in the balance
sheet at the present value of the future minimum lease payments and
are depreciated over the shorter of the lease term and their
remaining useful lives. The corresponding liabilities are recorded
in the balance sheet and the interest element of the capital lease
rental is charged to interest expense.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes |
(q) Income
taxes
The
Company applies the asset and liability method of accounting for
income taxes. Under the asset and liability method, deferred tax
assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and
their respective tax bases and operating loss and tax credit
carryforwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the
years in which these temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the
period that includes the enactment date. The Company recognizes the
effect of income tax positions only if those positions will more
likely than not be sustained. Recognized income tax positions are
measured at the largest amount of tax benefit that is greater than
50 percent likely of being realized upon settlement. Interest and
penalties related to income taxes are included in income tax
expense and classified with the related liability on the
consolidated balance sheet.
On
November 21, 2015 FASB issued ASU 2015-17 on the balance sheet
classification of deferred taxes. The new standard requires that
all deferred taxes are presented as non-current in a classified
Statement of Financial Position. The new guidance is effective for
public business entities for annual periods beginning after
December 15, 2016 and for non-public business entities for annual
periods beginning after December 15, 2017. Early adoption is
available for all entities for any set of financial statements that
had not been released as at November 21, 2015 with an option to
apply on either a prospective or a retrospective basis. The Company
elected for early adoption of ASU 2015 – 17 on a prospective
basis for all financial statements issued after November 21, 2015.
The effect of this is that all deferred tax assets and liabilities
are classified as non-current assets and liabilities in the
December 31, 2016 and December 31, 2015 balance
sheets.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government Grants |
(r) Government
grants
Government grants received relating to capital expenditures are
shown as deferred income and credited to income on a basis
consistent with the depreciation policy of the relevant assets.
Grants relating to categories of operating expenditures are
credited to income in the period in which the expenditure to which
they relate is charged.
Under the grant agreements amounts received may become repayable in
full should certain circumstances specified within the grant
agreements occur, including downsizing by the Company, disposing of
the related assets, ceasing to carry on its business or the
appointment of a receiver over any of its assets. The Company has
not recognized any loss contingency having assessed as remote the
likelihood of these events arising.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research and Development Credits |
(s) Research
and development credits
Research
and development credits are available to the Company under the tax
laws in certain jurisdictions, based on qualifying research and
development spend as defined under those tax laws. Research and
development credits are generally recognized as a reduction of
income tax expense. However, certain tax jurisdictions provide
refundable credits that are not wholly dependent on the Company's
ongoing income tax status or income tax position. In these
circumstances the benefit of these credits is not recorded as a
reduction to income tax expense, but rather as a reduction of
operating expenditure.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pension Costs |
(t) Pension
costs
The
Company contributes to defined contribution plans covering all
eligible employees. The Company contributes to these plans based
upon various fixed percentages of employee compensation and such
contributions are expensed as incurred.
The
Company operates, through a subsidiary, a defined benefit plan for
certain of its United Kingdom and Swiss employees. The Company
accounts for the costs of these plans using actuarial models
required by FASB ASC 715-30 and these plans are presented in
accordance with the requirements of FASB ASC 715-60 Defined
Benefit Plans – Other Post retirement.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Income per Ordinary Share |
(u) Net
income per ordinary share
Basic
net income per ordinary share has been computed by dividing net
income available to ordinary shareholders by the weighted average
number of ordinary shares outstanding during the period. Diluted
net income per ordinary share is computed by adjusting the weighted
average number of ordinary shares outstanding during the period for
all potentially dilutive ordinary shares outstanding during the
period and adjusting net income for any changes in income or loss
that would result from the conversion of such potential ordinary
shares.
There
is no difference in net income used for basic and diluted net
income per ordinary share. The reconciliation of the number of
shares used in the computation of basic and diluted net income per
ordinary share is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-Based Compensation |
(v) Share-based
compensation
The
Company accounts for its share options, restricted share units
("RSUs") and performance share units ("PSUs") in accordance with
the provisions of FASB ASC 718, Compensation
– Stock Compensation. Share-based
compensation expense for equity-settled awards made to employees
and Directors is measured and recognized based on estimated grant
date fair values. These equity-settled awards include employee
share options, RSUs and PSUs.
Share-based
compensation expense for share options awarded to employees and
Directors is estimated at the grant date based on each option's
fair value as calculated using the Black-Scholes option-pricing
model. Share-based compensation for RSUs and PSUs awarded to
employees and Directors is calculated based on the market value of
the Company's shares on the date of award of the RSUs and PSUs. The
value of awards expected to vest is recognized as an expense over
the requisite service periods. Forfeitures are estimated on the
date of grant and revised if actual or expected forfeiture activity
differs materially from original estimates.
Estimating
the grant date fair value of share options as of the grant date
using an option-pricing model, such as the Black-Scholes model, is
affected by the Company's share price as well as assumptions
regarding a number of complex variables. These variables include,
but are not limited to, the expected share price volatility over
the term of the awards, risk-free interest rates and the expected
term of the awards.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Impairment of Long-Lived Assets |
(w) Impairment
of long-lived assets
Long-lived
assets are reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability of assets to be held and used is
measured by a comparison of the carrying amount of the asset to
future undiscounted net cash flows expected to be generated by the
asset. If such assets are considered to be impaired, the impairment
to be recognized is measured at the amount by which the carrying
amount of the asset exceeds the fair value of the asset. Assets to
be disposed of are reported at the lower of the carrying amount of
the asset or fair value less selling costs.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative Financial Instruments |
(x) Derivative
financial instruments
We
enter into transactions in the normal course of business using
various financial instruments in order to hedge against exposure to
fluctuating exchange and interest rates. We use derivative
financial instruments to reduce exposure to fluctuations in
interest rates. A derivative is a financial instrument or other
contract whose value changes in response to some underlying
variable, which has an initial net investment smaller than would be
required for other instruments that have a similar response to the
variable and that will be settled at a future date. We do not enter
into derivative financial instruments for trading or speculative
purposes. We did not hold any interest rate swap contracts or
forward currency contracts at December 31, 2016, December 31, 2015
or December 31, 2014.
Our
accounting policies for derivative financial instruments are based
on whether they meet the criteria for designation as cash flow or
fair value hedges. A designated hedge of the exposure to
variability in the future cash flows of an asset or a liability, or
of a forecasted transaction, is referred to as a cash flow hedge. A
designated hedge of the exposure to changes in fair value of an
asset or a liability is referred to as a fair value hedge. The
criterion for designating a derivative as a hedge includes the
assessment of the instrument's effectiveness in risk reduction,
matching of the derivative instrument to its underlying transaction
and the probability that the underlying transaction will occur. For
derivatives with cash flow hedge accounting designation, we report
the gain or loss from the effective portion of the hedge as a
component of Other Comprehensive Income and reclassify it into
earnings in the same period or periods in which the hedged
transaction affects earnings and within the same income statement
line item as the impact of the hedged transaction. For derivatives
with fair value hedge accounting designation, we recognize gains or
losses from the change in fair value of these derivatives, as well
as the offsetting change in the fair value of the underlying hedged
item, in earnings. Fair value gains and losses arising on
derivative financial instruments not qualifying for hedge
accounting are reported in our Consolidated Statement of
Operations.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financing Costs and Gain on Interest Rate Hedge |
(y) Financing
costs and gain on interest rate hedge
The
interest rate in respect of the Senior Notes is fixed at 3.64% for
the five year term of the agreement. The associated interest cost
is recognized in interest expense in the period since drawdown in
December 2015.
On
October 5, 2015, the Company entered into an interest rate hedge in
respect of the planned issuance of the Senior Notes in December
2015. The interest rate hedge matured on November 17, 2015 when the
interest rate on the Senior Notes was fixed. The interest rate
hedge was effective in accordance with Financial Accounting
Standards Board ("FASB") ASC 815, "Derivatives and Hedging". The
cash proceeds ($4.6 million), representing the realized gain on the
interest rate hedge, were received on maturity in November 2015 and
are recorded within Other Comprehensive Income. The realized gain
will be amortized to the income statement, net against interest
payable, over the period of the Senior Notes.
Deferred
financing costs (including issue costs relating to the Senior
Notes) are reported at cost less accumulated amortization and the
related amortization expense is included in interest expense, in
our consolidated statement of income.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassifications |
(z) Reclassifications
Certain
amounts in the consolidated financial statements have been
reclassified where necessary to conform to the current year
presentation.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Government Grants, Policy No definition available.
|
| X | ||||||||||
- Definition Reclassifications [Policy Text Block] No definition available.
|
| X | ||||||||||
- Definition Reimbursable expenses No definition available.
|
| X | ||||||||||
- Definition Short Term Investments , Policy No definition available.
|
| X | ||||||||||
- Definition Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for its derivative instruments and hedging activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for determining the fair value of financial instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Significant Accounting Policies (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adjustments Resulting From Foreign Currency Translations |
Amounts charged or credited to the statement of operations for the
years ended December 31, 2016, December 31, 2015 and December 31,
2014 were as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimated Useful Lives of Assets |
Property, plant and equipment is stated at cost less accumulated
depreciation. Depreciation of property, plant and equipment is
computed using the straight line method based on the estimated
useful lives of the assets as listed below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share |
There is no difference in net income used for basic and diluted net
income per ordinary share. The reconciliation of the number of
shares used in the computation of basic and diluted net income per
ordinary share is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Foreign Currency Disclosure No definition available.
|
| X | ||||||||||
- Definition Schedule Of Useful Lives For Property Plant Equipment No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Short term investments - available for sale (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cost and Fair Value of Investments |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Available For Sale Short Term Investments by Major Security Type |
The following table represents our available for sale short term
investments by major security type as of December 31, 2016:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. No definition available.
|
Goodwill (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clinical Research Management Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The table following summarizes the Company's provisional estimates
of the fair values of the assets acquired and liabilities
assumed:
*Goodwill represents the acquisition of an established workforce
with experience in preclinical through Phase IV support of clinical
research and clinical trial services for biologics, drugs and
devices. Goodwill related to the US portion of the business
acquired is tax deductible.
**The Company has made an initial estimate of separate intangible
assets (comprised of customer relationships and order book)
acquired of $8.6 million. This assessment is under review and will
be finalized within 12 months of the date of acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proforma Effect in Net Revenue Net Income and Earnings Per Share |
The proforma effect of the ClinicalRM acquisition if completed on
January 1, 2015 would have resulted in net revenue, net income and
earnings per share for the fiscal years ended December 31, 2016 and
December 31, 2015 as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PMG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The acquisition of PMG has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The table following summarizes the
fair values of the assets acquired and liabilities assumed;
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. In finalizing the goodwill on
acquisition of PMG in the twelve month period from acquisition,
fair value adjustments were made to deferred tax liabilities ($3.1
million), accounts receivable acquired ($1.4 million), other
liabilities ($1.2 million) and the value of the customer list and
order backlog assets acquired ($0.4 million). Additional
consideration of $1.6 million was provided on completion of the
contractual working capital process.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proforma Effect in Net Revenue Net Income and Earnings Per Share |
The proforma effect of the PMG acquisition if completed on January
1, 2014 would have resulted in net revenue, net income and earnings
per share for the fiscal years ended December 31, 2015 and December
31, 2014 as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MediMedia Pharma Solutions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The acquisition of MediMedia Pharma Solutions has been accounted
for as a business combination in accordance with FASB ASC
805 Business
Combinations. The following table summarizes the fair values
of the assets acquired and liabilities assumed:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proforma Effect in Net Revenue Net Income and Earnings Per Share |
The proforma effect of the MediMedia Pharma Solutions acquisition
if completed on January 1, 2014 would have resulted in net revenue,
net income and earnings per share for the fiscal years ended
December 31, 2015 and December 31, 2014 as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aptiv Solutions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The acquisition of Aptiv has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The following table summarizes the
fair values of the assets acquired and the liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. Goodwill related to the US
portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time
liabilities (including loan notes) identified at the acquisition
date which have subsequently been paid.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proforma Effect in Net Revenue Net Income and Earnings Per Share |
The proforma effect of the Aptiv Solutions acquisition if completed
on January 1, 2013 would have resulted in net revenue, net income
and earnings per share for the fiscal years ended December 31, 2013
and December 31, 2014 as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Intangible Assets (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Future Intangible Asset Amortization Expense |
Future intangible asset amortization expense for the years ended
December 31, 2017 to December 31, 2021 is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Property, Plant and Equipment, net (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property Plant and Equipment Net |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Other Liabilities (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of other liabilities. No definition available.
|
Other Non-Current Liabilities (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Non-Current Liabilities |
*An amount of $6.0 million is included within other non-current
liabilities in respect of contingent consideration for the
acquisition of ClinicalRM. See note 4 (a).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of other noncurrent liabilities. No definition available.
|
Employee Benefits (Tables) - Foreign Postretirement Benefit Plan |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| UNITED KINGDOM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pension Costs of Plan |
The plan has been closed to new entrants with effect from July 1,
2003.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Funded Status |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Components of Net Periodic Benefit Cost |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assumptions Used in Calculating Net Periodic Benefit Cost |
The following assumptions were used at the commencement of the year
in determining the net periodic pension benefit cost for the years
ended December 31, 2014, December 31, 2015 and December 31,
2016:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amounts Recognized in Accumulated Other Comprehensive Income Which Have Not Yet Been Recognized as Components of Net Periodic Benefit Cost |
Amounts recognized in accumulated other comprehensive income that
have not yet been recognized as components of net periodic benefit
cost are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assumptions Used in Calculating Pension Benefit Obligations |
The following assumptions were used in determining the benefit
obligation at December 31, 2016 and December 31, 2015:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Expected Long Term Rates of Return on Different Asset Classes |
The expected long term rates of return on different asset classes
are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Actual Plan Asset Allocations |
The underlying asset split of the fund is shown below.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Annual Benefit Payments which Reflect Expected Future Service |
The following annual benefit payments, which reflect expected
future service as appropriate, are expected to be paid.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SWITZERLAND | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pension Costs of Plan |
The pension costs of this plan are presented in the following
tables in accordance with the requirements of ASC 715-60,
Defined Benefit Plans – Other Postretirement.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Funded Status |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Components of Net Periodic Benefit Cost |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assumptions Used in Calculating Net Periodic Benefit Cost |
The following assumptions were used at the commencement of the year
in determining the net periodic pension benefit cost for the years
ended December 31, 2016 and December 31, 2015:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amounts Recognized in Accumulated Other Comprehensive Income Which Have Not Yet Been Recognized as Components of Net Periodic Benefit Cost |
Amounts recognized in accumulated other comprehensive income that
have not yet been recognized as components of net periodic benefit
cost are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assumptions Used in Calculating Pension Benefit Obligations |
The following assumptions were used in determining the benefit
obligation at December 31, 2016 and December 31, 2015:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Actual Plan Asset Allocations |
The following annual benefit payments, which reflect expected
future service as appropriate, are expected to be paid.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value, Inputs, Level 1 | UNITED KINGDOM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plan Asset Fair Value Measurements |
Plan Asset Fair Value Measurements
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Expected Long Term Rate of Return on Plan Assets No definition available.
|
| X | ||||||||||
- Definition Schedule of Assumptions Used in Calculating Net Periodic Benefit Cost [Table Text Block] No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the aggregate benefit obligation and aggregate fair value of plan assets for pension plans and/or other employee benefit plans with benefit obligations in excess of plan assets as of the measurement date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of net funded status of pension plans and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Equity Incentive Schemes and Stock Compensation Charges (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transactions for Company's Share Option Plans |
The following table summarizes the transactions for the Company's
share option plans for the years ended December 31, 2016, December
31, 2015 and December 31, 2014:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non Vested Shares Outstanding | Non-vested shares outstanding as at December 31, 2016 are as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Information Concerning Outstanding and Exercisable Share Options |
The following table summarizes information concerning outstanding
and exercisable share options as of December 31, 2016:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted Average Fair Values and Assumptions Used |
The weighted average fair values and assumptions were as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RSU and PSU Activity |
The following table summarizes RSU and PSU activity for the year
ended December 31, 2016:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Non-cash Stock Compensation Expense |
Non-cash stock compensation expense has been allocated as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Schedule of Non Cash Stock Compensation Expense. No definition available.
|
| X | ||||||||||
- Definition Schedule Of Share Based Compensation Restricted Stock Units Performance Stock Units Award Activity [Table Text Block] No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of the changes in outstanding nonvested shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Government Grants (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government Grant |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Government Grants No definition available.
|
Income Taxes (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Components of Income Before Provision for Income Taxes |
The components of income before provision for income taxes are as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Components of Provision for Income Taxes | The components of provision for income taxes are as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Consolidated Reported Provision for Income Taxes and Statutory Rate |
The Company's consolidated reported provision for income taxes
differed from the amount that would result from applying the Irish
statutory rate as set forth below;
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Tax Assets and Deferred Tax Liabilities |
The tax effects of temporary differences that give rise to
significant portions of deferred tax assets and deferred tax
liabilities are presented below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Expected Expiry Dates of NOL's | The expected expiry dates of these
losses are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Beginning and Ending Amount of Total Unrecognized Tax Benefits |
A reconciliation of the beginning and ending amount of total
unrecognized tax benefits is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Income Before Income Tax, Table No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Restructuring and other items (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recognized Restructuring and Other Items, Net |
Restructuring and other items recognized during the year ended
December 31, 2016 comprise:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring Charges |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Restructuring Charges. No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Provision for Doubtful Debts (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Provision for Doubtful Debts |
The Company does business with most major
international pharmaceutical companies. Provision for doubtful
debts at December 31, 2016 comprises:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Allowance for Doubtful Accounts, Table No definition available.
|
Commitments and Contingencies (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Future Minimum Rental Commitments for Operating Leases with Non-cancelable Terms |
Future minimum rental commitments for operating leases with
non-cancelable terms in excess of one year are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Segment and Geographical Information (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Geographical Area |
a) The distribution of net revenue by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Geographical Area |
b) The distribution of income from operations, including
restructuring and other items, by geographical area was as
follows:
c) The distribution of income from operations, excluding
restructuring and other items, by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Geographical Area |
d) The distribution of property, plant and equipment, net, by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Geographical Area |
e) The distribution of depreciation and amortization by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Geographical Area |
f) The distribution of total assets by geographical area was as
follows:
* The December 31, 2015 Balance Sheet has been retrospectively
restated as required to reflect the requirements of new guidance in
respect of the presentation of debt issue costs.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Capital Expenditures by Geographical Area |
g) The distribution of capital expenditures by geographical area
was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clients Representing Company's Net Revenue |
h) The following table sets forth the clients which represented 10%
or more of the Company's net revenue in each of the periods set out
below.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Interest Income by Business Segment |
i) The distribution of interest income by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Tax Charge by Geographical Area |
j) The distribution of the income tax charge by geographical area
was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Operating Income by Geography. No definition available.
|
| X | ||||||||||
- Definition Schedule Of Capital Expenditures by Geographic Area No definition available.
|
| X | ||||||||||
- Definition Schedule Of Depreciation And Amortization Expense By Geographical Area. No definition available.
|
| X | ||||||||||
- Definition Schedule Of Income Tax Expense Benefit by Geographic Area No definition available.
|
| X | ||||||||||
- Definition Schedule Of Interest Incom by Segment No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. No definition available.
|
Supplemental Disclosure of Cash Flow Information (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Supplemental Disclosure of Cash Flow Information |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of supplemental cash flow information for the periods presented. No definition available.
|
Accumulated Other Comprehensive Income (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accumulated Other Comprehensive Income |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Description of Business - Additional Information (Detail) |
12 Months Ended |
|---|---|
|
Dec. 31, 2016
Employee
Country
Location
| |
| Product Information [Line Items] | |
| Number of employees | Employee | 12,500 |
| Number of locations in which company operates | Location | 87 |
| Number of countries in which company operates | Country | 38 |
| Geographic Concentration Risk | United States | Sales Revenue, Net | |
| Product Information [Line Items] | |
| Percentage of company revenue | 45.80% |
| Geographic Concentration Risk | Europe | Sales Revenue, Net | |
| Product Information [Line Items] | |
| Percentage of company revenue | 43.40% |
| Geographic Concentration Risk | Rest of World | Sales Revenue, Net | |
| Product Information [Line Items] | |
| Percentage of company revenue | 10.80% |
| X | ||||||||||
- Definition Number of persons employed by the Entity No definition available.
|
| X | ||||||||||
- Definition Number of Locations No definition available.
|
| X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of countries in which the entity operates as of balance sheet date. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Significant Accounting Policies - Additional Information (Detail) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Significant Accounting Policies [Line Items] | |||
| Advertising and promotion costs | $ 7,167,050 | $ 4,513,750 | $ 3,563,900 |
| Impairment charge | 0 | 0 | $ 0 |
| Carrying value of inventory | $ 2,400,000 | 1,800,000 | |
| Cash proceeds from interest rate hedge | $ 4,658,000 | ||
| Senior Notes | |||
| Significant Accounting Policies [Line Items] | |||
| Debt instrument, interest rate | 3.64% | ||
| Debt instrument, term | 5 years | ||
| Cash proceeds from interest rate hedge | $ 4,658,000 | ||
| Interest rate hedge, inception date | Oct. 05, 2015 | ||
| Interest rate hedge, maturity date | Nov. 17, 2015 | ||
| X | ||||||||||
- Definition Significant Accounting Policies [Line Items] No definition available.
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Contractual interest rate for funds borrowed, under the debt agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Date the entity entered into the derivative contract, in CCYY-MM-DD format. No definition available.
|
| X | ||||||||||
- Definition Date the derivative contract matures, in CCYY-MM-DD format. No definition available.
|
| X | ||||||||||
- Definition Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The total expense recognized in the period for promotion, public relations, and brand or product advertising. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Adjustments Resulting from Foreign Currency Translation (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Intercompany Foreign Currency Balance [Line Items] | |||
| Amounts charged/(credited) | $ 2,094 | $ (3,608) | $ (5,942) |
| X | ||||||||||
- Definition Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
Estimated Useful Lives of Assets (Detail) |
12 Months Ended |
|---|---|
Dec. 31, 2016 | |
| Building | |
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives | 40 years |
| Office furniture and fixtures | |
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives | 8 years |
| Laboratory equipment | |
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives | 5 years |
| Motor vehicles | |
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives | 5 years |
| Computer equipment and software | Minimum | |
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives | 2 years |
| Computer equipment and software | Maximum | |
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives | 8 years |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail) - shares |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] | |||
| Weighted average number of ordinary shares outstanding for basic net income per ordinary share | 55,248,900 | 58,746,935 | 61,496,115 |
| Effect of dilutive share options outstanding | 1,158,236 | 1,543,098 | 1,635,302 |
| Weighted average number of ordinary shares outstanding for diluted net income per ordinary share | 56,407,136 | 60,290,033 | 63,131,417 |
| X | ||||||||||
- Definition Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] No definition available.
|
| X | ||||||||||
- Definition The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Cost and Fair Value of Investments (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|||||
| Schedule of Available-for-sale Securities [Line Items] | |||||||
| At start of year | $ 85,990 | [1] | $ 97,100 | ||||
| Purchases | 22,030 | 14,194 | |||||
| Sales and maturities | (40,858) | (25,708) | |||||
| Interest on short term investments | 823 | 571 | $ 910 | ||||
| Realized gain/(loss) on sale of short term investments | 50 | (113) | |||||
| Unrealized capital gain/(loss) - investments | 11 | (54) | |||||
| At end of year | $ 68,046 | $ 85,990 | [1] | $ 97,100 | |||
| |||||||
| X | ||||||||||
- Definition Available For Sale Securities, Debt Securities Current, Additions No definition available.
|
| X | ||||||||||
- Definition Available For Sale Securities, Debt Securities Current, Disposals No definition available.
|
| X | ||||||||||
- Definition Interest On Short Term Investments No definition available.
|
| X | ||||||||||
- Definition Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investments in debt and equity securities classified as available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
Short Team Investments - Available for Sale - Additional Information (Detail) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
| Schedule of Available-for-sale Securities [Line Items] | ||
| Short term investments average maturity period | 1 year 4 months 13 days | 1 year 4 months 6 days |
| X | ||||||||||
- Definition Short Term Available For Sale Investments Average Remaining Maturity Period No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
Available For Sale Short Term Investments by Major Security Type (Detail) $ in Thousands |
Dec. 31, 2016
USD ($)
|
|---|---|
| Schedule of Available-for-sale Securities [Line Items] | |
| Cost Total | $ 68,070 |
| Unrealized gains / (losses) | (20) |
| Fair Value Total | 68,050 |
| Maturity by period, less than 1 year | 29,190 |
| Maturity by period, 1 to 5 years | 38,860 |
| Us Government Debt Securities | |
| Schedule of Available-for-sale Securities [Line Items] | |
| Cost Total | 13,980 |
| Unrealized gains / (losses) | (40) |
| Fair Value Total | 13,940 |
| Maturity by period, less than 1 year | 3,000 |
| Maturity by period, 1 to 5 years | 10,940 |
| Corporate Securities | |
| Schedule of Available-for-sale Securities [Line Items] | |
| Cost Total | 52,980 |
| Unrealized gains / (losses) | 20 |
| Fair Value Total | 53,000 |
| Maturity by period, less than 1 year | 25,080 |
| Maturity by period, 1 to 5 years | 27,920 |
| Term Deposits | |
| Schedule of Available-for-sale Securities [Line Items] | |
| Cost Total | 1,110 |
| Fair Value Total | 1,110 |
| Maturity by period, less than 1 year | $ 1,110 |
| X | ||||||||||
- Definition Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale. No definition available.
|
| X | ||||||||||
- Definition This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of debt securities categorized neither as held-to-maturity nor trading. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Goodwill (Detail) - USD ($) $ in Thousands |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|||||
| Goodwill [Line Items] | ||||||
| Opening goodwill | $ 588,434 | [1] | $ 463,324 | |||
| Current year acquisitions (note 4 (a)) | 34,576 | 133,123 | ||||
| Prior period acquisition (note 4(b)) | 7,689 | 4,418 | ||||
| Foreign exchange movement | (14,611) | (12,431) | ||||
| Closing goodwill | $ 616,088 | $ 588,434 | [1] | |||
| ||||||
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Goodwill - Additional Information (Detail) $ in Thousands |
12 Months Ended | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 15, 2016
USD ($)
|
Dec. 04, 2015
USD ($)
Patient
Site
|
Mar. 25, 2015
USD ($)
|
Feb. 27, 2015
USD ($)
|
May 07, 2014
USD ($)
|
Dec. 31, 2016
USD ($)
|
Dec. 31, 2015
USD ($)
|
[1] |
Dec. 31, 2014
USD ($)
|
|||||||||||||||||
| Business Acquisition [Line Items] | |||||||||||||||||||||||||
| Goodwill | $ 616,088 | $ 588,434 | $ 463,324 | ||||||||||||||||||||||
| Clinical Research Management Inc. | |||||||||||||||||||||||||
| Business Acquisition [Line Items] | |||||||||||||||||||||||||
| Goodwill | $ 34,576 | [2] | 34,576 | ||||||||||||||||||||||
| Net cash outflow | 52,400 | ||||||||||||||||||||||||
| Other liabilities assumed | 9,200 | ||||||||||||||||||||||||
| Maximum additional consideration that might be payable | 12,000 | ||||||||||||||||||||||||
| Fair Value of the deferred consideration on acquisition | 6,000 | ||||||||||||||||||||||||
| Cash consideration | $ 52,396 | ||||||||||||||||||||||||
| PMG | |||||||||||||||||||||||||
| Business Acquisition [Line Items] | |||||||||||||||||||||||||
| Goodwill | [3] | $ 48,728 | |||||||||||||||||||||||
| Other liabilities assumed | 10,060 | ||||||||||||||||||||||||
| Cash consideration | $ 53,681 | $ 1,613 | |||||||||||||||||||||||
| Number of clinical research sites acquired | Site | 48 | ||||||||||||||||||||||||
| Working capital adjustment | $ 1,613 | ||||||||||||||||||||||||
| PMG | Minimum | |||||||||||||||||||||||||
| Business Acquisition [Line Items] | |||||||||||||||||||||||||
| Number of active patients via electronic medical records acquired | Patient | 2,000,000 | ||||||||||||||||||||||||
| MediMedia Pharma Solutions | |||||||||||||||||||||||||
| Business Acquisition [Line Items] | |||||||||||||||||||||||||
| Goodwill | [4] | $ 92,084 | |||||||||||||||||||||||
| Net cash outflow | 116,002 | ||||||||||||||||||||||||
| Other liabilities assumed | [5] | 11,283 | |||||||||||||||||||||||
| Cash consideration | 108,717 | ||||||||||||||||||||||||
| Cash consideration, net of working capital adjustment | 104,719 | ||||||||||||||||||||||||
| Working capital adjustment | $ 3,998 | ||||||||||||||||||||||||
| Aptiv Solutions | |||||||||||||||||||||||||
| Business Acquisition [Line Items] | |||||||||||||||||||||||||
| Goodwill | [6] | $ 125,627 | |||||||||||||||||||||||
| Cash consideration | 143,500 | ||||||||||||||||||||||||
| Working capital adjustment | $ 1,964 | $ 1,964 | |||||||||||||||||||||||
| Percentage of common stock acquired | 100.00% | ||||||||||||||||||||||||
| Adjustments to cash consideration | [7] | $ 22,399 | |||||||||||||||||||||||
| |||||||||||||||||||||||||
| X | ||||||||||
- Definition The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
- Definition Number of Clinical Research Sites Acquired No definition available.
|
| X | ||||||||||
- Definition Number of Patients No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Clinical Research Management, Inc. (Detail) - USD ($) $ in Thousands |
Sep. 15, 2016 |
Dec. 31, 2016 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | ||||||||||||
| Goodwill | $ 616,088 | $ 588,434 | $ 463,324 | |||||||||
| Clinical Research Management Inc. | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Cash | $ 3,168 | |||||||||||
| Property, plant and equipment | 939 | |||||||||||
| Goodwill | 34,576 | [2] | $ 34,576 | |||||||||
| Intangible assets | [3] | 8,644 | ||||||||||
| Accounts receivable | 11,725 | |||||||||||
| Unbilled revenue | 2,814 | |||||||||||
| Prepayments and other current assets | 1,673 | |||||||||||
| Accounts payable | (621) | |||||||||||
| Other liabilities | (4,515) | |||||||||||
| Non-current other liabilities | (7) | |||||||||||
| Net assets acquired | 58,396 | |||||||||||
| Cash consideration | 52,396 | |||||||||||
| Contingent consideration | $ 6,000 | |||||||||||
| ||||||||||||
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Clinical Research Management, Inc. (Parenthetical) (Detail) $ in Thousands |
Sep. 15, 2016
USD ($)
|
|||
|---|---|---|---|---|
| Clinical Research Management Inc. | ||||
| Business Acquisition [Line Items] | ||||
| Intangible asset | $ 8,644 | [1] | ||
| ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Proforma Effect in Net Revenue, Net Income and Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands |
12 Months Ended | |||
|---|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
|
| Clinical Research Management Inc. | ||||
| Business Acquisition [Line Items] | ||||
| Net revenue | $ 1,713,245 | $ 1,639,085 | ||
| Net income | $ 266,148 | $ 244,167 | ||
| Basic earnings per share | $ 4.82 | $ 4.16 | ||
| Diluted earnings per share | $ 4.72 | $ 4.05 | ||
| PMG | ||||
| Business Acquisition [Line Items] | ||||
| Net revenue | $ 1,601,891 | $ 1,527,685 | ||
| Net income | $ 243,004 | $ 172,390 | ||
| Basic earnings per share | $ 4.14 | $ 2.80 | ||
| Diluted earnings per share | $ 4.03 | $ 2.73 | ||
| MediMedia Pharma Solutions | ||||
| Business Acquisition [Line Items] | ||||
| Net revenue | $ 1,581,816 | $ 1,556,936 | ||
| Net income | $ 239,361 | $ 179,289 | ||
| Basic earnings per share | $ 4.07 | $ 2.92 | ||
| Diluted earnings per share | $ 3.97 | $ 2.84 | ||
| Aptiv Solutions | ||||
| Business Acquisition [Line Items] | ||||
| Net revenue | $ 1,543,820 | $ 1,451,682 | ||
| Net income | $ 172,508 | $ 101,857 | ||
| Basic earnings per share | $ 2.81 | $ 1.67 | ||
| Diluted earnings per share | $ 2.73 | $ 1.64 | ||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Dec. 04, 2015 |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
||||||
| Business Acquisition [Line Items] | |||||||||
| Goodwill | $ 616,088 | $ 588,434 | [1] | $ 463,324 | |||||
| Total cash outflows | 54,209 | $ 166,292 | $ 124,301 | ||||||
| PMG | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Cash | $ 194 | ||||||||
| Property, plant and equipment | 712 | ||||||||
| Goodwill | [2] | 48,728 | |||||||
| Accounts receivable | 11,597 | ||||||||
| Prepayments and other current assets | 1,329 | ||||||||
| Accounts payable | (530) | ||||||||
| Other liabilities | (3,456) | ||||||||
| Non-current deferred tax liability | (3,106) | ||||||||
| Net assets acquired | 65,354 | ||||||||
| Cash consideration | 53,681 | $ 1,613 | |||||||
| Other liabilities assumed | 10,060 | ||||||||
| Working capital adjustment | 1,613 | ||||||||
| Total cash outflows | 65,354 | ||||||||
| PMG | Customer Lists | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Intangible assets | 6,938 | ||||||||
| PMG | Order Backlog | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Intangible assets | $ 2,948 | ||||||||
| |||||||||
| X | ||||||||||
- Definition The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Parenthetical) (Detail) - PMG - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 04, 2015 |
Dec. 31, 2016 |
|
| Business Acquisition [Line Items] | ||
| Fair value adjustment to deferred tax liability | $ 3,100 | |
| Fair value adjustment to accounts receivable | 1,400 | |
| Fair value adjustment to other liabilities | 1,200 | |
| Cash consideration | $ 53,681 | 1,613 |
| Customer list and order backlog | ||
| Business Acquisition [Line Items] | ||
| Fair value adjustment to intangible assets | $ 400 |
| X | ||||||||||
- Definition Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities, Other No definition available.
|
| X | ||||||||||
- Definition Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities No definition available.
|
| X | ||||||||||
- Definition Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Detail) - USD ($) $ in Thousands |
Feb. 27, 2015 |
Dec. 31, 2016 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | ||||||||||||
| Goodwill | $ 616,088 | $ 588,434 | $ 463,324 | |||||||||
| MediMedia Pharma Solutions | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Property, plant and equipment | $ 1,049 | |||||||||||
| Goodwill | [2] | 92,084 | ||||||||||
| Accounts receivable | 5,240 | |||||||||||
| Unbilled revenue | 4,324 | |||||||||||
| Prepayments and other current assets | 621 | |||||||||||
| Accounts payable | (749) | |||||||||||
| Payments on account | (4,186) | |||||||||||
| Deferred tax liability | (2,171) | |||||||||||
| Other liabilities | (5,483) | |||||||||||
| Net assets acquired | 116,002 | |||||||||||
| Cash consideration | 108,717 | |||||||||||
| Other liabilities assumed | [3] | 11,283 | ||||||||||
| Gross cash outflows | 120,000 | |||||||||||
| Working capital adjustment | (3,998) | |||||||||||
| Net cash outflows | 116,002 | |||||||||||
| MediMedia Pharma Solutions | Customer Lists | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Intangible asset | 22,752 | |||||||||||
| MediMedia Pharma Solutions | Order Backlog | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Intangible asset | $ 2,521 | |||||||||||
| ||||||||||||
| X | ||||||||||
- Definition The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
- Definition Business Combination, Consideration Transferred, Gross No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Payments on Account No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as current. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Parenthetical) (Detail) $ in Thousands |
Feb. 27, 2015
USD ($)
|
|||
|---|---|---|---|---|
| MediMedia Pharma Solutions | ||||
| Business Acquisition [Line Items] | ||||
| Other liabilities assumed | $ 11,283 | [1] | ||
| ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Aptiv Solutions (Detail) - USD ($) $ in Thousands |
Mar. 25, 2015 |
May 07, 2014 |
Dec. 31, 2016 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | |||||||||||||
| Goodwill | $ 616,088 | $ 588,434 | $ 463,324 | ||||||||||
| Aptiv Solutions | |||||||||||||
| Business Acquisition [Line Items] | |||||||||||||
| Property, plant and equipment | $ 6,924 | ||||||||||||
| Goodwill | [2] | 125,627 | |||||||||||
| Cash and cash equivalents | 3,484 | ||||||||||||
| Accounts receivable | 25,091 | ||||||||||||
| Unbilled revenue | 21,154 | ||||||||||||
| Prepayments and other current assets | 4,180 | ||||||||||||
| Non-current assets | 2,911 | ||||||||||||
| Accounts payable | (9,565) | ||||||||||||
| Other liabilities | (29,782) | ||||||||||||
| Payments on account | (31,094) | ||||||||||||
| Non-current other liabilities | (11,303) | ||||||||||||
| Loan notes payable | [3] | (17,790) | |||||||||||
| Net assets acquired | 119,137 | ||||||||||||
| Cash consideration | 143,500 | ||||||||||||
| Working capital adjustment | $ (1,964) | (1,964) | |||||||||||
| Gross cash outflows | 141,536 | ||||||||||||
| Adjustments to cash consideration | [3] | (22,399) | |||||||||||
| Net assets acquired/Net purchase consideration | 119,137 | ||||||||||||
| Aptiv Solutions | Customer Relationships | |||||||||||||
| Business Acquisition [Line Items] | |||||||||||||
| Intangible asset | 21,400 | ||||||||||||
| Aptiv Solutions | Order Backlog | |||||||||||||
| Business Acquisition [Line Items] | |||||||||||||
| Intangible asset | $ 7,900 | ||||||||||||
| |||||||||||||
| X | ||||||||||
- Definition The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
- Definition Business Combination, Consideration Transferred, Gross No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Payments on Account No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Intangible Assets (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||
|---|---|---|---|---|---|
| Cost | |||||
| Foreign exchange movement | $ (6,578) | $ (5,092) | |||
| Intangible assets gross | 120,164 | 113,381 | |||
| Accumulated amortization | (67,037) | (49,587) | |||
| Foreign exchange movement | 3,483 | 2,333 | |||
| Net book value | 56,610 | 66,127 | [1] | ||
| Customer Relationships | |||||
| Cost | |||||
| Intangible assets gross | 87,218 | 90,541 | |||
| Technology Assets | |||||
| Cost | |||||
| Intangible assets gross | 11,169 | 11,169 | |||
| Order Backlog | |||||
| Cost | |||||
| Intangible assets gross | 16,540 | 13,592 | |||
| Trade Names | |||||
| Cost | |||||
| Intangible assets gross | 1,357 | 1,357 | |||
| Volunteer List Acquired | |||||
| Cost | |||||
| Intangible assets gross | 1,325 | 1,325 | |||
| Non-compete Agreements | |||||
| Cost | |||||
| Intangible assets gross | 489 | $ 489 | |||
| ClinicalRM Intangible Asset | |||||
| Cost | |||||
| Intangible assets gross | $ 8,644 | ||||
| |||||
| X | ||||||||||
- Definition Finite Lived Intangible Assets Accumulated Amortizations Foreign Exchange Movement No definition available.
|
| X | ||||||||||
- Definition Finite Lived Intangible Assets Foreign Exchange Movement No definition available.
|
| X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Intangible Assets - Additional Information (Detail) $ in Thousands |
Sep. 15, 2016
USD ($)
|
Dec. 04, 2015
USD ($)
Site
|
Feb. 27, 2015
USD ($)
|
May 07, 2014
USD ($)
|
Feb. 15, 2013
USD ($)
|
Feb. 28, 2012
USD ($)
|
Feb. 15, 2012
USD ($)
|
Jul. 14, 2011
USD ($)
|
Jan. 14, 2011
USD ($)
|
Nov. 14, 2008
USD ($)
|
Feb. 11, 2008
USD ($)
|
Dec. 31, 2016
USD ($)
|
Dec. 31, 2015
USD ($)
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | $ 67,037 | $ 49,587 | |||||||||||
| PMG | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 2,700 | ||||||||||||
| Number of clinical research sites acquired | Site | 48 | ||||||||||||
| PMG | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 6,900 | ||||||||||||
| Amortization period | 7 years | ||||||||||||
| PMG | Order Backlog | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 3,000 | ||||||||||||
| Amortization period | 2 years | ||||||||||||
| MediMedia Pharma Solutions | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 8,500 | ||||||||||||
| MediMedia Pharma Solutions | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 22,800 | ||||||||||||
| Amortization period | 7 years | ||||||||||||
| MediMedia Pharma Solutions | Order Backlog | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 2,500 | ||||||||||||
| Amortization period | 1 year | ||||||||||||
| Aptiv Solutions | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 15,200 | ||||||||||||
| Aptiv Solutions | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 21,400 | ||||||||||||
| Amortization period | 7 years | ||||||||||||
| Aptiv Solutions | Order Backlog | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 7,900 | ||||||||||||
| Amortization period | 3 years | ||||||||||||
| Clinical Trial Services of Cross Country Healthcare Inc. | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 3,900 | ||||||||||||
| Clinical Trial Services of Cross Country Healthcare Inc. | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 3,300 | ||||||||||||
| Amortization period | 3 years | ||||||||||||
| Clinical Trial Services of Cross Country Healthcare Inc. | Order Backlog | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 600 | ||||||||||||
| Amortization period | 1 year | ||||||||||||
| PriceSpective | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 5,700 | ||||||||||||
| PriceSpective | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 10,200 | ||||||||||||
| Amortization period | 10 years | ||||||||||||
| PriceSpective | Order Backlog | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 400 | ||||||||||||
| Amortization period | 9 months 18 days | ||||||||||||
| PriceSpective | Non-compete Agreements | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 400 | ||||||||||||
| Amortization period | 3 years | ||||||||||||
| BeijingWits Medical | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 1,300 | ||||||||||||
| BeijingWits Medical | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 1,800 | ||||||||||||
| Amortization period | 10 years | ||||||||||||
| BeijingWits Medical | Order Backlog | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 400 | ||||||||||||
| Amortization period | 4 years | ||||||||||||
| BeijingWits Medical | Non-compete Agreements | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 10 | ||||||||||||
| Amortization period | 5 years | ||||||||||||
| Firecrest Clinical Limited | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 12,800 | ||||||||||||
| Firecrest Clinical Limited | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 5,200 | ||||||||||||
| Amortization period | 7 years 6 months | ||||||||||||
| Firecrest Clinical Limited | Order Backlog | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 1,200 | ||||||||||||
| Amortization period | 1 year 2 months 12 days | ||||||||||||
| Firecrest Clinical Limited | Technology Assets | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 11,200 | ||||||||||||
| Amortization period | 7 years 6 months | ||||||||||||
| Firecrest Clinical Limited | Trade Names | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 1,400 | ||||||||||||
| Amortization period | 4 years 6 months | ||||||||||||
| Oxford Outcomes Limited | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 6,700 | ||||||||||||
| Oxford Outcomes Limited | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 6,600 | ||||||||||||
| Amortization period | 6 years 6 months | ||||||||||||
| Oxford Outcomes Limited | Order Backlog | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 600 | ||||||||||||
| Amortization period | 2 years | ||||||||||||
| Prevalere Life Sciences | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 6,400 | ||||||||||||
| Prevalere Life Sciences | Customer Lists | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 7,400 | ||||||||||||
| Prevalere Life Sciences | Minimum | Customer Lists | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amortization period | 7 years | ||||||||||||
| Prevalere Life Sciences | Maximum | Customer Lists | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amortization period | 11 years | ||||||||||||
| Healthcare Discoveries | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amount amortized since date of acquisition | 2,900 | ||||||||||||
| Healthcare Discoveries | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 1,600 | ||||||||||||
| Healthcare Discoveries | Volunteer List Acquired | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 1,300 | ||||||||||||
| Healthcare Discoveries | Minimum | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amortization period | 2 years | ||||||||||||
| Healthcare Discoveries | Minimum | Volunteer List Acquired | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amortization period | 6 years | ||||||||||||
| Healthcare Discoveries | Maximum | Customer Relationships | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Amortization period | 9 years | ||||||||||||
| Clinical Research Management Inc. | |||||||||||||
| Indefinite-lived Intangible Assets [Line Items] | |||||||||||||
| Value of amortizable intangible asset acquired | $ 8,600 | ||||||||||||
| Amortization period | 6 years | ||||||||||||
| Amount amortized since date of acquisition | $ 900 |
| X | ||||||||||
- Definition Number of Clinical Research Sites Acquired No definition available.
|
| X | ||||||||||
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Future Intangible Asset Amortization Expense (Detail) $ in Thousands |
Dec. 31, 2016
USD ($)
|
|---|---|
| Finite-Lived Intangible Assets [Line Items] | |
| 2017 | $ 15,449 |
| 2018 | 11,815 |
| 2019 | 9,921 |
| 2020 | 9,634 |
| 2021 | 7,597 |
| Finite Lived Intangible Assets, Amortization Expense, Net, Total | $ 54,416 |
| X | ||||||||||
- Definition Finite Lived Intangible Assets, Amortization Expense, Net No definition available.
|
| X | ||||||||||
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
Property, Plant and Equipment, Net (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||
|---|---|---|---|---|---|
| Cost | |||||
| Land | $ 3,464 | $ 3,464 | |||
| Building | 77,950 | 80,861 | |||
| Computer equipment and software | 315,984 | 282,909 | |||
| Office furniture and fixtures | 70,218 | 65,152 | |||
| Laboratory equipment | 31,487 | 31,098 | |||
| Leasehold improvements | 20,933 | 20,647 | |||
| Motor vehicles | 43 | 47 | |||
| Property, Plant and Equipment, Gross, Total | 520,079 | 484,178 | |||
| Less accumulated depreciation and asset write offs | (371,112) | (333,960) | |||
| Property, plant and equipment (net) | $ 148,967 | $ 150,218 | [1] | ||
| |||||
| X | ||||||||||
- Definition Vehicles, Gross No definition available.
|
| X | ||||||||||
- Definition Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accumulated depletion of real estate held for productive use, excluding land held for sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
Other Liabilities (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||
|---|---|---|---|---|---|
| Other Liabilities [Line Items] | |||||
| Personnel related liabilities | $ 135,349 | $ 159,339 | |||
| Facility related liabilities | 14,182 | 22,517 | |||
| General overhead liabilities | 31,126 | 29,257 | |||
| Other liabilities | 7,584 | 18,607 | |||
| Short term government grants (note 11) | 54 | 43 | |||
| Restructuring and other items (note 14) | 2,432 | 2,116 | |||
| Other liabilities (Note 7) | $ 190,727 | $ 231,879 | [1] | ||
| |||||
| X | ||||||||||
- Definition Capital Government Grants Current No definition available.
|
| X | ||||||||||
- Definition Other Liabilities [Line Items] No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Other Non-Current Liabilities (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||||
|---|---|---|---|---|---|---|---|
| Schedule of Accrued Liabilities [Line Items] | |||||||
| Defined benefit pension obligations, net (note 9) | $ 8,952 | $ 7,189 | |||||
| Other non-current liabilities | [1] | 14,800 | 5,035 | ||||
| Non-current other liabilities | $ 23,752 | $ 12,224 | [2] | ||||
| |||||||
| X | ||||||||||
- Definition Schedule of Accrued Liabilities [Line Items] No definition available.
|
| X | ||||||||||
- Definition This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Other Non-Current Liabilities (Parenthetical) (Detail) $ in Millions |
Sep. 15, 2016
USD ($)
|
|---|---|
| Clinical Research Management Inc. | |
| Schedule of Accrued Liabilities [Line Items] | |
| Contingent consideration | $ 6 |
| X | ||||||||||
- Definition Schedule of Accrued Liabilities [Line Items] No definition available.
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Employee Benefits - Additional Information (Detail) - USD ($) $ in Thousands |
12 Months Ended | |||
|---|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
May 07, 2014 |
|
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Defined contribution plan description | Certain Company employees are eligible to participate in a defined contribution plan (the "Plan"). Participants in the Plan may elect to defer a portion of their pre-tax earnings into a pension plan, which is run by an independent party. The Company matches participant's contributions typically at 6% of the participant's annual compensation. | |||
| Aptiv Solutions | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Percentage of common stock acquired | 100.00% | |||
| Defined Benefit Plan Contributions | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Contributions percentage of annual compensation | 6.00% | |||
| Employer contributions | $ 20,952 | $ 20,439 | $ 22,370 | |
| Defined Contribution Pension Plan 401(k) | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Participant's contributions percentage matches | 50.00% | |||
| Participant's contributions percentage of annual compensation | 6.00% | |||
| Deferred salary arrangement employer contribution | $ 15,223 | $ 12,802 | $ 10,514 | |
| Foreign Postretirement Benefit Plan | UNITED KINGDOM | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Net loss for defined benefit pension plan that will be amortized from accumulated other comprehensive income into net periodic benefit cost over the next year | (200) | |||
| Net prior service cost for defined benefit pension plan that will be amortized from accumulated other comprehensive income into net periodic benefit cost over the next year | $ 0 | |||
| Expected long-term rate of return after application of a market value reduction factor | 2.10% | |||
| Expected long term rate of return on bonds Description | Applying the above expected long term rates of return to the asset distribution at December 31, 2016, gives rise to an expected overall rate of return of scheme assets of approximately 2.1% per annum. | |||
| Contribution to pension fund in the year ending December 31, 2017 | $ 100 | |||
| Expected benefit cash flow description | The expected cash flows are estimated figures based on the members expected to retire over the next 10 years assuming no early retirements plus an additional amount based on recent average withdrawal experience. | |||
| Retirement period used as a basis to estimate expected cash flows | 10 years | |||
| Foreign Postretirement Benefit Plan | UNITED KINGDOM | iboxx Corporate Bonds | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Basis point increase in benefits obligation discount rate | 0.10% | |||
| Defined benefit plan bond maturity period | 15 years | |||
| Foreign Postretirement Benefit Plan | UNITED KINGDOM | Gilts | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Percentage of investments | 75.00% | |||
| Foreign Postretirement Benefit Plan | UNITED KINGDOM | Corporate Bond Securities | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Percentage of investments | 25.00% | |||
| Foreign Postretirement Benefit Plan | UNITED KINGDOM | Legal and General over 15 year Gilts Index | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Expected long term rate of return on bonds Description | The long-term expected return on corporate bonds and gilts (fixed interest and index linked) is determined by reference to bond yields and gilt yields at the balance sheet date. | |||
| Foreign Postretirement Benefit Plan | SWITZERLAND | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Net loss for defined benefit pension plan that will be amortized from accumulated other comprehensive income into net periodic benefit cost over the next year | $ (41) | |||
| Net prior service cost for defined benefit pension plan that will be amortized from accumulated other comprehensive income into net periodic benefit cost over the next year | 8 | |||
| Foreign Pension Plan | SWITZERLAND | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Contribution to pension fund in the year ending December 31, 2017 | $ 200 | |||
| Foreign Pension Plan | SWITZERLAND | Aptiv Solutions | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Percentage of common stock acquired | 100.00% | |||
| X | ||||||||||
- Definition Basis Point Increase In Pension And Postretirement Benefits Discount Rate No definition available.
|
| X | ||||||||||
- Definition Defined Benefit Plan, Expected Long Term Return on Assets after Application of Market Value Reduction Factor No definition available.
|
| X | ||||||||||
- Definition Defined Benefit Plan High Quality Bond Maturity Maximum Range Used To Determine Yield Curve Period No definition available.
|
| X | ||||||||||
- Definition Expected Retirement period No definition available.
|
| X | ||||||||||
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of payment into the fund established for purposes of making future disbursements to the individual in accordance with the terms and understanding of the deferred compensation arrangement. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount included in accumulated other comprehensive income (AOCI) related to gain (loss) expected to be recognized as components of net periodic benefit cost for the fiscal year that follows the most recent annual statement of financial position. No definition available.
|
| X | ||||||||||
- Definition Amount included in accumulated other comprehensive income (AOCI) related to prior service cost (credit) expected to be recognized as components of net periodic benefit cost for the fiscal year that follows the most recent annual statement of financial position. No definition available.
|
| X | ||||||||||
- Definition A narrative description of the basis used to determine the overall expected long-term rate-of-return on assets assumption, such as the general approach used, the extent to which the overall rate-of-return on assets assumption was based on historical returns, the extent to which adjustments were made to those historical returns to reflect expectations of future returns, and how those adjustments were determined. The description would generally consider the major categories of assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Target allocation of investments of this type to total plan assets presented on a weighted average basis. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of employer's best estimate of contributions expected to be paid to the plan during the next fiscal year beginning after the date of the latest statement of financial position. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of discretionary contributions made by an employer to a defined contribution plan. No definition available.
|
| X | ||||||||||
- Definition Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan. No definition available.
|
| X | ||||||||||
- Definition Percentage employer matches of the employee's percentage contribution matched. No definition available.
|
| X | ||||||||||
- Definition Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan. No definition available.
|
| X | ||||||||||
- Definition Description of the terms and benefits provided by the employer's defined contribution plans. A defined contribution plan provides benefits in return for services rendered, provides an individual account for each participant, and has terms that specify how contributions to the individual's account are to be determined rather than the amount of benefits the individual is to receive. Under a defined contribution pension plan, the benefits a participant will receive depend solely on the amount contributed to the participant's account, the returns earned on investments of those contributions, and forfeitures of other participants' benefits that may be allocated to such participant's account. A description of the plan(s) including employee groups covered, the basis for determining contributions, and the nature and effects of significant matters affecting comparability of information for all periods presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Description of and general information regarding the types of plans utilized by the employer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Change in Benefit Obligations (Detail) - Foreign Postretirement Benefit Plan - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| UNITED KINGDOM | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Benefit obligation at beginning of year | $ 27,369 | $ 32,875 | |
| Service cost | 75 | 78 | $ 91 |
| Interest cost | 1,017 | 1,140 | 1,235 |
| Plan participants' contributions | 22 | 26 | |
| Expenses | 8 | 359 | |
| Benefits paid | (104) | (1,111) | |
| Actuarial (gain)/loss | 10,057 | (3,992) | |
| Foreign currency exchange rate changes | (5,538) | (1,647) | |
| Benefit obligation at end of year | 32,906 | 27,369 | 32,875 |
| SWITZERLAND | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Benefit obligation at beginning of year | 8,537 | 8,884 | |
| Service cost | 352 | 618 | |
| Interest cost | 82 | 159 | |
| Plan participants' contributions | 150 | ||
| Settlement | (909) | ||
| Prior service cost | (88) | ||
| Transferred balances/(benefits paid) | 53 | (1,146) | |
| Actuarial (gain)/loss | (1,157) | 81 | |
| Foreign currency exchange rate changes | (92) | (59) | |
| Benefit obligation at end of year | $ 6,928 | $ 8,537 | $ 8,884 |
| X | ||||||||||
- Definition Define Benefit Plan Expenses No definition available.
|
| X | ||||||||||
- Definition Amount of gain (loss) related to change in benefit obligation resulting from changes in actuarial assumptions, for example, but not limited to, interest, mortality, employee turnover, salary, and temporary deviation from the substantive plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of the prior service cost or credit recognized in net periodic benefit cost relating to benefit changes attributable to plan participants' prior service pursuant to a plan amendment or a plan initiation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Fair value of assets transferred into (out of) a defined benefit pension plan. No definition available.
|
| X | ||||||||||
- Definition 1) For defined benefit pension plans, the benefit obligation is the projected benefit obligation, which is the actuarial present value as of a date of all benefits attributed by the pension benefit formula to employee service rendered prior to that date. 2) For other postretirement defined benefit plans, the benefit obligation is the accumulated postretirement benefit obligation, which is the actuarial present value of benefits attributed to employee service rendered to a particular date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of payments made for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services. This item represents a periodic decrease to the plan obligations and a decrease to plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of contributions made by plan participants. This item represents a periodic increase to the plan obligation and an increase to plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of gain (loss) from foreign currency exchange rate changes for benefit obligation for plans of a foreign operation whose functional currency is not the reporting currency. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The actuarial present value of benefits attributed by the pension benefit formula to services rendered by employees during the period. The portion of the expected postretirement benefit obligation attributed to employee service during the period. The service cost component is a portion of the benefit obligation and is unaffected by the funded status of the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of decrease that relates to an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include (a) making lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and (b) purchasing nonparticipating annuity contracts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Change in Plan Assets (Detail) - Foreign Postretirement Benefit Plan - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| UNITED KINGDOM | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets at beginning of year | $ 23,367 | $ 25,409 | |
| Expected return on plan assets | 646 | 661 | $ 1,299 |
| Actual return on plan assets | 5,861 | 277 | |
| Employer contributions | 108 | 114 | |
| Plan participants' contributions | 22 | 26 | |
| Benefits paid | (104) | (1,111) | |
| Foreign currency exchange rate changes | (4,378) | (1,348) | |
| Fair value of plan assets at end of year | 24,876 | 23,367 | 25,409 |
| SWITZERLAND | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets at beginning of year | 5,350 | 7,061 | |
| Expected return on plan assets | 48 | 93 | |
| Actual return on plan assets | 1,233 | (1,075) | |
| Scheme contributions | 195 | 194 | |
| Plan participants' contributions | 150 | 216 | |
| Transferred balances/(benefits paid) | 53 | (1,146) | |
| Settlement | (909) | ||
| Foreign currency exchange rate changes | (114) | 7 | |
| Fair value of plan assets at end of year | $ 6,006 | $ 5,350 | $ 7,061 |
| X | ||||||||||
- Definition Defined Benefit Plan Contributions By Plan Participants To Plan Assets No definition available.
|
| X | ||||||||||
- Definition Defined Benefit Plan, Scheme Contributions No definition available.
|
| X | ||||||||||
- Definition The difference between fair value of plan assets at the end of the period and the fair value at the beginning of the period, adjusted for contributions and payments of benefits during the period, and after adjusting for taxes and other expenses, as applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Fair value of assets transferred into (out of) a defined benefit pension plan. No definition available.
|
| X | ||||||||||
- Definition The amount of payments made for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services. This item represents a periodic decrease to the plan obligations and a decrease to plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of contributions made by the employer to defined benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition An amount calculated as a basis for determining the extent of delayed recognition of the effects of changes in the fair value of assets. The expected return on plan assets is determined based on the expected long-term rate of return on plan assets and the market-related value of plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Fair value of assets that have been segregated and restricted to provide pension or postretirement benefits. Assets include, but are not limited to, stocks, bonds, other investments, earnings from investments, and contributions by the employer and employees. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of increase or decrease in plan assets attributed to foreign currency changes. The effects of foreign currency exchange rate changes that are to be disclosed are those applicable to plans of a foreign operation whose functional currency is not the reporting currency. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of decrease that relates to an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include (a) making lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and (b) purchasing nonparticipating annuity contracts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Funded Status - United Kingdom (Detail) - Foreign Postretirement Benefit Plan - UNITED KINGDOM - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|---|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Projected benefit obligation | $ (32,906) | $ (27,369) | |
| Fair value of plan assets | 24,876 | 23,367 | $ 25,409 |
| Funded status | (8,030) | (4,002) | |
| Non-current other liabilities (note 8) | $ (8,030) | $ (4,002) |
| X | ||||||||||
- Definition The aggregate net amount recognized in the balance sheet associated with the defined benefit plan(s). Will normally be the same as the Defined Benefit Plan, Funded Status of Plan, Total. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Fair value of assets that have been segregated and restricted to provide pension or postretirement benefits. Assets include, but are not limited to, stocks, bonds, other investments, earnings from investments, and contributions by the employer and employees. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The funded status is measured as the difference between the fair value of plan assets and the benefit obligation. Will normally be the same as the net Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition If aggregate disclosures are presented, the aggregate projected benefit obligation for pension plans with accumulated benefit obligations in excess of plan assets as of the measurement date of each statement of financial position presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Components of Net Periodic Benefit Cost (Detail) - Foreign Postretirement Benefit Plan - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| UNITED KINGDOM | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Service cost | $ 75 | $ 78 | $ 91 |
| Interest cost | 1,017 | 1,140 | 1,235 |
| Expected return on plan assets | (646) | (661) | (1,299) |
| Amortization of net loss | 224 | 20 | |
| Expenses | 8 | 359 | |
| Net periodic benefit cost | 454 | 781 | $ 406 |
| SWITZERLAND | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Service cost | 352 | 618 | |
| Interest cost | 82 | 159 | |
| Expected return on plan assets | (48) | (93) | |
| Amortization of prior service credit | 88 | ||
| Settlement | (909) | ||
| SWITZERLAND | Includes Financial Instruments, Property Occupied by, or Other Assets | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Service cost | 352 | 402 | |
| Interest cost | 82 | 159 | |
| Expected return on plan assets | (48) | (119) | |
| Amortization of net loss | 22 | ||
| Amortization of prior service credit | (8) | ||
| Settlement | (136) | ||
| Curtailment loss | 18 | ||
| Net periodic benefit cost | $ 264 | $ 460 | |
| X | ||||||||||
- Definition Define Benefit Plan Expenses No definition available.
|
| X | ||||||||||
- Definition The amount of gains or losses recognized in net periodic benefit cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of the prior service cost or credit recognized in net periodic benefit cost relating to benefit changes attributable to plan participants' prior service pursuant to a plan amendment or a plan initiation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition An amount calculated as a basis for determining the extent of delayed recognition of the effects of changes in the fair value of assets. The expected return on plan assets is determined based on the expected long-term rate of return on plan assets and the market-related value of plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The total amount of net periodic benefit cost for defined benefit plans for the period. Periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net gain (loss) recognized in net periodic benefit cost as a result of an event that significantly reduces the expected years of future service of present employees or eliminates for a significant number of employees the accrual of defined benefits for some or all of their future services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The actuarial present value of benefits attributed by the pension benefit formula to services rendered by employees during the period. The portion of the expected postretirement benefit obligation attributed to employee service during the period. The service cost component is a portion of the benefit obligation and is unaffected by the funded status of the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of decrease that relates to an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include (a) making lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and (b) purchasing nonparticipating annuity contracts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Net Periodic Pension Benefit Cost Assumptions (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Total | $ 2,485 | $ (2,693) | $ 4,125 |
| Foreign Postretirement Benefit Plan | UNITED KINGDOM | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Discount rate | 4.00% | 3.60% | 4.70% |
| Rate of compensation increase | 3.70% | 3.60% | 4.00% |
| Expected rate of return on plan assets | 3.00% | 2.70% | 6.10% |
| Actuarial (gain)/loss - benefit obligation | $ 10,057 | $ (3,992) | $ 8,270 |
| Actuarial (gain)/loss - plan assets | (5,215) | 384 | (4,125) |
| Actuarial gain recognized in net periodic benefit cost | (224) | (20) | |
| Total | $ 4,842 | $ (3,832) | $ 4,125 |
| Foreign Postretirement Benefit Plan | SWITZERLAND | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Discount rate | 0.95% | 1.35% | |
| Rate of compensation increase | 2.00% | 2.00% | |
| Expected rate of return on plan assets | 0.95% | 1.35% | |
| Actuarial (gain)/loss - benefit obligation | $ (1,157) | $ 81 | |
| Actuarial (gain)/loss - plan assets | (1,233) | 1,075 | |
| Prior service credit/(cost) recognized in net periodic benefit cost | 136 | (17) | |
| Actuarial gain recognized in net periodic benefit cost | (22) | ||
| Amortization of net prior service credit | 8 | ||
| Net prior service credit occurring during the year | (89) | ||
| Total | $ (2,357) | $ 1,139 | |
| X | ||||||||||
- Definition Defined Benefit Plan, Actuarial Losses to be Amortized and Reclassified from Accumulated Other Comprehensive Income (Loss) to Net Pension Cost No definition available.
|
| X | ||||||||||
- Definition Other Comprehensive Income, Amortization of Net Actuarial Gain (Loss), Net of Tax No definition available.
|
| X | ||||||||||
- Definition Other Comprehensive Income Amortization of Net Period Service Credit Net of Tax No definition available.
|
| X | ||||||||||
- Definition The interest rate used to adjust for the time value of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition An assumption as to the rate of return on plan assets reflecting the average rate of earnings expected on the funds invested or to be invested to provide for the benefits included in the benefit obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Expected rate of compensation increases (for pay-related plans). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of cost (credit) of benefit changes attributable to plan participants' prior service resulting from a plan amendment or plan initiation that has not been recognized in net periodic benefit cost (credit). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) related to pension and other postretirement benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of reclassification adjustment from accumulated other comprehensive income (loss) for actuarial gain (loss) related to pension and other postretirement benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of reclassification adjustment from accumulated other comprehensive income (loss) for net transition asset (obligation) related to pension and other postretirement benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Amounts recognized in accumulated other comprehensive income that have not been recognized (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|---|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Total | $ 5,905 | $ 3,420 | |
| Foreign Postretirement Benefit Plan | UNITED KINGDOM | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Net actuarial (gain)/loss | 7,123 | 2,281 | $ 6,113 |
| Total | 7,123 | 2,281 | $ 6,113 |
| Foreign Postretirement Benefit Plan | SWITZERLAND | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Net actuarial (gain)/loss | (1,218) | 1,139 | |
| Total | $ (1,218) | $ 1,139 |
| X | ||||||||||
- Definition The total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition After tax net amount of gain (loss) that are not yet recognized as a component of net periodic benefit cost, and that are recognized as increases (decreases) in other comprehensive income as they arise. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Assumptions Used in Determining Benefit Obligation (Detail) - Foreign Postretirement Benefit Plan |
Dec. 31, 2016 |
Dec. 31, 2015 |
|---|---|---|
| UNITED KINGDOM | ||
| Defined Benefit Plan Disclosure [Line Items] | ||
| Discount rate | 2.70% | 4.00% |
| Rate of compensation increase | 3.90% | 3.70% |
| SWITZERLAND | ||
| Defined Benefit Plan Disclosure [Line Items] | ||
| Discount rate | 0.75% | 0.95% |
| Rate of compensation increase | 2.00% | 2.00% |
| X | ||||||||||
- Definition The interest rate used to adjust for the time value of money for the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Expected rate of compensation increases (for pay-related plans). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Expected Long Term Rates of Return on Different Asset Classes (Detail) - Foreign Postretirement Benefit Plan - UNITED KINGDOM |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Expected long-term return per annum | 3.00% | 2.70% | 6.10% |
| Corporate Bond Securities | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Expected long-term return per annum | 2.70% | ||
| Gilts | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Expected long-term return per annum | 1.90% | ||
| X | ||||||||||
- Definition An assumption as to the rate of return on plan assets reflecting the average rate of earnings expected on the funds invested or to be invested to provide for the benefits included in the benefit obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Actual Plan Asset Allocation (Detail) - UNITED KINGDOM - Foreign Postretirement Benefit Plan |
Dec. 31, 2016 |
Dec. 31, 2015 |
|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | ||
| Actual plan asset allocations | 100.00% | 100.00% |
| Corporate Bond Securities | ||
| Defined Benefit Plan Disclosure [Line Items] | ||
| Actual plan asset allocations | 25.00% | 26.00% |
| Gilts | ||
| Defined Benefit Plan Disclosure [Line Items] | ||
| Actual plan asset allocations | 75.00% | 74.00% |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Percentage of fair value of investments (categorized by debt securities, equity securities, real estate and other plan assets) to the fair value of plan assets held. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Plan Asset Fair Value Measurements (Detail) - Foreign Postretirement Benefit Plan - UNITED KINGDOM - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|---|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | $ 24,876 | $ 23,367 | $ 25,409 |
| Fair Value, Inputs, Level 1 | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 24,876 | 23,367 | |
| Fair Value, Inputs, Level 1 | Cash | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 16 | 3 | |
| Fair Value, Inputs, Level 1 | Fixed Income Securities | Legal and General Active Corporate Bond Over - 10 Year | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 6,095 | 6,256 | |
| Fair Value, Inputs, Level 1 | Fixed Income Securities | Legal and General Gilt Funds | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 6,725 | 6,528 | |
| Fair Value, Inputs, Level 1 | Fixed Income Securities | Legal and General Index Linked Gilt Funds | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | $ 12,040 | $ 10,580 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Fair value of assets that have been segregated and restricted to provide pension or postretirement benefits. Assets include, but are not limited to, stocks, bonds, other investments, earnings from investments, and contributions by the employer and employees. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Annual Benefit Payments (Detail) - Foreign Postretirement Benefit Plan $ in Thousands |
Dec. 31, 2016
USD ($)
|
|---|---|
| UNITED KINGDOM | |
| Defined Benefit Plan Disclosure [Line Items] | |
| Expected future benefit payments in 2017 | $ 64 |
| Expected future benefit payments in 2018 | 65 |
| Expected future benefit payments in 2019 | 68 |
| Expected future benefit payments in 2020 | 70 |
| Expected future benefit payments in 2021 | 73 |
| Expected future benefit payments in Years 2022 - 2026 | 362 |
| SWITZERLAND | |
| Defined Benefit Plan Disclosure [Line Items] | |
| Expected future benefit payments in 2017 | 305 |
| Expected future benefit payments in 2018 | 306 |
| Expected future benefit payments in 2019 | 685 |
| Expected future benefit payments in 2020 | 251 |
| Expected future benefit payments in 2021 | 249 |
| Expected future benefit payments in Years 2022 - 2026 | $ 1,676 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of benefits from a defined benefit plan expected to be paid in the five fiscal years after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of benefits from a defined benefit plan expected to be paid in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of benefits from a defined benefit plan expected to be paid in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of benefits from a defined benefit plan expected to be paid in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of benefits from a defined benefit plan expected to be paid in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of benefits from a defined benefit plan expected to be paid in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Funded Status - Switzerland (Detail) - Foreign Postretirement Benefit Plan - SWITZERLAND - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|---|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Projected benefit obligation | $ (6,928) | $ (8,537) | |
| Fair value of plan assets | 6,006 | 5,350 | $ 7,061 |
| Funded status | (922) | (3,187) | |
| Non-current other liabilities (note 8) | $ (922) | $ (3,187) |
| X | ||||||||||
- Definition The aggregate net amount recognized in the balance sheet associated with the defined benefit plan(s). Will normally be the same as the Defined Benefit Plan, Funded Status of Plan, Total. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Fair value of assets that have been segregated and restricted to provide pension or postretirement benefits. Assets include, but are not limited to, stocks, bonds, other investments, earnings from investments, and contributions by the employer and employees. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The funded status is measured as the difference between the fair value of plan assets and the benefit obligation. Will normally be the same as the net Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition If aggregate disclosures are presented, the aggregate projected benefit obligation for pension plans with accumulated benefit obligations in excess of plan assets as of the measurement date of each statement of financial position presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Equity Incentive Schemes and Stock Compensation Charges - Additional Information (Detail) - USD ($) $ in Thousands |
12 Months Ended | 36 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Feb. 14, 2017 |
May 11, 2015 |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2016 |
Dec. 31, 2017 |
|
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Weighted average contractual term of options outstanding | 4 years 8 months 1 day | 4 years 9 months 4 days | |||||
| Exercisable - weighted average remaining contractual life | 3 years 3 months 18 days | 3 years 4 months 21 days | |||||
| Options expected to vest | 336,993 | 336,993 | |||||
| Intrinsic value of option exercised | $ 19,600 | ||||||
| Intrinsic value of option outstanding | 46,600 | $ 46,600 | |||||
| Intrinsic value of option exercisable | 29,600 | 29,600 | |||||
| Share-based compensation expense | 40,343 | $ 33,317 | $ 22,742 | ||||
| Non-cash stock compensation expense not yet recognized | $ 64,900 | $ 64,900 | |||||
| Unrecognized stock-based compensation expense, weighted average period (years) | 2 years 26 days | ||||||
| Tax benefit on exercise of options | $ 4,332 | 1,905 | $ 2,404 | ||||
| Income tax expense related to stock compensation | 3,500 | 1,500 | |||||
| Cash tax benefit related to stock options exercised | $ 3,400 | 5,600 | |||||
| Scenario, Forecast | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Options expected to vest | 333,433 | ||||||
| Employee Stock Plan, 2008 Plan | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | 6,000,000 | |||||
| Employee Stock Plan, 2008 Plan | Individual Employee | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Ordinary shares which have been reserved for issuance | 400,000 | 400,000 | |||||
| Employee Stock Plan, 2008 Plan | Minimum | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Percentage of option price for fair value of ordinary share | 100.00% | ||||||
| Employee Stock Plan, 2008 Plan | Minimum | Subsequent Event | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Additional number of ordinary shares which have been reserved for issuance | 400,000 | ||||||
| Employee Stock Plan, 2008 Plan | Maximum | Subsequent Event | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Additional number of ordinary shares which have been reserved for issuance | 1,000,000 | ||||||
| Employee Stock Plan, 2003 Plan | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | 6,000,000 | |||||
| Maximum number of award as percentage of shares outstanding | 10.00% | ||||||
| Employee Stock Plan, 2003 Plan | Individual Employee | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Ordinary shares which have been reserved for issuance | 400,000 | 400,000 | |||||
| Employee Stock Option | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Shares vesting period | 5 years | ||||||
| Shares expiration period | 8 years | ||||||
| Employee Stock Option | Vested and Unvested Options | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Options vesting percentage | 20.00% | ||||||
| Employee Stock Option | Maximum | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Weighted average contractual term of options outstanding | 8 years | ||||||
| Restricted Stock Units 2008 | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Ordinary shares which have been reserved for issuance | 1,000,000 | 1,000,000 | |||||
| Restricted Stock Units 2013 | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Additional number of ordinary shares which have been reserved for issuance | 2,500,000 | ||||||
| Ordinary shares which have been reserved for issuance | 4,100,000 | ||||||
| Restricted Stock Units (RSUs) | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Fair value of stock units vested | $ 10,800 | 7,000 | |||||
| Stock units granted | 391,196 | ||||||
| Performance Share Unit (PSUs) | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Fair value of stock units vested | $ 10,300 | $ 300 | |||||
| Stock units granted | 247,992 | ||||||
| PSUs Based on Service and EPS Targets | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Stock units granted | 421,079 | ||||||
| PSUs Based on Service and EPS Targets | Minimum | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Cumulative EPS vesting period | 2013 | ||||||
| PSUs Based on Service and EPS Targets | Maximum | |||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||
| Stock units to be granted | 409,444 | 409,444 | |||||
| Cumulative EPS vesting period | 2019 | ||||||
| X | ||||||||||
- Definition Compensation Related Costs Share Based Payments Disclosure [Line Items] No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award Other Than Options Expected Vesting Period No definition available.
|
| X | ||||||||||
- Definition Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Unrecognized cost of unvested share-based compensation awards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Disclosure of the aggregate tax benefit realized from the exercise of stock options and the conversion of similar instruments during the annual period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of additional shares authorized for issuance under an established share-based compensation plan. No definition available.
|
| X | ||||||||||
- Definition The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. No definition available.
|
| X | ||||||||||
- Definition Percentage of vesting of share-based compensation awards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Purchase price of common stock expressed as a percentage of its fair value. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Stock Option Activity (Detail) - Stock Option And Award Plans - $ / shares |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Options Granted Under Plans | |||
| Beginning balance | 1,626,582 | 2,227,700 | 2,973,788 |
| Granted | 256,191 | 259,059 | 366,985 |
| Exercised | (393,240) | (773,753) | (926,407) |
| Cancelled | (23,089) | (86,424) | (186,666) |
| Ending Balance | 1,466,444 | 1,626,582 | 2,227,700 |
| Vested and exercisable at end of period | 651,574 | ||
| Number of Shares | |||
| Beginning balance | 1,626,582 | 2,227,700 | 2,973,788 |
| Granted | 256,191 | 259,059 | 366,985 |
| Exercised | (393,240) | (773,753) | (926,407) |
| Cancelled | (23,089) | (86,424) | (186,666) |
| Ending balance | 1,466,444 | 1,626,582 | 2,227,700 |
| Vested and exercisable at end of period | 651,574 | ||
| Weighted Average Exercise Price | |||
| Beginning balance | $ 34.87 | $ 28.00 | $ 24.20 |
| Granted | 69.61 | 68.25 | 45.82 |
| Exercised | 25.79 | 27.13 | 24.02 |
| Cancelled | 29.74 | 27.32 | 22.17 |
| Ending balance | 43.45 | 34.87 | 28.00 |
| Vested and exercisable at end of period | 29.80 | ||
| Weighted Average Grant Date Fair Value | |||
| Beginning balance | 11.94 | 10.40 | 9.57 |
| Granted | 20.10 | 19.75 | 14.09 |
| Exercised | 9.84 | 10.31 | 9.45 |
| Cancelled | 11.19 | 10.31 | 9.01 |
| Ending balance | 13.94 | $ 11.94 | $ 10.40 |
| Vested and exercisable at end of period | $ 10.69 | ||
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Additional Grant No definition available.
|
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Outstanding, Number No definition available.
|
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Outstanding [Abstract] No definition available.
|
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Grants in Period No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant, Options Cancelled In Period No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant, Options Exercised In Period No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable and Vested, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Abstract] No definition available.
|
| X | ||||||||||
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. No definition available.
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. No definition available.
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Movement in Non-Vested Share Options (Detail) - Employee Stock Option - $ / shares |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Options Outstanding Number of Shares | |||
| Beginning Balance | 968,853 | ||
| Granted | 256,191 | ||
| Vested | (391,918) | ||
| Forfeited | (18,256) | ||
| Ending Balance | 814,870 | 968,853 | |
| Weighted Average Exercise Price | |||
| Beginning balance | $ 42.14 | ||
| Granted | 69.61 | ||
| Vested | 35.17 | ||
| Forfeited | 31.48 | ||
| Ending balance | 54.37 | $ 42.14 | |
| Weighted Average Fair Value | |||
| Beginning Balance | 13.69 | ||
| Granted | 20.10 | 19.75 | $ 14.09 |
| Vested | 12.04 | ||
| Forfeited | 11.62 | ||
| Ending Balance | $ 16.55 | $ 13.69 | |
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Exercise Price Abstract No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Number of non-vested options forfeited. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options forfeited. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of options vested. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of options vested. No definition available.
|
| X | ||||||||||
- Details
|
Outstanding and Exercisable Share Options (Detail) |
12 Months Ended |
|---|---|
|
Dec. 31, 2016
$ / shares
shares
| |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 71.95 |
| Range Exercise Price Minimum | $ 15.84 |
| Options Outstanding Number of Shares | shares | 1,466,444 |
| Options Outstanding Weighted Average Remaining Contractual Life | 4 years 8 months 1 day |
| Options Outstanding Weighted Average Exercise Price | $ 43.45 |
| Options Exercisable Number of Shares | shares | 651,574 |
| Options Exercisable Weighted Average Exercise Price | $ 29.80 |
| Range 1 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 15.84 |
| Options Outstanding Number of Shares | shares | 50,000 |
| Options Outstanding Weighted Average Remaining Contractual Life | 3 months 26 days |
| Options Outstanding Weighted Average Exercise Price | $ 15.84 |
| Options Exercisable Number of Shares | shares | 50,000 |
| Options Exercisable Weighted Average Exercise Price | $ 15.84 |
| Range 2 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 16.80 |
| Options Outstanding Number of Shares | shares | 60,000 |
| Options Outstanding Weighted Average Remaining Contractual Life | 2 years 9 months 29 days |
| Options Outstanding Weighted Average Exercise Price | $ 16.80 |
| Options Exercisable Number of Shares | shares | 60,000 |
| Options Exercisable Weighted Average Exercise Price | $ 16.80 |
| Range 3 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 17.17 |
| Options Outstanding Number of Shares | shares | 6,000 |
| Options Outstanding Weighted Average Remaining Contractual Life | 2 years 10 months 6 days |
| Options Outstanding Weighted Average Exercise Price | $ 17.17 |
| Options Exercisable Number of Shares | shares | 6,000 |
| Options Exercisable Weighted Average Exercise Price | $ 17.17 |
| Range 4 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 20.28 |
| Options Outstanding Number of Shares | shares | 107,588 |
| Options Outstanding Weighted Average Remaining Contractual Life | 2 years 1 month 28 days |
| Options Outstanding Weighted Average Exercise Price | $ 20.28 |
| Options Exercisable Number of Shares | shares | 107,588 |
| Options Exercisable Weighted Average Exercise Price | $ 20.28 |
| Range 5 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 20.59 |
| Options Outstanding Number of Shares | shares | 33,000 |
| Options Outstanding Weighted Average Remaining Contractual Life | 3 years 1 month 21 days |
| Options Outstanding Weighted Average Exercise Price | $ 20.59 |
| Options Exercisable Number of Shares | shares | 7,200 |
| Options Exercisable Weighted Average Exercise Price | $ 20.59 |
| Range 6 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 22.26 |
| Options Outstanding Number of Shares | shares | 2,160 |
| Options Outstanding Weighted Average Remaining Contractual Life | 1 month 24 days |
| Options Outstanding Weighted Average Exercise Price | $ 22.26 |
| Options Exercisable Number of Shares | shares | 2,160 |
| Options Exercisable Weighted Average Exercise Price | $ 22.26 |
| Range 7 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 22.30 |
| Options Outstanding Number of Shares | shares | 173,642 |
| Options Outstanding Weighted Average Remaining Contractual Life | 3 years 3 months 26 days |
| Options Outstanding Weighted Average Exercise Price | $ 22.30 |
| Options Exercisable Number of Shares | shares | 112,061 |
| Options Exercisable Weighted Average Exercise Price | $ 22.30 |
| Range 8 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 23.66 |
| Options Outstanding Number of Shares | shares | 3,520 |
| Options Outstanding Weighted Average Remaining Contractual Life | 3 years 6 months 26 days |
| Options Outstanding Weighted Average Exercise Price | $ 23.66 |
| Options Exercisable Number of Shares | shares | 1,910 |
| Options Exercisable Weighted Average Exercise Price | $ 23.66 |
| Range 9 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 24.46 |
| Options Outstanding Number of Shares | shares | 60,816 |
| Options Outstanding Weighted Average Remaining Contractual Life | 1 year 2 months 1 day |
| Options Outstanding Weighted Average Exercise Price | $ 24.46 |
| Options Exercisable Number of Shares | shares | 60,816 |
| Options Exercisable Weighted Average Exercise Price | $ 24.46 |
| Range 10 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 26.20 |
| Options Outstanding Number of Shares | shares | 450 |
| Options Outstanding Weighted Average Remaining Contractual Life | 1 year 4 months 17 days |
| Options Outstanding Weighted Average Exercise Price | $ 26.20 |
| Options Exercisable Number of Shares | shares | 450 |
| Options Exercisable Weighted Average Exercise Price | $ 26.20 |
| Range 11 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 26.71 |
| Options Outstanding Number of Shares | shares | 4,450 |
| Options Outstanding Weighted Average Remaining Contractual Life | 3 years 8 months 9 days |
| Options Outstanding Weighted Average Exercise Price | $ 26.71 |
| Options Exercisable Number of Shares | shares | 3,560 |
| Options Exercisable Weighted Average Exercise Price | $ 26.71 |
| Range 12 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 29.45 |
| Options Outstanding Number of Shares | shares | 3,000 |
| Options Outstanding Weighted Average Remaining Contractual Life | 1 year 3 months 26 days |
| Options Outstanding Weighted Average Exercise Price | $ 29.45 |
| Options Exercisable Number of Shares | shares | 3,000 |
| Options Exercisable Weighted Average Exercise Price | $ 29.45 |
| Range 13 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 32.37 |
| Options Outstanding Number of Shares | shares | 165,865 |
| Options Outstanding Weighted Average Remaining Contractual Life | 4 years 3 months 29 days |
| Options Outstanding Weighted Average Exercise Price | $ 32.37 |
| Options Exercisable Number of Shares | shares | 95,457 |
| Options Exercisable Weighted Average Exercise Price | $ 32.37 |
| Range 14 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 36.22 |
| Options Outstanding Number of Shares | shares | 20,178 |
| Options Outstanding Weighted Average Remaining Contractual Life | 4 years 5 months 16 days |
| Options Outstanding Weighted Average Exercise Price | $ 36.22 |
| Options Exercisable Number of Shares | shares | 8,443 |
| Options Exercisable Weighted Average Exercise Price | $ 36.22 |
| Range 15 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 37.90 |
| Options Outstanding Number of Shares | shares | 5,720 |
| Options Outstanding Weighted Average Remaining Contractual Life | 4 years 11 months 5 days |
| Options Outstanding Weighted Average Exercise Price | $ 37.90 |
| Options Exercisable Number of Shares | shares | 1,600 |
| Options Exercisable Weighted Average Exercise Price | $ 37.90 |
| Range 16 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 40.83 |
| Options Outstanding Number of Shares | shares | 81,658 |
| Options Outstanding Weighted Average Remaining Contractual Life | 5 years 4 months 21 days |
| Options Outstanding Weighted Average Exercise Price | $ 40.83 |
| Options Exercisable Number of Shares | shares | 24,646 |
| Options Exercisable Weighted Average Exercise Price | $ 40.83 |
| Range 17 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 47.03 |
| Options Outstanding Number of Shares | shares | 63,813 |
| Options Outstanding Weighted Average Remaining Contractual Life | 5 years 2 months 1 day |
| Options Outstanding Weighted Average Exercise Price | $ 47.03 |
| Options Exercisable Number of Shares | shares | 15,693 |
| Options Exercisable Weighted Average Exercise Price | $ 47.03 |
| Range 18 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 48.67 |
| Options Outstanding Number of Shares | shares | 118,493 |
| Options Outstanding Weighted Average Remaining Contractual Life | 5 years 2 months 16 days |
| Options Outstanding Weighted Average Exercise Price | $ 48.67 |
| Options Exercisable Number of Shares | shares | 22,992 |
| Options Exercisable Weighted Average Exercise Price | $ 48.67 |
| Range 19 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 51.35 |
| Options Outstanding Number of Shares | shares | 4,030 |
| Options Outstanding Weighted Average Remaining Contractual Life | 5 years 7 months 6 days |
| Options Outstanding Weighted Average Exercise Price | $ 51.35 |
| Options Exercisable Number of Shares | shares | 1,612 |
| Options Exercisable Weighted Average Exercise Price | $ 51.35 |
| Range 20 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 65.60 |
| Options Outstanding Number of Shares | shares | 93,534 |
| Options Outstanding Weighted Average Remaining Contractual Life | 7 years 4 months 17 days |
| Options Outstanding Weighted Average Exercise Price | $ 65.60 |
| Options Exercisable Number of Shares | shares | 10,557 |
| Options Exercisable Weighted Average Exercise Price | $ 65.60 |
| Range 21 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 66.47 |
| Options Outstanding Number of Shares | shares | 11,931 |
| Options Outstanding Weighted Average Remaining Contractual Life | 6 years 4 months 21 days |
| Options Outstanding Weighted Average Exercise Price | $ 66.47 |
| Options Exercisable Number of Shares | shares | 1,417 |
| Options Exercisable Weighted Average Exercise Price | $ 66.47 |
| Range 22 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 66.97 |
| Options Outstanding Number of Shares | shares | 3,118 |
| Options Outstanding Weighted Average Remaining Contractual Life | 6 years 5 months 12 days |
| Options Outstanding Weighted Average Exercise Price | $ 66.97 |
| Options Exercisable Number of Shares | shares | 623 |
| Options Exercisable Weighted Average Exercise Price | $ 66.97 |
| Range 23 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 68.39 |
| Options Outstanding Number of Shares | shares | 231,687 |
| Options Outstanding Weighted Average Remaining Contractual Life | 6 years 2 months 5 days |
| Options Outstanding Weighted Average Exercise Price | $ 68.39 |
| Options Exercisable Number of Shares | shares | 53,789 |
| Options Exercisable Weighted Average Exercise Price | $ 68.39 |
| Range 24 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Range Exercise Price Maximum | $ 71.95 |
| Options Outstanding Number of Shares | shares | 161,791 |
| Options Outstanding Weighted Average Remaining Contractual Life | 7 years 2 months 1 day |
| Options Outstanding Weighted Average Exercise Price | $ 71.95 |
| Options Exercisable Weighted Average Exercise Price | $ 71.95 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) - Employee Stock Option - $ / shares |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Weighted average fair value | $ 20.10 | $ 19.75 | $ 14.09 |
| Assumptions: | |||
| Expected volatility | 30.00% | 30.00% | 32.00% |
| Dividend yield | 0.00% | 0.00% | 0.00% |
| Risk-free interest rate | 1.39% | 1.58% | 1.57% |
| Expected life | 5 years | 5 years | 5 years |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of RSU and PSU Activity (Detail) - $ / shares |
12 Months Ended | |
|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
| Performance Share Unit (PSUs) | ||
| Outstanding Number of Shares | ||
| Outstanding at beginning of period | 901,773 | |
| Granted | 247,992 | |
| Shares vested | (311,492) | |
| Forfeited | (7,750) | |
| Outstanding at ending of period | 830,523 | 901,773 |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | $ 48.33 | |
| Granted | 71.58 | |
| Shares vested | 33.09 | |
| Forfeited | 56.58 | |
| Outstanding at end of period | $ 60.73 | $ 48.33 |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 1 year 1 month 10 days | 1 year 2 months 19 days |
| Restricted Stock Units (RSUs) | ||
| Outstanding Number of Shares | ||
| Outstanding at beginning of period | 1,067,613 | |
| Granted | 391,196 | |
| Shares vested | (300,019) | |
| Forfeited | (133,306) | |
| Outstanding at ending of period | 1,025,484 | 1,067,613 |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | $ 48.30 | |
| Granted | 67.45 | |
| Shares vested | 36.13 | |
| Forfeited | 52.36 | |
| Outstanding at end of period | $ 58.64 | $ 48.30 |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 1 year 4 months 24 days | 1 year 5 months 23 days |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Schedule of Non-cash Stock Compensation Expense (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Share-based compensation expense | $ 40,343 | $ 33,317 | $ 22,742 |
| Direct costs | |||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Share-based compensation expense | 21,903 | 18,358 | 12,531 |
| Selling, general and administrative | |||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Share-based compensation expense | $ 18,440 | $ 14,959 | $ 10,211 |
| X | ||||||||||
- Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Government Grants (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
||||
| Government Grants [Line Items] | |||||
| Received | $ 3,539 | $ 3,539 | |||
| Less accumulated amortization | (2,701) | (2,657) | |||
| Foreign exchange translation adjustment | 103 | 120 | |||
| Total government grants | 941 | 1,002 | |||
| Less current portion | (54) | (43) | |||
| Non-current government grants | $ 887 | $ 959 | [1] | ||
| |||||
| X | ||||||||||
- Definition Accumulated Amortization, Capital Government Grants No definition available.
|
| X | ||||||||||
- Definition Capital Government Grants Current No definition available.
|
| X | ||||||||||
- Definition Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
- Definition Deferred Items Grants From Outside Parties No definition available.
|
| X | ||||||||||
- Definition Foreign Currency Translation Adjustment No definition available.
|
| X | ||||||||||
- Definition Government Grant [Line Items] No definition available.
|
| X | ||||||||||
- Definition Total carrying amount of consideration received or receivable as of the balance sheet date representing potential earnings that were not as yet recognized as revenue or other forms of income in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Government Grants - Additional Information (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Government Grants [Line Items] | |||
| Amortization of government grants | $ 44 | $ (53) | $ 213 |
| Restricted retained earnings | $ 600 | ||
| X | ||||||||||
- Definition Government Grant [Line Items] No definition available.
|
| X | ||||||||||
- Definition Amortization of Government Grants. No definition available.
|
| X | ||||||||||
- Definition A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Share Capital - Additional Information (Detail) - USD ($) |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
Oct. 03, 2016 |
Jul. 31, 2015 |
May 01, 2015 |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Equity, Class of Treasury Stock [Line Items] | ||||||
| Share allotment description | Every holder of an ordinary share present in person or proxy at a general meeting of shareholders shall have one vote, for each ordinary share held with no individual having more than one vote. | |||||
| Ordinary shares redeemed, value | $ 110,000,000 | $ 457,892,000 | $ 140,030,000 | |||
| Ordinary shares repurchased | 2,640,610 | |||||
| Ordinary shares repurchased, value | $ 140,000,000 | |||||
| Employee Stock Option | ||||||
| Equity, Class of Treasury Stock [Line Items] | ||||||
| Options exercised by employees | 393,240 | 773,753 | 926,407 | |||
| Average exercise price of Option per share | $ 25.79 | $ 27.13 | $ 24.02 | |||
| Total proceeds from exercise of stock options by employees | $ 10,100,000 | $ 21,000,000 | $ 22,300,000 | |||
| Restricted Stock Units (RSUs) | ||||||
| Equity, Class of Treasury Stock [Line Items] | ||||||
| Ordinary shares issued in respect of certain RSUs previously awarded by the Company | 296,386 | 268,870 | 233,726 | |||
| Performance Share Unit (PSUs) | ||||||
| Equity, Class of Treasury Stock [Line Items] | ||||||
| Ordinary shares issued in respect of certain PSUs previously awarded by the Company | 311,492 | 7,990 | ||||
| Buyback Program | ||||||
| Equity, Class of Treasury Stock [Line Items] | ||||||
| Ordinary shares redeemed | 5,316,062 | 882,419 | 1,429,187 | 6,198,481 | ||
| Ordinary shares redeemed, value | $ 400,000,000 | $ 57,900,000 | $ 110,000,000 | $ 457,900,000 | ||
| Stock repurchase program, authorized amount | $ 400,000,000 | $ 400,000,000 | $ 60,000,000 | |||
| Buyback Program | Maximum | ||||||
| Equity, Class of Treasury Stock [Line Items] | ||||||
| Share repurchase program, authorized percentage | 10.00% | |||||
| X | ||||||||||
- Definition Stock Repurchase Program Authorized Percentage No definition available.
|
| X | ||||||||||
- Definition Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. No definition available.
|
| X | ||||||||||
- Definition Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. No definition available.
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of stock repurchase plan authorized. No definition available.
|
| X | ||||||||||
- Definition Number of shares that have been repurchased and retired during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares that have been repurchased during the period and are being held in treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Components of Income Before Provision for Income Taxes (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] | |||
| Income before provision for income taxes | $ 300,172 | $ 278,850 | $ 202,716 |
| Ireland | |||
| Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] | |||
| Income before provision for income taxes | 201,221 | 184,643 | 143,889 |
| United States | |||
| Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] | |||
| Income before provision for income taxes | 11,466 | 15,436 | 6,966 |
| Other | |||
| Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] | |||
| Income before provision for income taxes | $ 87,485 | $ 78,771 | $ 51,861 |
| X | ||||||||||
- Definition Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] No definition available.
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Components of Provision for Income Taxes (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Current tax expense: | |||
| Current tax expense | $ 36,448 | $ 36,154 | $ 38,148 |
| Deferred expense/(benefit): | |||
| Deferred tax expense/(benefit) | 1,545 | 3,157 | (7,900) |
| Provision for income taxes | 37,993 | 39,311 | 30,248 |
| Impact on shareholders equity and other comprehensive income of the tax consequence of : | |||
| Excess tax benefit on stock compensation | (4,332) | (1,905) | (2,404) |
| Currency impact on long term funding | (396) | 3,574 | 178 |
| Total | 33,265 | 40,980 | 28,022 |
| Ireland | |||
| Current tax expense: | |||
| Current tax expense | 22,931 | 21,769 | 19,562 |
| Deferred expense/(benefit): | |||
| Deferred tax expense/(benefit) | 1,284 | 26 | (1,178) |
| Provision for income taxes | 24,215 | 21,795 | 18,384 |
| United States | |||
| Current tax expense: | |||
| Current tax expense | 7,768 | 684 | 7,891 |
| Deferred expense/(benefit): | |||
| Deferred tax expense/(benefit) | 613 | 2,896 | (3,031) |
| Provision for income taxes | 8,381 | 3,580 | 4,860 |
| Other | |||
| Current tax expense: | |||
| Current tax expense | 5,749 | 13,701 | 10,695 |
| Deferred expense/(benefit): | |||
| Deferred tax expense/(benefit) | (352) | 235 | (3,691) |
| Provision for income taxes | $ (131) | $ 5,929 | $ 4,149 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The sum of the tax effects of all items occurring during the period that have been charged or credited directly to other comprehensive income or to related components of shareholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The tax effects of employee stock option transactions that are recognized differently for financial reporting and tax purposes, occurring during the period and charged or credited directly to shareholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Irish statutory rate | 12.50% | 12.50% | 12.50% |
| Valuation allowance for deferred tax assets | $ 20,337 | $ 17,184 | $ 23,145 |
| Net change in the total valuation allowance | 3,100 | (5,900) | |
| Deferred tax expense/(benefit) resulted from valuation allowance release | 3,200 | ||
| Unrecognized tax benefit, potentially expire in 2016 | 4,900 | ||
| Increase related to acquired tax positions | 0 | 778 | 14,552 |
| Total unrecognized tax benefits net of potential benefits | 26,620 | 28,166 | 23,201 |
| Interest and penalties recognized as an expense | 100 | 900 | $ 200 |
| Total accrued interest and penalties | $ 3,300 | 3,300 | |
| Tax Jurisdiction Description | In the United States tax periods open to audit include the years ended December 31, 2013, December 31, 2014, December 31, 2015 and December 31, 2016. In Ireland, tax periods open to audit include the years ended December 31, 2012, December 31, 2013, December 31, 2014, December 31, 2015 and December 31, 2016. During such audits, local tax authorities may challenge the positions taken by us in tax returns. | ||
| Provision for income taxes | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Net change in the total valuation allowance | $ 1,200 | (4,100) | |
| Goodwill | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Net change in the total valuation allowance | 2,400 | ||
| Other Comprehensive Income | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Net change in the total valuation allowance | (500) | (1,800) | |
| Foreign Country | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Ireland subsidiaries additional tax credit carryforward for income tax | 3,300 | 2,900 | |
| Other non-U.S subsidiaries operating loss carryforwards for income tax | 70,100 | 68,600 | |
| Other non-U.S subsidiaries tax credit carryforwards for income tax | 3,900 | $ 3,000 | |
| Additional operating loss carryforward | $ 3,500 | ||
| Expiration period | Expire between 2017 and 2023. | ||
| Ireland | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Irish statutory rate | 12.50% | ||
| United States | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Expiration period | Expire between 2017 and 2036 | ||
| U.S. Federal net operating loss carry forwards currently available for offset | $ 22,800 | ||
| Limitation description | Due to changes of ownership in 2000, 2010 and 2014, as defined by Section 382 of the Internal Revenue Code of 1986, as amended. | ||
| Alternative minimum tax credit carry forwards | $ 400 | ||
| Business credit carry forwards that are available to offset | 300 | ||
| United States | Federal | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Additional operating loss carryforward | 50,587 | ||
| U.S. federal net operating loss carry forwards | 28,600 | ||
| United States | Additional Paid-in Capital | Federal | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Additional operating loss carryforward | 16,100 | ||
| United States | 2016 | Federal | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| U.S. federal net operating loss carry forwards | 2,900 | ||
| United States | 2017 - 2019 | Federal | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| U.S. federal net operating loss carry forwards | 12,800 | ||
| United States | 2020 - 2022 | Federal | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| U.S. federal net operating loss carry forwards | 7,700 | ||
| United States | 2023 - 2026 | Federal | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| U.S. federal net operating loss carry forwards | 5,200 | ||
| United States | State | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Additional operating loss carryforward | 50,168 | ||
| United States | State | Additional Paid-in Capital | |||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | |||
| Additional operating loss carryforward | $ 30,900 | ||
| X | ||||||||||
- Definition Deferred Income Tax Expense Benefit Change In Valuation Allowance No definition available.
|
| X | ||||||||||
- Definition Deferred Tax Assets, Additional Tax Credit Carryforwards Not Subject to Expiration No definition available.
|
| X | ||||||||||
- Definition Deferred Tax Assets Tax Credit Carry Forwards Not Subject To Expiration No definition available.
|
| X | ||||||||||
- Definition Open Tax Years No definition available.
|
| X | ||||||||||
- Definition Operating Loss Carryforwards Expiration Periods No definition available.
|
| X | ||||||||||
- Definition Operating Loss Carryforwards, US Federal No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Percentage of domestic federal statutory tax rate applicable to pretax income (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income. No definition available.
|
| X | ||||||||||
- Definition The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in unrecognized tax benefits resulting from acquisitions. No definition available.
|
| X | ||||||||||
- Definition The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Consolidated Reported Provision for Income Taxes Differed from Statutory Rate (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Taxes at Irish statutory rate of 12.5% (2015:12.5%; 2014:12.5%) | $ 37,522 | $ 34,856 | $ 25,340 |
| Foreign and other income taxed at higher rates | 4,642 | 4,614 | 3,152 |
| Research & development tax incentives | (907) | (695) | (1,810) |
| Movement in valuation allowance | 1,208 | (4,133) | (1,965) |
| Effects of change in tax rates | 576 | (16) | 543 |
| Increase/(decrease) in unrecognized tax benefits | (1,521) | 5,085 | 2,869 |
| Effects of permanent items | (4,259) | (463) | 2,048 |
| Other | 732 | 63 | 71 |
| Provision for income taxes | $ 37,993 | $ 39,311 | $ 30,248 |
| X | ||||||||||
- Definition Schedule of Deferred Income Tax Assets and Liabilities [Line Items] No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Consolidated Reported Provision for Income Taxes Differed from Statutory Rate (Parenthetical) (Detail) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Irish statutory rate | 12.50% | 12.50% | 12.50% |
| X | ||||||||||
- Definition Schedule of Deferred Income Tax Assets and Liabilities [Line Items] No definition available.
|
| X | ||||||||||
- Definition Percentage of domestic federal statutory tax rate applicable to pretax income (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Tax Effects of Temporary Differences That Gives Rise to Significant Portions of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|---|---|---|---|
| Deferred tax liabilities: | |||
| Property, plant and equipment | $ 979 | $ 1,239 | |
| Goodwill | 26,617 | 22,170 | |
| Other intangible assets | 6,700 | 5,865 | |
| Other | 1,441 | 1,293 | |
| Total deferred tax liabilities recognized | 35,737 | 30,567 | |
| Deferred tax assets: | |||
| Operating loss and tax credits carryforwards | 22,705 | 22,186 | |
| Property, plant and equipment | 3,121 | 2,487 | |
| Accrued expenses and payments on account | 28,904 | 29,473 | |
| Stock compensation | 13,062 | 12,959 | |
| Deferred compensation expense | 3,327 | 2,174 | |
| Other | 15 | 566 | |
| Total deferred tax assets | 71,134 | 69,845 | |
| Valuation allowance for deferred tax assets | (20,337) | (17,184) | $ (23,145) |
| Deferred tax assets recognized | 50,797 | 52,661 | |
| Overall net deferred tax asset | $ 15,060 | $ 22,094 |
| X | ||||||||||
- Definition Deferred Tax Assets Operating Loss And Tax Credits Carryforwards No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from long-lived assets other than property, plant, and equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Expected Expiry Dates of NOI's (Detail) - United States $ in Thousands |
Dec. 31, 2016
USD ($)
|
|---|---|
| Federal | |
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | $ 50,587 |
| Federal | Expiring 2017-2018 | |
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 226 |
| Federal | Expiring 2021-2034 | |
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 34,735 |
| Federal | Expiring 2035-2036 | |
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 15,626 |
| State | |
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 50,168 |
| State | Expiring 2021-2034 | |
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 29,049 |
| State | Expiring 2035-2036 | |
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | $ 21,119 |
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Reconciliation of Beginning and Ending Amount of Total Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Income Tax Contingency [Line Items] | |||
| Unrecognized tax benefits at start of year | $ 28,166 | $ 23,201 | $ 5,780 |
| Increase related to acquired tax positions | 0 | 778 | 14,552 |
| Increase related to prior year tax positions | 1,151 | 1,482 | 565 |
| Decrease related to prior year tax positions | (2,483) | (315) | (183) |
| Increase related to current year tax positions | 1,104 | 3,063 | 3,709 |
| Settlements | (837) | (2) | |
| Lapse of statute of limitations | (481) | (43) | (1,220) |
| Unrecognized tax benefits at end of year | $ 26,620 | $ 28,166 | $ 23,201 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of unrecognized tax benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in unrecognized tax benefits resulting from acquisitions. No definition available.
|
| X | ||||||||||
- Definition Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Recognized Restructuring and Other Items, Net (Detail) - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2014 |
|
| Restructuring Cost and Reserve [Line Items] | ||
| Restructuring charges | $ 8,159 | $ 8,796 |
| Net charge | $ 8,159 | $ 8,796 |
| X | ||||||||||
- Definition Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
Restructuring and Other Items - Additional Information (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2014 |
Dec. 31, 2015 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | $ 8,159 | $ 8,796 | |
| Restructuring and other items | 2,432 | $ 2,116 | |
| Resource Rationalizations | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | 8,159 | ||
| Onerous Lease | Resource Rationalizations | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | 1,969 | ||
| Workforce reduction | Resource Rationalizations | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | $ 6,190 | ||
| Manchester, United Kingdom facility closure | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | 8,796 | ||
| Manchester, United Kingdom facility closure | Asset Impairment | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | 5,629 | ||
| Manchester, United Kingdom facility closure | Onerous Lease | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | $ 3,167 | ||
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Restructuring Charges (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Total provision recognized | $ 8,159 | $ 8,796 | |
| Manchester, United Kingdom facility closure | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Total provision recognized | 8,796 | ||
| Utilized | (1,359) | $ (1,167) | |
| Asset write-off | (5,629) | ||
| Closing provision | 641 | 2,000 | 3,167 |
| Resource Rationalizations | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Total provision recognized | 8,159 | ||
| Utilized | (6,305) | ||
| Foreign exchange | (63) | ||
| Closing provision | 1,791 | ||
| Workforce reduction | Resource Rationalizations | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Total provision recognized | 6,190 | ||
| Utilized | (5,734) | ||
| Foreign exchange | (63) | ||
| Closing provision | 393 | ||
| Onerous Lease | Manchester, United Kingdom facility closure | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Total provision recognized | 3,167 | ||
| Utilized | (1,359) | (1,167) | |
| Closing provision | 641 | $ 2,000 | 3,167 |
| Onerous Lease | Resource Rationalizations | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Total provision recognized | 1,969 | ||
| Utilized | (571) | ||
| Closing provision | $ 1,398 | ||
| Asset Impairment | Manchester, United Kingdom facility closure | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Total provision recognized | 5,629 | ||
| Asset write-off | $ (5,629) | ||
| X | ||||||||||
- Definition Restructuring Reserve, Accrual Adjustment Related to Asset Write-off No definition available.
|
| X | ||||||||||
- Definition Restructuring Reserve Utilizations No definition available.
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Provision for Doubtful Debts (Detail) - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
| Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
| Opening provision | $ 10,383 | $ 5,458 |
| Amounts used during the year | (3,782) | (161) |
| Amounts provided during the year | 4,651 | 7,572 |
| Amounts released during the year | (1,814) | (2,244) |
| Translation | 12 | (242) |
| Closing provision | $ 9,450 | $ 10,383 |
| X | ||||||||||
- Definition Allowance For Doubtful Accounts Foreign Currency Translation Adjustments No definition available.
|
| X | ||||||||||
- Definition Allowance for doubtful accounts amounts released during the year. No definition available.
|
| X | ||||||||||
- Definition Allowance for Doubtful Accounts, Provisions No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of direct write-downs of accounts receivable charged against the allowance. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Operating Leased Assets [Line Items] | |||
| Non-cancelable operating leases for facilities expiration period | 10 years | ||
| Operating leases rental expense | $ 44.0 | $ 49.9 | $ 54.3 |
| X | ||||||||||
- Definition Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Future Minimum Rental Commitments for Operating Leases (Detail) $ in Thousands |
Dec. 31, 2016
USD ($)
|
|---|---|
| Operating Leased Assets [Line Items] | |
| 2017 | $ 34,682 |
| 2018 | 28,219 |
| 2019 | 21,358 |
| 2020 | 15,646 |
| 2021 | 12,477 |
| Thereafter | 40,132 |
| Total | $ 152,514 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Distribution of Net Revenue by Geographical Area (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Segment Reporting Information [Line Items] | |||
| Net Revenue | $ 1,666,487 | $ 1,574,978 | $ 1,503,316 |
| Ireland | |||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 410,572 | 429,631 | 360,376 |
| Rest Of Europe | |||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 313,185 | 330,487 | 372,634 |
| United States | |||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 763,821 | 650,941 | 605,815 |
| Other | |||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | $ 178,909 | $ 163,919 | $ 164,491 |
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Income from operations, including Restructuring, by Geographical Area (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Segment Reporting Information [Line Items] | |||
| Income from operations | $ 311,694 | $ 281,536 | $ 202,350 |
| Ireland | |||
| Segment Reporting Information [Line Items] | |||
| Income from operations | 216,149 | 189,035 | 138,185 |
| Rest Of Europe | |||
| Segment Reporting Information [Line Items] | |||
| Income from operations | 34,200 | 38,166 | 14,481 |
| United States | |||
| Segment Reporting Information [Line Items] | |||
| Income from operations | 41,348 | 45,320 | 39,058 |
| Other | |||
| Segment Reporting Information [Line Items] | |||
| Income from operations | $ 19,997 | $ 9,015 | $ 10,626 |
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Income from operations, excluding Restructuring, by Geographical Area (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Segment Reporting Information [Line Items] | |||
| Income from operations, excluding restructuring and other items | $ 319,853 | $ 281,536 | $ 211,146 |
| Ireland | |||
| Segment Reporting Information [Line Items] | |||
| Income from operations, excluding restructuring and other items | 218,334 | 189,035 | 138,185 |
| Rest Of Europe | |||
| Segment Reporting Information [Line Items] | |||
| Income from operations, excluding restructuring and other items | 36,509 | 38,166 | 23,277 |
| United States | |||
| Segment Reporting Information [Line Items] | |||
| Income from operations, excluding restructuring and other items | 44,590 | 45,320 | 39,058 |
| Other | |||
| Segment Reporting Information [Line Items] | |||
| Income from operations, excluding restructuring and other items | $ 20,420 | $ 9,015 | $ 10,626 |
| X | ||||||||||
- Definition Operating Income Loss Before Restructuring Charges No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||
|---|---|---|---|---|---|
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | $ 148,967 | $ 150,218 | [1] | ||
| Ireland | |||||
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | 105,684 | 101,736 | |||
| Rest Of Europe | |||||
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | 6,231 | 7,334 | |||
| United States | |||||
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | 29,428 | 34,520 | |||
| Other | |||||
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | $ 7,624 | $ 6,628 | |||
| |||||
| X | ||||||||||
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Depreciation and Amortization by Geographical Area (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | $ 59,575 | $ 57,677 | $ 52,542 |
| Ireland | |||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | 25,766 | 22,100 | 20,731 |
| Rest Of Europe | |||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | 6,914 | 11,055 | 7,478 |
| United States | |||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | 23,462 | 20,106 | 20,491 |
| Other | |||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | $ 3,433 | $ 4,416 | $ 3,842 |
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Total Assets by Geographical Area (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
[2] | ||||
|---|---|---|---|---|---|---|---|
| Segment Reporting Information [Line Items] | |||||||
| Assets | $ 1,825,843 | $ 1,717,209 | [1] | ||||
| Ireland | |||||||
| Segment Reporting Information [Line Items] | |||||||
| Assets | 766,120 | 663,060 | |||||
| Rest Of Europe | |||||||
| Segment Reporting Information [Line Items] | |||||||
| Assets | 337,062 | 343,733 | |||||
| United States | |||||||
| Segment Reporting Information [Line Items] | |||||||
| Assets | 651,160 | 641,769 | |||||
| Other | |||||||
| Segment Reporting Information [Line Items] | |||||||
| Assets | $ 71,501 | $ 68,647 | |||||
| |||||||
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Capital Expenditure by Geographical Area (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Segment Reporting Information [Line Items] | |||
| Purchase of property, plant and equipment | $ 42,601 | $ 49,730 | $ 32,779 |
| Ireland | |||
| Segment Reporting Information [Line Items] | |||
| Purchase of property, plant and equipment | 27,670 | 30,900 | 15,117 |
| Rest Of Europe | |||
| Segment Reporting Information [Line Items] | |||
| Purchase of property, plant and equipment | 2,851 | 1,916 | 2,278 |
| United States | |||
| Segment Reporting Information [Line Items] | |||
| Purchase of property, plant and equipment | 8,432 | 15,256 | 12,224 |
| Other | |||
| Segment Reporting Information [Line Items] | |||
| Purchase of property, plant and equipment | $ 3,648 | $ 1,658 | $ 3,160 |
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Clients Representing Company's Net Revenue (Detail) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Customer Concentration Risk [Member] | Sales Revenue, Net | Client A | |||
| Revenue, Major Customer [Line Items] | |||
| Clients which represented 10% or more of the company's net revenue | 26.00% | 31.00% | 31.00% |
| X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Interest Income by Geographical Area (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Segment Reporting Information [Line Items] | |||
| Interest income | $ 1,484 | $ 1,306 | $ 1,151 |
| Ireland | |||
| Segment Reporting Information [Line Items] | |||
| Interest income | 407 | 102 | 284 |
| Rest Of Europe | |||
| Segment Reporting Information [Line Items] | |||
| Interest income | 1,040 | 1,151 | 798 |
| United States | |||
| Segment Reporting Information [Line Items] | |||
| Interest income | 2 | 4 | |
| Other | |||
| Segment Reporting Information [Line Items] | |||
| Interest income | $ 35 | $ 49 | $ 69 |
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Income Tax Charge by Geographical Area (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Segment Reporting Information [Line Items] | |||
| Provision for income taxes | $ 37,993 | $ 39,311 | $ 30,248 |
| Ireland | |||
| Segment Reporting Information [Line Items] | |||
| Provision for income taxes | 24,215 | 21,795 | 18,384 |
| Rest Of Europe | |||
| Segment Reporting Information [Line Items] | |||
| Provision for income taxes | 5,528 | 8,007 | 2,855 |
| United States | |||
| Segment Reporting Information [Line Items] | |||
| Provision for income taxes | 8,381 | 3,580 | 4,860 |
| Other | |||
| Segment Reporting Information [Line Items] | |||
| Provision for income taxes | $ (131) | $ 5,929 | $ 4,149 |
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Supplemental Disclosure of Cash Flow Information (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Schedule of Cash Flow, Supplemental [Line Items] | |||
| Cash paid for interest | $ 13,615 | $ 2,175 | $ 533 |
| Cash paid for income taxes | $ 10,205 | $ 14,829 | $ 17,829 |
| X | ||||||||||
- Definition Schedule of Cash Flow, Supplemental [Line Items] No definition available.
|
| X | ||||||||||
- Definition The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of cash paid for interest during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||
|---|---|---|---|---|---|
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||
| Currency translation adjustments | $ (70,154) | $ (57,315) | |||
| Currency impact on long term funding (Net of tax) | (13,912) | (5,484) | |||
| Actuarial loss on defined benefit pension plan (note 9) | (5,905) | (3,420) | |||
| Unrealized capital gain/(loss) - investments (note 3) | (23) | (34) | |||
| Net realized gain on interest rate hedge | 3,694 | 4,617 | |||
| Total | $ (86,300) | $ (61,636) | [1] | ||
| |||||
| X | ||||||||||
- Definition Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Currency Impact on Long Term Funding, Net of Tax No definition available.
|
| X | ||||||||||
- Definition Accumulated appreciation or loss, net of tax, in value of the total of available-for-sale securities at the end of an accounting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Long-Term Debt - Senior Notes - Additional Information (Detail) - USD ($) |
12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
||||
| Debt Instrument [Line Items] | |||||
| Long term debt | $ 348,511,000 | $ 348,306,000 | [1] | ||
| Cash proceeds from interest rate hedge | 4,658,000 | ||||
| Restatement Adjustment | |||||
| Debt Instrument [Line Items] | |||||
| Debt issue costs | (1,694,000) | ||||
| Senior Notes | |||||
| Debt Instrument [Line Items] | |||||
| Long term debt | 350,000,000 | ||||
| Cash proceeds from interest rate hedge | $ 4,658,000 | ||||
| Interest rate hedge, maturity date | Nov. 17, 2015 | ||||
| Interest rate hedge, inception date | Oct. 05, 2015 | ||||
| |||||
| X | ||||||||||
- Definition Debt Issuance Cost No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Date the entity entered into the derivative contract, in CCYY-MM-DD format. No definition available.
|
| X | ||||||||||
- Definition Date the derivative contract matures, in CCYY-MM-DD format. No definition available.
|
| X | ||||||||||
- Definition The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Related Parties - Additional Information (Detail) |
12 Months Ended | |||
|---|---|---|---|---|
|
Dec. 31, 2016
USD ($)
|
Dec. 31, 2016
EUR (€)
|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2016
EUR (€)
|
|
| Subsidiaries | Dignity Sciences Limited | ||||
| Related Party Transaction [Line Items] | ||||
| Revenue earned from related parties | $ 100,000 | $ 100,000 | ||
| Amounts due from related parties | 45,700 | |||
| Mr. Thomas Lynch | ||||
| Related Party Transaction [Line Items] | ||||
| Related party transaction amounts | $ 256,315 | € 231,750 | ||
| Amounts due to related parties | € | € 96,560 | |||
| Term of agreement | 3 years | 3 years | ||
| Related party agreement beginning date | Aug. 01, 2016 | Aug. 01, 2016 | ||
| X | ||||||||||
- Definition Agreement Term No definition available.
|
| X | ||||||||||
- Definition Related Party Agreement Beginning Date No definition available.
|
| X | ||||||||||
- Definition For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of obligations due all related parties. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of transactions with related party during the financial reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|